id	sid	tid	token	lemma	pos
gs-894	1	1	georgian	georgian	ADJ
gs-894	1	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-894	1	3	მეცნიერები	მეცნიერები	VERB
gs-894	1	4	4(02	4(02	NUM
gs-894	1	5	)	)	PUNCT
gs-894	1	6	,	,	PUNCT
gs-894	1	7	2022	2022	NUM
gs-894	1	8	193	193	NUM
gs-894	1	9	georgian	georgian	PROPN
gs-894	1	10	scientists	scientist	NOUN
gs-894	1	11	ქართველი	ქართველი	ADJ
gs-894	1	12	მეცნიერები	მეცნიერები	PROPN
gs-894	1	13	vol	vol	NOUN
gs-894	1	14	.	.	NOUN
gs-894	1	15	4	4	NUM
gs-894	1	16	issue	issue	NOUN
gs-894	1	17	2	2	NUM
gs-894	1	18	,	,	PUNCT
gs-894	1	19	2022	2022	NUM
gs-894	1	20	https://doi.org/10.52340/gs.2022.04.02.17	https://doi.org/10.52340/gs.2022.04.02.17	PROPN
gs-894	1	21	the	the	DET
gs-894	1	22	prevalence	prevalence	NOUN
gs-894	1	23	of	of	ADP
gs-894	1	24	type	type	NOUN
gs-894	1	25	2	2	NUM
gs-894	1	26	diabetes	diabetes	NOUN
gs-894	1	27	among	among	ADP
gs-894	1	28	people	people	NOUN
gs-894	1	29	living	live	VERB
gs-894	1	30	with	with	ADP
gs-894	1	31	hiv	hiv	PROPN
gs-894	1	32	in	in	ADP
gs-894	1	33	georgia	georgia	PROPN
gs-894	1	34	1borkowska	1borkowska	NUM
gs-894	1	35	t	t	PROPN
gs-894	1	36	,	,	PUNCT
gs-894	1	37	1karkashadze	1karkashadze	NUM
gs-894	1	38	e	e	NOUN
gs-894	1	39	,	,	PUNCT
gs-894	1	40	1chokoshvili	1chokoshvili	NUM
gs-894	1	41	o	o	NOUN
gs-894	1	42	,	,	PUNCT
gs-894	1	43	1chkhartishvili	1chkhartishvili	NUM
gs-894	1	44	n	n	CCONJ
gs-894	1	45	,	,	PUNCT
gs-894	1	46	1tsertsvadze	1tsertsvadze	NUM
gs-894	1	47	t	t	NOUN
gs-894	1	48	1infectious	1infectious	NUM
gs-894	1	49	diseases	disease	NOUN
gs-894	1	50	,	,	PUNCT
gs-894	1	51	aids	aid	NOUN
gs-894	1	52	and	and	CCONJ
gs-894	1	53	clinical	clinical	ADJ
gs-894	1	54	immunology	immunology	NOUN
gs-894	1	55	research	research	NOUN
gs-894	1	56	center	center	NOUN
gs-894	1	57	abstract	abstract	ADJ
gs-894	1	58	backround	backround	NOUN
gs-894	1	59	:	:	PUNCT
gs-894	1	60	the	the	DET
gs-894	1	61	number	number	NOUN
gs-894	1	62	of	of	ADP
gs-894	1	63	people	people	NOUN
gs-894	1	64	living	live	VERB
gs-894	1	65	with	with	ADP
gs-894	1	66	human	human	ADJ
gs-894	1	67	immunodeficiency	immunodeficiency	NOUN
gs-894	1	68	virus	virus	NOUN
gs-894	1	69	(	(	PUNCT
gs-894	1	70	hiv	hiv	PROPN
gs-894	1	71	)	)	PUNCT
gs-894	1	72	is	be	AUX
gs-894	1	73	increasing	increase	VERB
gs-894	1	74	due	due	ADJ
gs-894	1	75	to	to	ADP
gs-894	1	76	improved	improved	ADJ
gs-894	1	77	screening	screening	NOUN
gs-894	1	78	,	,	PUNCT
gs-894	1	79	faster	fast	ADJ
gs-894	1	80	diagnosis	diagnosis	NOUN
gs-894	1	81	,	,	PUNCT
gs-894	1	82	newer	new	ADJ
gs-894	1	83	methods	method	NOUN
gs-894	1	84	,	,	PUNCT
gs-894	1	85	availability	availability	NOUN
gs-894	1	86	and	and	CCONJ
gs-894	1	87	acceptance	acceptance	NOUN
gs-894	1	88	of	of	ADP
gs-894	1	89	treatment	treatment	NOUN
gs-894	1	90	,	,	PUNCT
gs-894	1	91	but	but	CCONJ
gs-894	1	92	the	the	DET
gs-894	1	93	prevalence	prevalence	NOUN
gs-894	1	94	of	of	ADP
gs-894	1	95	non	non	ADJ
gs-894	1	96	-	-	ADJ
gs-894	1	97	communicable	communicable	ADJ
gs-894	1	98	diseases	disease	NOUN
gs-894	1	99	,	,	PUNCT
gs-894	1	100	particularly	particularly	ADV
gs-894	1	101	metabolic	metabolic	ADJ
gs-894	1	102	disorders	disorder	NOUN
gs-894	1	103	,	,	PUNCT
gs-894	1	104	has	have	AUX
gs-894	1	105	grown	grow	VERB
gs-894	1	106	among	among	ADP
gs-894	1	107	hiv	hiv	PROPN
gs-894	1	108	infected	infect	VERB
gs-894	1	109	patients.the	patients.the	PRON
gs-894	1	110	aim	aim	NOUN
gs-894	1	111	of	of	ADP
gs-894	1	112	the	the	DET
gs-894	1	113	study	study	NOUN
gs-894	1	114	was	be	AUX
gs-894	1	115	to	to	PART
gs-894	1	116	calculate	calculate	VERB
gs-894	1	117	the	the	DET
gs-894	1	118	prevalence	prevalence	NOUN
gs-894	1	119	of	of	ADP
gs-894	1	120	t2d	t2d	NOUN
gs-894	1	121	among	among	ADP
gs-894	1	122	people	people	NOUN
gs-894	1	123	living	live	VERB
gs-894	1	124	with	with	ADP
gs-894	1	125	hiv	hiv	PROPN
gs-894	1	126	in	in	ADP
gs-894	1	127	georgia	georgia	PROPN
gs-894	1	128	and	and	CCONJ
gs-894	1	129	find	find	VERB
gs-894	1	130	the	the	DET
gs-894	1	131	association	association	NOUN
gs-894	1	132	between	between	ADP
gs-894	1	133	diabetes	diabete	NOUN
gs-894	1	134	and	and	CCONJ
gs-894	1	135	other	other	ADJ
gs-894	1	136	comorbidities	comorbiditie	NOUN
gs-894	1	137	to	to	PART
gs-894	1	138	fill	fill	VERB
gs-894	1	139	up	up	ADP
gs-894	1	140	knowledge	knowledge	NOUN
gs-894	1	141	gap	gap	NOUN
gs-894	1	142	.	.	PUNCT
gs-894	2	1	materials	material	NOUN
gs-894	2	2	and	and	CCONJ
gs-894	2	3	methods	method	NOUN
gs-894	2	4	:	:	PUNCT
gs-894	2	5	we	we	PRON
gs-894	2	6	have	have	AUX
gs-894	2	7	conducted	conduct	VERB
gs-894	2	8	a	a	DET
gs-894	2	9	prospective	prospective	ADJ
gs-894	2	10	cohort	cohort	NOUN
gs-894	2	11	study	study	NOUN
gs-894	2	12	among	among	ADP
gs-894	2	13	plwh	plwh	NOUN
gs-894	2	14	receiving	receive	VERB
gs-894	2	15	care	care	NOUN
gs-894	2	16	at	at	ADP
gs-894	2	17	the	the	DET
gs-894	2	18	infectious	infectious	ADJ
gs-894	2	19	diseases	disease	NOUN
gs-894	2	20	,	,	PUNCT
gs-894	2	21	aids	aid	NOUN
gs-894	2	22	and	and	CCONJ
gs-894	2	23	clinical	clinical	ADJ
gs-894	2	24	immunology	immunology	NOUN
gs-894	2	25	research	research	NOUN
gs-894	2	26	center	center	NOUN
gs-894	2	27	in	in	ADP
gs-894	2	28	tbilisi	tbilisi	PROPN
gs-894	2	29	,	,	PUNCT
gs-894	2	30	georgia	georgia	PROPN
gs-894	2	31	.	.	PUNCT
gs-894	3	1	the	the	DET
gs-894	3	2	study	study	NOUN
gs-894	3	3	included	include	VERB
gs-894	3	4	hiv	hiv	PROPN
gs-894	3	5	positive	positive	ADJ
gs-894	3	6	adults	adult	NOUN
gs-894	3	7	(	(	PUNCT
gs-894	3	8	age	age	NOUN
gs-894	3	9	≥	≥	NUM
gs-894	3	10	18	18	NUM
gs-894	3	11	years	year	NOUN
gs-894	3	12	)	)	PUNCT
gs-894	3	13	diagnosed	diagnose	VERB
gs-894	3	14	in	in	ADP
gs-894	3	15	2012	2012	NUM
gs-894	3	16	-	-	SYM
gs-894	3	17	2018	2018	NUM
gs-894	3	18	.	.	PUNCT
gs-894	4	1	participants	participant	NOUN
gs-894	4	2	were	be	AUX
gs-894	4	3	followed	follow	VERB
gs-894	4	4	-	-	PUNCT
gs-894	4	5	up	up	NOUN
gs-894	4	6	from	from	ADP
gs-894	4	7	aids	aid	NOUN
gs-894	4	8	diagnosis	diagnosis	NOUN
gs-894	4	9	till	till	SCONJ
gs-894	4	10	the	the	DET
gs-894	4	11	1st	1st	NOUN
gs-894	4	12	of	of	ADP
gs-894	4	13	october	october	PROPN
gs-894	4	14	2021	2021	NUM
gs-894	4	15	.	.	PUNCT
gs-894	5	1	american	american	ADJ
gs-894	5	2	diabetes	diabetes	PROPN
gs-894	5	3	association	association	PROPN
gs-894	5	4	(	(	PUNCT
gs-894	5	5	ada	ada	PROPN
gs-894	5	6	)	)	PUNCT
gs-894	5	7	guidelines	guideline	NOUN
gs-894	5	8	were	be	AUX
gs-894	5	9	used	use	VERB
gs-894	5	10	to	to	PART
gs-894	5	11	define	define	VERB
gs-894	5	12	hyperglycemia	hyperglycemia	NOUN
gs-894	5	13	and	and	CCONJ
gs-894	5	14	diabetes	diabetes	NOUN
gs-894	5	15	.	.	PUNCT
gs-894	6	1	results	result	NOUN
gs-894	6	2	:	:	PUNCT
gs-894	6	3	in	in	ADP
gs-894	6	4	total	total	ADJ
gs-894	6	5	cohort	cohort	NOUN
gs-894	6	6	4.47	4.47	NUM
gs-894	6	7	%	%	NOUN
gs-894	6	8	had	have	AUX
gs-894	6	9	prediabetes	prediabete	NOUN
gs-894	6	10	and	and	CCONJ
gs-894	6	11	2.65	2.65	NUM
gs-894	6	12	%	%	NOUN
gs-894	6	13	type	type	NOUN
gs-894	6	14	2	2	NUM
gs-894	6	15	diabetes	diabetes	NOUN
gs-894	6	16	.	.	PUNCT
gs-894	7	1	our	our	PRON
gs-894	7	2	research	research	NOUN
gs-894	7	3	demonstrates	demonstrate	VERB
gs-894	7	4	that	that	SCONJ
gs-894	7	5	the	the	DET
gs-894	7	6	prevalence	prevalence	NOUN
gs-894	7	7	of	of	ADP
gs-894	7	8	hyperglycemia	hyperglycemia	NOUN
gs-894	7	9	increases	increase	NOUN
gs-894	7	10	by	by	ADP
gs-894	7	11	the	the	DET
gs-894	7	12	age	age	NOUN
gs-894	7	13	.	.	PUNCT
gs-894	8	1	in	in	ADP
gs-894	8	2	total	total	ADJ
gs-894	8	3	171	171	NUM
gs-894	8	4	(	(	PUNCT
gs-894	8	5	5.87	5.87	NUM
gs-894	8	6	%	%	NOUN
gs-894	8	7	)	)	PUNCT
gs-894	8	8	participants	participant	NOUN
gs-894	8	9	had	have	VERB
gs-894	8	10	tb	tb	X
gs-894	8	11	.	.	PUNCT
gs-894	8	12	hyperglycemia	hyperglycemia	NOUN
gs-894	8	13	and	and	CCONJ
gs-894	8	14	tb	tb	NOUN
gs-894	8	15	together	together	ADV
gs-894	8	16	was	be	AUX
gs-894	8	17	detected	detect	VERB
gs-894	8	18	in	in	ADP
gs-894	8	19	48.5	48.5	NUM
gs-894	8	20	%	%	NOUN
gs-894	8	21	(	(	PUNCT
gs-894	8	22	83	83	NUM
gs-894	8	23	)	)	PUNCT
gs-894	8	24	of	of	ADP
gs-894	8	25	all	all	PRON
gs-894	8	26	tb	tb	ADP
gs-894	8	27	patients	patient	NOUN
gs-894	8	28	.	.	PUNCT
gs-894	9	1	relative	relative	ADJ
gs-894	9	2	risk	risk	NOUN
gs-894	9	3	(	(	PUNCT
gs-894	9	4	rr	rr	NOUN
gs-894	9	5	)	)	PUNCT
gs-894	9	6	of	of	ADP
gs-894	9	7	tb	tb	PROPN
gs-894	9	8	was	be	AUX
gs-894	9	9	0.94	0.94	NUM
gs-894	9	10	(	(	PUNCT
gs-894	9	11	95	95	NUM
gs-894	9	12	%	%	NOUN
gs-894	9	13	ci	ci	NOUN
gs-894	9	14	:	:	PUNCT
gs-894	9	15	0.85	0.85	NUM
gs-894	9	16	-	-	SYM
gs-894	9	17	1.56	1.56	NUM
gs-894	9	18	)	)	PUNCT
gs-894	9	19	.	.	PUNCT
gs-894	10	1	32	32	NUM
gs-894	10	2	participants	participant	NOUN
gs-894	10	3	had	have	VERB
gs-894	10	4	ckd	ckd	PROPN
gs-894	10	5	,	,	PUNCT
gs-894	10	6	50	50	NUM
gs-894	10	7	%	%	NOUN
gs-894	10	8	(	(	PUNCT
gs-894	10	9	p=0.08	p=0.08	NOUN
gs-894	10	10	)	)	PUNCT
gs-894	10	11	had	have	VERB
gs-894	10	12	hyperglycemia	hyperglycemia	NOUN
gs-894	10	13	.	.	PUNCT
gs-894	11	1	cvd	cvd	PROPN
gs-894	11	2	was	be	AUX
gs-894	11	3	detected	detect	VERB
gs-894	11	4	in	in	ADP
gs-894	11	5	92	92	NUM
gs-894	11	6	participants	participant	NOUN
gs-894	11	7	,	,	PUNCT
gs-894	11	8	44.6	44.6	NUM
gs-894	11	9	%	%	NOUN
gs-894	11	10	(	(	PUNCT
gs-894	11	11	p=0.07	p=0.07	X
gs-894	11	12	)	)	PUNCT
gs-894	11	13	was	be	AUX
gs-894	11	14	hyperglycemic.16	hyperglycemic.16	ADJ
gs-894	11	15	patients	patient	NOUN
gs-894	11	16	had	have	VERB
gs-894	11	17	a	a	DET
gs-894	11	18	stroke	stroke	NOUN
gs-894	11	19	,	,	PUNCT
gs-894	11	20	from	from	ADP
gs-894	11	21	which	which	PRON
gs-894	11	22	11	11	NUM
gs-894	11	23	(	(	PUNCT
gs-894	11	24	68.8	68.8	NUM
gs-894	11	25	%	%	NOUN
gs-894	11	26	)	)	PUNCT
gs-894	11	27	had	have	VERB
gs-894	11	28	hyperglycemia	hyperglycemia	NOUN
gs-894	11	29	.	.	PUNCT
gs-894	12	1	the	the	DET
gs-894	12	2	rr	rr	PROPN
gs-894	12	3	of	of	ADP
gs-894	12	4	stroke	stroke	NOUN
gs-894	12	5	=	=	NOUN
gs-894	12	6	1.8	1.8	NUM
gs-894	12	7	(	(	PUNCT
gs-894	12	8	95	95	NUM
gs-894	12	9	%	%	NOUN
gs-894	12	10	ci	ci	NOUN
gs-894	12	11	:	:	PUNCT
gs-894	12	12	1.45	1.45	NUM
gs-894	12	13	-	-	SYM
gs-894	12	14	4.76	4.76	NUM
gs-894	12	15	)	)	PUNCT
gs-894	12	16	.	.	PUNCT
gs-894	13	1	550	550	NUM
gs-894	13	2	(	(	PUNCT
gs-894	13	3	18.9	18.9	NUM
gs-894	13	4	%	%	NOUN
gs-894	13	5	)	)	PUNCT
gs-894	13	6	patients	patient	NOUN
gs-894	13	7	had	have	VERB
gs-894	13	8	high	high	ADJ
gs-894	13	9	total	total	ADJ
gs-894	13	10	cholesterol	cholesterol	NOUN
gs-894	13	11	and	and	CCONJ
gs-894	13	12	ldl	ldl	NOUN
gs-894	13	13	level	level	NOUN
gs-894	13	14	,	,	PUNCT
gs-894	13	15	195	195	NUM
gs-894	13	16	(	(	PUNCT
gs-894	13	17	35	35	NUM
gs-894	13	18	%	%	NOUN
gs-894	13	19	)	)	PUNCT
gs-894	13	20	had	have	VERB
gs-894	13	21	hyperglycemia	hyperglycemia	NOUN
gs-894	13	22	.	.	PUNCT
gs-894	14	1	conclusions	conclusion	NOUN
gs-894	14	2	:	:	PUNCT
gs-894	14	3	prevention	prevention	NOUN
gs-894	14	4	or	or	CCONJ
gs-894	14	5	early	early	ADJ
gs-894	14	6	detection	detection	NOUN
gs-894	14	7	of	of	ADP
gs-894	14	8	t2d	t2d	NOUN
gs-894	14	9	and	and	CCONJ
gs-894	14	10	timely	timely	ADJ
gs-894	14	11	management	management	NOUN
gs-894	14	12	of	of	ADP
gs-894	14	13	metabolic	metabolic	NOUN
gs-894	14	14	disturbance	disturbance	NOUN
gs-894	14	15	,	,	PUNCT
gs-894	14	16	reduces	reduce	VERB
gs-894	14	17	risk	risk	NOUN
gs-894	14	18	of	of	ADP
gs-894	14	19	morbidity	morbidity	NOUN
gs-894	14	20	and	and	CCONJ
gs-894	14	21	mortality	mortality	NOUN
gs-894	14	22	during	during	ADP
gs-894	14	23	hiv	hiv	PROPN
gs-894	14	24	.	.	PUNCT
gs-894	15	1	screening	screening	NOUN
gs-894	15	2	and	and	CCONJ
gs-894	15	3	management	management	NOUN
gs-894	15	4	of	of	ADP
gs-894	15	5	hyperglycemia	hyperglycemia	NOUN
gs-894	15	6	should	should	AUX
gs-894	15	7	be	be	AUX
gs-894	15	8	part	part	NOUN
gs-894	15	9	of	of	ADP
gs-894	15	10	the	the	DET
gs-894	15	11	routine	routine	ADJ
gs-894	15	12	hiv	hiv	PROPN
gs-894	15	13	clinical	clinical	ADJ
gs-894	15	14	services	service	NOUN
gs-894	15	15	.	.	PUNCT
gs-894	16	1	keywords	keyword	NOUN
gs-894	16	2	:	:	PUNCT
gs-894	16	3	type	type	NOUN
gs-894	16	4	2	2	NUM
gs-894	16	5	diabetes	diabetes	NOUN
gs-894	16	6	,	,	PUNCT
gs-894	16	7	hyperglycemia	hyperglycemia	NOUN
gs-894	16	8	,	,	PUNCT
gs-894	16	9	hiv	hiv	PROPN
gs-894	16	10	,	,	PUNCT
gs-894	16	11	prevalence	prevalence	NOUN
gs-894	16	12	,	,	PUNCT
gs-894	16	13	georgia	georgia	PROPN
gs-894	16	14	georgian	georgian	PROPN
gs-894	16	15	scientists/ქართველი	scientists/ქართველი	PROPN
gs-894	16	16	მეცნიერები	მეცნიერები	VERB
gs-894	16	17	4(02	4(02	NUM
gs-894	16	18	)	)	PUNCT
gs-894	16	19	,	,	PUNCT
gs-894	16	20	2022	2022	NUM
gs-894	16	21	194	194	NUM
gs-894	16	22	introduction	introduction	NOUN
gs-894	16	23	the	the	DET
gs-894	16	24	number	number	NOUN
gs-894	16	25	of	of	ADP
gs-894	16	26	people	people	NOUN
gs-894	16	27	living	live	VERB
gs-894	16	28	with	with	ADP
gs-894	16	29	human	human	ADJ
gs-894	16	30	immunodeficiency	immunodeficiency	NOUN
gs-894	16	31	virus	virus	NOUN
gs-894	16	32	(	(	PUNCT
gs-894	16	33	hiv	hiv	PROPN
gs-894	16	34	)	)	PUNCT
gs-894	16	35	is	be	AUX
gs-894	16	36	increasing	increase	VERB
gs-894	16	37	due	due	ADJ
gs-894	16	38	to	to	ADP
gs-894	16	39	improved	improved	ADJ
gs-894	16	40	screening	screening	NOUN
gs-894	16	41	,	,	PUNCT
gs-894	16	42	faster	fast	ADJ
gs-894	16	43	diagnosis	diagnosis	NOUN
gs-894	16	44	,	,	PUNCT
gs-894	16	45	newer	new	ADJ
gs-894	16	46	methods	method	NOUN
gs-894	16	47	,	,	PUNCT
gs-894	16	48	availability	availability	NOUN
gs-894	16	49	and	and	CCONJ
gs-894	16	50	acceptance	acceptance	NOUN
gs-894	16	51	of	of	ADP
gs-894	16	52	treatment1	treatment1	NOUN
gs-894	16	53	,	,	PUNCT
gs-894	16	54	2	2	NUM
gs-894	16	55	,	,	PUNCT
gs-894	16	56	but	but	CCONJ
gs-894	16	57	the	the	DET
gs-894	16	58	prevalence	prevalence	NOUN
gs-894	16	59	of	of	ADP
gs-894	16	60	non	non	ADJ
gs-894	16	61	-	-	ADJ
gs-894	16	62	communicable	communicable	ADJ
gs-894	16	63	diseases	disease	NOUN
gs-894	16	64	,	,	PUNCT
gs-894	16	65	particularly	particularly	ADV
gs-894	16	66	metabolic	metabolic	ADJ
gs-894	16	67	disorders	disorder	NOUN
gs-894	16	68	,	,	PUNCT
gs-894	16	69	has	have	AUX
gs-894	16	70	grown	grow	VERB
gs-894	16	71	among	among	ADP
gs-894	16	72	hiv	hiv	PROPN
gs-894	16	73	infected	infect	VERB
gs-894	16	74	patients1,3	patients1,3	PROPN
gs-894	16	75	-	-	PUNCT
gs-894	16	76	6	6	NUM
gs-894	16	77	.	.	PUNCT
gs-894	17	1	a	a	DET
gs-894	17	2	lot	lot	NOUN
gs-894	17	3	of	of	ADP
gs-894	17	4	studies	study	NOUN
gs-894	17	5	have	have	AUX
gs-894	17	6	found	find	VERB
gs-894	17	7	that	that	SCONJ
gs-894	17	8	hiv	hiv	PROPN
gs-894	17	9	infection	infection	NOUN
gs-894	17	10	and	and	CCONJ
gs-894	17	11	art	art	NOUN
gs-894	17	12	(	(	PUNCT
gs-894	17	13	antiretroviral	antiretroviral	ADJ
gs-894	17	14	treatment	treatment	NOUN
gs-894	17	15	)	)	PUNCT
gs-894	17	16	are	be	AUX
gs-894	17	17	increasing	increase	VERB
gs-894	17	18	insulin	insulin	NOUN
gs-894	17	19	resistance	resistance	NOUN
gs-894	17	20	,	,	PUNCT
gs-894	17	21	which	which	PRON
gs-894	17	22	leads	lead	VERB
gs-894	17	23	type	type	NOUN
gs-894	17	24	2	2	NUM
gs-894	17	25	diabetes	diabetes	NOUN
gs-894	17	26	(	(	PUNCT
gs-894	17	27	t2d)7	t2d)7	PROPN
gs-894	17	28	-	-	PUNCT
gs-894	17	29	10	10	NUM
gs-894	17	30	.	.	PUNCT
gs-894	18	1	risk	risk	NOUN
gs-894	18	2	factors	factor	NOUN
gs-894	18	3	of	of	ADP
gs-894	18	4	t2d	t2d	NUM
gs-894	18	5	are	be	AUX
gs-894	18	6	well	well	ADV
gs-894	18	7	known	know	VERB
gs-894	18	8	in	in	ADP
gs-894	18	9	the	the	DET
gs-894	18	10	general	general	ADJ
gs-894	18	11	population	population	NOUN
gs-894	18	12	,	,	PUNCT
gs-894	18	13	but	but	CCONJ
gs-894	18	14	hiv	hiv	PROPN
gs-894	18	15	and	and	CCONJ
gs-894	18	16	art	art	NOUN
gs-894	18	17	are	be	AUX
gs-894	18	18	adding	add	VERB
gs-894	18	19	additional	additional	ADJ
gs-894	18	20	risk	risk	NOUN
gs-894	18	21	factors	factor	NOUN
gs-894	18	22	.	.	PUNCT
gs-894	19	1	many	many	ADJ
gs-894	19	2	factors	factor	NOUN
gs-894	19	3	influence	influence	VERB
gs-894	19	4	the	the	DET
gs-894	19	5	development	development	NOUN
gs-894	19	6	of	of	ADP
gs-894	19	7	hyperglycemia	hyperglycemia	NOUN
gs-894	19	8	and	and	CCONJ
gs-894	19	9	t2d	t2d	NOUN
gs-894	19	10	during	during	ADP
gs-894	19	11	hiv	hiv	PROPN
gs-894	19	12	infection	infection	NOUN
gs-894	19	13	,	,	PUNCT
gs-894	19	14	including	include	VERB
gs-894	19	15	the	the	DET
gs-894	19	16	duration	duration	NOUN
gs-894	19	17	of	of	ADP
gs-894	19	18	the	the	DET
gs-894	19	19	infection	infection	NOUN
gs-894	19	20	,	,	PUNCT
gs-894	19	21	systematic	systematic	ADJ
gs-894	19	22	inflammation	inflammation	NOUN
gs-894	19	23	,	,	PUNCT
gs-894	19	24	the	the	DET
gs-894	19	25	degree	degree	NOUN
gs-894	19	26	of	of	ADP
gs-894	19	27	immunosuppression	immunosuppression	NOUN
gs-894	19	28	,	,	PUNCT
gs-894	19	29	arv	arv	NOUN
gs-894	19	30	(	(	PUNCT
gs-894	19	31	antiretroviral	antiretroviral	ADJ
gs-894	19	32	)	)	PUNCT
gs-894	19	33	medications	medication	NOUN
gs-894	19	34	,	,	PUNCT
gs-894	19	35	length	length	NOUN
gs-894	19	36	of	of	ADP
gs-894	19	37	art	art	NOUN
gs-894	19	38	and	and	CCONJ
gs-894	19	39	coinfections	coinfection	NOUN
gs-894	19	40	7	7	NUM
gs-894	19	41	-	-	SYM
gs-894	19	42	15	15	NUM
gs-894	19	43	.	.	PUNCT
gs-894	20	1	based	base	VERB
gs-894	20	2	on	on	ADP
gs-894	20	3	studies	study	NOUN
gs-894	20	4	the	the	DET
gs-894	20	5	prevalence	prevalence	NOUN
gs-894	20	6	of	of	ADP
gs-894	20	7	t2d	t2d	NOUN
gs-894	20	8	ranges	range	VERB
gs-894	20	9	from	from	ADP
gs-894	20	10	2	2	NUM
gs-894	20	11	%	%	NOUN
gs-894	20	12	to	to	PART
gs-894	20	13	14	14	NUM
gs-894	20	14	%	%	NOUN
gs-894	20	15	1	1	NUM
gs-894	20	16	.	.	PUNCT
gs-894	21	1	after	after	SCONJ
gs-894	21	2	art	art	NOUN
gs-894	21	3	has	have	AUX
gs-894	21	4	appeared	appear	VERB
gs-894	21	5	the	the	DET
gs-894	21	6	number	number	NOUN
gs-894	21	7	of	of	ADP
gs-894	21	8	metabolic	metabolic	NOUN
gs-894	21	9	complications	complication	NOUN
gs-894	21	10	during	during	ADP
gs-894	21	11	hiv	hiv	PROPN
gs-894	21	12	has	have	VERB
gs-894	21	13	increased6	increased6	PROPN
gs-894	21	14	,	,	PUNCT
gs-894	21	15	16	16	NUM
gs-894	21	16	-	-	SYM
gs-894	21	17	21	21	NUM
gs-894	21	18	.	.	PUNCT
gs-894	22	1	the	the	DET
gs-894	22	2	researchers	researcher	NOUN
gs-894	22	3	thought	think	VERB
gs-894	22	4	,	,	PUNCT
gs-894	22	5	that	that	SCONJ
gs-894	22	6	metabolic	metabolic	NOUN
gs-894	22	7	complications	complication	NOUN
gs-894	22	8	were	be	AUX
gs-894	22	9	caused	cause	VERB
gs-894	22	10	by	by	ADP
gs-894	22	11	nucleoside	nucleoside	ADV
gs-894	22	12	reverse	reverse	ADJ
gs-894	22	13	transcriptase	transcriptase	NOUN
gs-894	22	14	inhibitors	inhibitor	NOUN
gs-894	22	15	(	(	PUNCT
gs-894	22	16	nrti	nrti	NOUN
gs-894	22	17	)	)	PUNCT
gs-894	22	18	,	,	PUNCT
gs-894	22	19	because	because	SCONJ
gs-894	22	20	of	of	ADP
gs-894	22	21	mitochondrial	mitochondrial	ADJ
gs-894	22	22	toxicities	toxicity	NOUN
gs-894	22	23	.	.	PUNCT
gs-894	23	1	other	other	ADJ
gs-894	23	2	studies	study	NOUN
gs-894	23	3	connected	connect	VERB
gs-894	23	4	metabolic	metabolic	NOUN
gs-894	23	5	complications	complication	NOUN
gs-894	23	6	to	to	PART
gs-894	23	7	protease	protease	VERB
gs-894	23	8	inhibitors	inhibitor	NOUN
gs-894	23	9	(	(	PUNCT
gs-894	23	10	pi	pi	NOUN
gs-894	23	11	)	)	PUNCT
gs-894	23	12	.	.	PUNCT
gs-894	24	1	at	at	ADP
gs-894	24	2	the	the	DET
gs-894	24	3	end	end	NOUN
gs-894	24	4	researches	research	NOUN
gs-894	24	5	suggested	suggest	VERB
gs-894	24	6	,	,	PUNCT
gs-894	24	7	that	that	SCONJ
gs-894	24	8	pis	pis	NOUN
gs-894	24	9	and	and	CCONJ
gs-894	24	10	nrtis	nrtis	PROPN
gs-894	24	11	have	have	VERB
gs-894	24	12	overlapping	overlap	VERB
gs-894	24	13	effect	effect	NOUN
gs-894	24	14	and	and	CCONJ
gs-894	24	15	they	they	PRON
gs-894	24	16	can	can	AUX
gs-894	24	17	induce	induce	VERB
gs-894	24	18	insulin	insulin	NOUN
gs-894	24	19	resistance	resistance	NOUN
gs-894	24	20	(	(	PUNCT
gs-894	24	21	ir	ir	NOUN
gs-894	24	22	)	)	PUNCT
gs-894	24	23	and	and	CCONJ
gs-894	24	24	diabetes	diabetes	NOUN
gs-894	24	25	8	8	NUM
gs-894	24	26	,	,	PUNCT
gs-894	24	27	12	12	NUM
gs-894	24	28	,	,	PUNCT
gs-894	24	29	18	18	NUM
gs-894	24	30	.	.	PUNCT
gs-894	24	31	old	old	ADJ
gs-894	24	32	age	age	NOUN
gs-894	24	33	,	,	PUNCT
gs-894	24	34	weight	weight	NOUN
gs-894	24	35	gain	gain	NOUN
gs-894	24	36	,	,	PUNCT
gs-894	24	37	family	family	NOUN
gs-894	24	38	history	history	NOUN
gs-894	24	39	of	of	ADP
gs-894	24	40	diabetes	diabetes	NOUN
gs-894	24	41	are	be	AUX
gs-894	24	42	risk	risk	NOUN
gs-894	24	43	factors	factor	NOUN
gs-894	24	44	for	for	ADP
gs-894	24	45	development	development	NOUN
gs-894	24	46	of	of	ADP
gs-894	24	47	diabetes	diabetes	NOUN
gs-894	24	48	during	during	ADP
gs-894	24	49	pi	pi	NOUN
gs-894	24	50	treatment	treatment	NOUN
gs-894	24	51	11	11	NUM
gs-894	24	52	.	.	PUNCT
gs-894	25	1	insulin	insulin	NOUN
gs-894	25	2	resistance	resistance	NOUN
gs-894	25	3	during	during	ADP
gs-894	25	4	pi	pi	NOUN
gs-894	25	5	treatment	treatment	NOUN
gs-894	25	6	is	be	AUX
gs-894	25	7	increased	increase	VERB
gs-894	25	8	via	via	ADP
gs-894	25	9	glut4	glut4	PROPN
gs-894	25	10	dependent	dependent	ADJ
gs-894	25	11	8	8	NUM
gs-894	25	12	,	,	PUNCT
gs-894	25	13	11	11	NUM
gs-894	25	14	and	and	CCONJ
gs-894	25	15	independent	independent	ADJ
gs-894	25	16	mechanisms	mechanism	NOUN
gs-894	25	17	8	8	NUM
gs-894	25	18	,	,	PUNCT
gs-894	25	19	12	12	NUM
gs-894	25	20	.	.	PUNCT
gs-894	26	1	pis	pis	AUX
gs-894	26	2	interfere	interfere	VERB
gs-894	26	3	glut4	glut4	NOUN
gs-894	26	4	translocation	translocation	NOUN
gs-894	26	5	from	from	ADP
gs-894	26	6	the	the	DET
gs-894	26	7	cytosol	cytosol	NOUN
gs-894	26	8	of	of	ADP
gs-894	26	9	the	the	DET
gs-894	26	10	cell	cell	NOUN
gs-894	26	11	to	to	ADP
gs-894	26	12	the	the	DET
gs-894	26	13	cell	cell	NOUN
gs-894	26	14	’s	’s	PART
gs-894	26	15	surface	surface	NOUN
gs-894	26	16	.	.	PUNCT
gs-894	27	1	also	also	ADV
gs-894	27	2	,	,	PUNCT
gs-894	27	3	they	they	PRON
gs-894	27	4	altert	altert	VERB
gs-894	27	5	adipogenic	adipogenic	ADJ
gs-894	27	6	proteins	protein	NOUN
gs-894	27	7	and	and	CCONJ
gs-894	27	8	inhibit	inhibit	VERB
gs-894	27	9	adipocyte	adipocyte	ADJ
gs-894	27	10	differentiation	differentiation	NOUN
gs-894	27	11	8	8	NUM
gs-894	27	12	.	.	PUNCT
gs-894	28	1	pancreatic	pancreatic	ADJ
gs-894	28	2	beta	beta	NOUN
gs-894	28	3	-	-	PUNCT
gs-894	28	4	cell	cell	NOUN
gs-894	28	5	lipotoxicity	lipotoxicity	NOUN
gs-894	28	6	and	and	CCONJ
gs-894	28	7	lipodystrophy	lipodystrophy	NOUN
gs-894	28	8	during	during	ADP
gs-894	28	9	art	art	NOUN
gs-894	28	10	,	,	PUNCT
gs-894	28	11	might	might	AUX
gs-894	28	12	be	be	AUX
gs-894	28	13	reason	reason	NOUN
gs-894	28	14	of	of	ADP
gs-894	28	15	glucose	glucose	NOUN
gs-894	28	16	level	level	NOUN
gs-894	28	17	elevation	elevation	NOUN
gs-894	28	18	.	.	PUNCT
gs-894	29	1	beta	beta	NOUN
gs-894	29	2	-	-	PUNCT
gs-894	29	3	cell	cell	NOUN
gs-894	29	4	function	function	NOUN
gs-894	29	5	and	and	CCONJ
gs-894	29	6	insulin	insulin	NOUN
gs-894	29	7	secretion	secretion	NOUN
gs-894	29	8	is	be	AUX
gs-894	29	9	decreased	decrease	VERB
gs-894	29	10	by	by	ADP
gs-894	29	11	25%–50	25%–50	NUM
gs-894	29	12	%	%	NOUN
gs-894	29	13	after	after	ADP
gs-894	29	14	pi	pi	NOUN
gs-894	29	15	treatment	treatment	NOUN
gs-894	29	16	initiation8	initiation8	NOUN
gs-894	29	17	.	.	PUNCT
gs-894	30	1	when	when	SCONJ
gs-894	30	2	pis	pis	X
gs-894	30	3	are	be	AUX
gs-894	30	4	discontinued	discontinue	VERB
gs-894	30	5	hyperglycemia	hyperglycemia	NOUN
gs-894	30	6	resolves	resolve	NOUN
gs-894	30	7	11	11	NUM
gs-894	30	8	.	.	PUNCT
gs-894	31	1	cvd	cvd	PROPN
gs-894	31	2	(	(	PUNCT
gs-894	31	3	cardiovascular	cardiovascular	ADJ
gs-894	31	4	disease	disease	NOUN
gs-894	31	5	)	)	PUNCT
gs-894	31	6	,	,	PUNCT
gs-894	31	7	ckd	ckd	PROPN
gs-894	31	8	(	(	PUNCT
gs-894	31	9	chronic	chronic	ADJ
gs-894	31	10	kidney	kidney	NOUN
gs-894	31	11	disease	disease	NOUN
gs-894	31	12	)	)	PUNCT
gs-894	31	13	and	and	CCONJ
gs-894	31	14	metabolic	metabolic	NOUN
gs-894	31	15	disturbance	disturbance	NOUN
gs-894	31	16	have	have	AUX
gs-894	31	17	been	be	AUX
gs-894	31	18	linked	link	VERB
gs-894	31	19	to	to	ADP
gs-894	31	20	hiv	hiv	PROPN
gs-894	31	21	and	and	CCONJ
gs-894	31	22	arv	arv	PROPN
gs-894	31	23	medications	medication	NOUN
gs-894	31	24	5,6,10	5,6,10	PROPN
gs-894	31	25	.	.	PUNCT
gs-894	32	1	in	in	ADP
gs-894	32	2	the	the	DET
gs-894	32	3	general	general	ADJ
gs-894	32	4	population	population	NOUN
gs-894	32	5	the	the	DET
gs-894	32	6	framingham	framingham	PROPN
gs-894	32	7	risk	risk	NOUN
gs-894	32	8	score	score	NOUN
gs-894	32	9	(	(	PUNCT
gs-894	32	10	frs	frs	PROPN
gs-894	32	11	)	)	PUNCT
gs-894	32	12	is	be	AUX
gs-894	32	13	a	a	DET
gs-894	32	14	widely	widely	ADV
gs-894	32	15	used	use	VERB
gs-894	32	16	tool	tool	NOUN
gs-894	32	17	to	to	PART
gs-894	32	18	assess	assess	VERB
gs-894	32	19	cardiovascular	cardiovascular	ADJ
gs-894	32	20	risk	risk	NOUN
gs-894	32	21	.	.	PUNCT
gs-894	33	1	it	it	PRON
gs-894	33	2	is	be	AUX
gs-894	33	3	used	use	VERB
gs-894	33	4	to	to	PART
gs-894	33	5	estimate	estimate	VERB
gs-894	33	6	10	10	NUM
gs-894	33	7	years	year	NOUN
gs-894	33	8	,	,	PUNCT
gs-894	33	9	cvd	cvd	PROPN
gs-894	33	10	risk	risk	VERB
gs-894	33	11	to	to	ADP
gs-894	33	12	the	the	DET
gs-894	33	13	individual	individual	NOUN
gs-894	33	14	.	.	PUNCT
gs-894	34	1	although	although	SCONJ
gs-894	34	2	its	its	PRON
gs-894	34	3	applicability	applicability	NOUN
gs-894	34	4	to	to	ADP
gs-894	34	5	hiv	hiv	PROPN
gs-894	34	6	patients	patient	NOUN
gs-894	34	7	is	be	AUX
gs-894	34	8	debatable	debatable	ADJ
gs-894	34	9	.	.	PUNCT
gs-894	35	1	unlike	unlike	ADP
gs-894	35	2	metabolic	metabolic	NOUN
gs-894	35	3	syndrome	syndrome	PROPN
gs-894	35	4	frs	frs	PROPN
gs-894	35	5	is	be	AUX
gs-894	35	6	age	age	NOUN
gs-894	35	7	dependent	dependent	ADJ
gs-894	35	8	and	and	CCONJ
gs-894	35	9	takes	take	VERB
gs-894	35	10	in	in	ADP
gs-894	35	11	account	account	NOUN
gs-894	35	12	cigarette	cigarette	NOUN
gs-894	35	13	smoking	smoking	NOUN
gs-894	35	14	,	,	PUNCT
gs-894	35	15	ldl	ldl	NOUN
gs-894	35	16	and	and	CCONJ
gs-894	35	17	total	total	ADJ
gs-894	35	18	cholesterol	cholesterol	NOUN
gs-894	35	19	concentrations	concentration	NOUN
gs-894	35	20	.	.	PUNCT
gs-894	36	1	frs	frs	PROPN
gs-894	36	2	divides	divide	VERB
gs-894	36	3	individuals	individual	NOUN
gs-894	36	4	as	as	ADP
gs-894	36	5	low	low	ADJ
gs-894	36	6	risk	risk	NOUN
gs-894	36	7	<	<	X
gs-894	36	8	10	10	NUM
gs-894	36	9	%	%	NOUN
gs-894	36	10	,	,	PUNCT
gs-894	36	11	moderate	moderate	ADJ
gs-894	36	12	risk	risk	NOUN
gs-894	36	13	10	10	NUM
gs-894	36	14	-	-	SYM
gs-894	36	15	20	20	NUM
gs-894	36	16	%	%	NOUN
gs-894	36	17	and	and	CCONJ
gs-894	36	18	high	high	ADJ
gs-894	36	19	risk	risk	NOUN
gs-894	36	20	>	>	NOUN
gs-894	36	21	20	20	NUM
gs-894	36	22	%	%	NOUN
gs-894	36	23	of	of	ADP
gs-894	36	24	cvd22	cvd22	PROPN
gs-894	36	25	,	,	PUNCT
gs-894	36	26	23	23	NUM
gs-894	36	27	.	.	PUNCT
gs-894	37	1	frs	frs	PROPN
gs-894	37	2	estimates	estimate	VERB
gs-894	37	3	that	that	SCONJ
gs-894	37	4	1/3	1/3	NUM
gs-894	37	5	-	-	SYM
gs-894	37	6	1/4	1/4	NUM
gs-894	37	7	of	of	ADP
gs-894	37	8	hiv	hiv	PROPN
gs-894	37	9	infected	infect	VERB
gs-894	37	10	adults	adult	NOUN
gs-894	37	11	are	be	AUX
gs-894	37	12	risk	risk	NOUN
gs-894	37	13	of	of	ADP
gs-894	37	14	cvd	cvd	PROPN
gs-894	37	15	,	,	PUNCT
gs-894	37	16	but	but	CCONJ
gs-894	37	17	some	some	DET
gs-894	37	18	authros	authro	NOUN
gs-894	37	19	are	be	AUX
gs-894	37	20	thinking	think	VERB
gs-894	37	21	,	,	PUNCT
gs-894	37	22	that	that	SCONJ
gs-894	37	23	it	it	PRON
gs-894	37	24	is	be	AUX
gs-894	37	25	underestimated22	underestimated22	NOUN
gs-894	37	26	-	-	PUNCT
gs-894	37	27	24	24	NUM
gs-894	37	28	.	.	PUNCT
gs-894	38	1	hyperglycemia	hyperglycemia	NOUN
gs-894	38	2	is	be	AUX
gs-894	38	3	known	know	VERB
gs-894	38	4	to	to	PART
gs-894	38	5	be	be	AUX
gs-894	38	6	a	a	DET
gs-894	38	7	risk	risk	NOUN
gs-894	38	8	factor	factor	NOUN
gs-894	38	9	of	of	ADP
gs-894	38	10	cvd	cvd	PROPN
gs-894	38	11	.	.	PUNCT
gs-894	39	1	poor	poor	ADJ
gs-894	39	2	glycemic	glycemic	ADJ
gs-894	39	3	control	control	NOUN
gs-894	39	4	is	be	AUX
gs-894	39	5	connected	connect	VERB
gs-894	39	6	to	to	AUX
gs-894	39	7	microvascular	microvascular	VERB
gs-894	39	8	and	and	CCONJ
gs-894	39	9	macrovascular	macrovascular	ADJ
gs-894	39	10	disease25	disease25	NOUN
gs-894	39	11	.	.	PUNCT
gs-894	40	1	stettler	stettler	PROPN
gs-894	40	2	et	et	PROPN
gs-894	40	3	al	al	PROPN
gs-894	40	4	.	.	PUNCT
gs-894	41	1	georgian	georgian	PROPN
gs-894	41	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-894	41	3	მეცნიერები	მეცნიერები	VERB
gs-894	41	4	4(02	4(02	NUM
gs-894	41	5	)	)	PUNCT
gs-894	41	6	,	,	PUNCT
gs-894	41	7	2022	2022	NUM
gs-894	41	8	195	195	NUM
gs-894	41	9	conducted	conduct	VERB
gs-894	41	10	a	a	DET
gs-894	41	11	study	study	NOUN
gs-894	41	12	in	in	ADP
gs-894	41	13	2006	2006	NUM
gs-894	41	14	and	and	CCONJ
gs-894	41	15	showed	show	VERB
gs-894	41	16	,	,	PUNCT
gs-894	41	17	that	that	SCONJ
gs-894	41	18	the	the	DET
gs-894	41	19	risk	risk	NOUN
gs-894	41	20	of	of	ADP
gs-894	41	21	macrovascular	macrovascular	ADJ
gs-894	41	22	disease	disease	NOUN
gs-894	41	23	was	be	AUX
gs-894	41	24	significantly	significantly	ADV
gs-894	41	25	decreased	decrease	VERB
gs-894	41	26	by	by	ADP
gs-894	41	27	improving	improve	VERB
gs-894	41	28	glycemic	glycemic	ADJ
gs-894	41	29	control26	control26	NOUN
gs-894	41	30	.	.	PUNCT
gs-894	42	1	the	the	DET
gs-894	42	2	mechanism	mechanism	NOUN
gs-894	42	3	of	of	ADP
gs-894	42	4	vascular	vascular	ADJ
gs-894	42	5	damage	damage	NOUN
gs-894	42	6	during	during	ADP
gs-894	42	7	hyperglycemia	hyperglycemia	NOUN
gs-894	42	8	is	be	AUX
gs-894	42	9	unknown	unknown	ADJ
gs-894	42	10	,	,	PUNCT
gs-894	42	11	but	but	CCONJ
gs-894	42	12	scientists	scientist	NOUN
gs-894	42	13	support	support	VERB
gs-894	42	14	the	the	DET
gs-894	42	15	idea	idea	NOUN
gs-894	42	16	,	,	PUNCT
gs-894	42	17	that	that	SCONJ
gs-894	42	18	it	it	PRON
gs-894	42	19	is	be	AUX
gs-894	42	20	caused	cause	VERB
gs-894	42	21	by	by	ADP
gs-894	42	22	oxidative	oxidative	ADJ
gs-894	42	23	stress	stress	NOUN
gs-894	42	24	.	.	PUNCT
gs-894	43	1	oxidative	oxidative	ADJ
gs-894	43	2	stress	stress	NOUN
gs-894	43	3	is	be	AUX
gs-894	43	4	the	the	DET
gs-894	43	5	reason	reason	NOUN
gs-894	43	6	for	for	ADP
gs-894	43	7	micro	micro	ADJ
gs-894	43	8	and	and	CCONJ
gs-894	43	9	macrovascular	macrovascular	ADJ
gs-894	43	10	complications	complication	NOUN
gs-894	43	11	during	during	ADP
gs-894	43	12	t2d25	t2d25	PROPN
gs-894	43	13	.	.	PROPN
gs-894	43	14	gerich	gerich	PROPN
gs-894	43	15	et	et	PROPN
gs-894	43	16	al	al	PROPN
gs-894	43	17	.	.	PROPN
gs-894	43	18	suggest	suggest	VERB
gs-894	43	19	that	that	SCONJ
gs-894	43	20	inflammation	inflammation	NOUN
gs-894	43	21	,	,	PUNCT
gs-894	43	22	vasoconstriction	vasoconstriction	NOUN
gs-894	43	23	and	and	CCONJ
gs-894	43	24	thrombosis	thrombosis	NOUN
gs-894	43	25	are	be	AUX
gs-894	43	26	caused	cause	VERB
gs-894	43	27	by	by	ADP
gs-894	43	28	oxidative	oxidative	ADJ
gs-894	43	29	stress	stress	NOUN
gs-894	43	30	and	and	CCONJ
gs-894	43	31	protein	protein	NOUN
gs-894	43	32	kinase	kinase	NOUN
gs-894	43	33	c	c	PROPN
gs-894	43	34	activation	activation	NOUN
gs-894	43	35	,	,	PUNCT
gs-894	43	36	which	which	PRON
gs-894	43	37	are	be	AUX
gs-894	43	38	induced	induce	VERB
gs-894	43	39	by	by	ADP
gs-894	43	40	hyperglycemia27	hyperglycemia27	NOUN
gs-894	43	41	.	.	PUNCT
gs-894	44	1	one	one	NUM
gs-894	44	2	of	of	ADP
gs-894	44	3	the	the	DET
gs-894	44	4	most	most	ADV
gs-894	44	5	frequent	frequent	ADJ
gs-894	44	6	complication	complication	NOUN
gs-894	44	7	of	of	ADP
gs-894	44	8	hiv	hiv	PROPN
gs-894	44	9	is	be	AUX
gs-894	44	10	a	a	DET
gs-894	44	11	ckd	ckd	NOUN
gs-894	44	12	.	.	PUNCT
gs-894	45	1	it	it	PRON
gs-894	45	2	ranges	range	VERB
gs-894	45	3	from	from	ADP
gs-894	45	4	3.5	3.5	NUM
gs-894	45	5	to	to	ADP
gs-894	45	6	48.5	48.5	NUM
gs-894	45	7	%	%	NOUN
gs-894	45	8	.	.	PUNCT
gs-894	46	1	hiv	hiv	PROPN
gs-894	46	2	-	-	PUNCT
gs-894	46	3	associated	associate	VERB
gs-894	46	4	nephropathy	nephropathy	NOUN
gs-894	46	5	(	(	PUNCT
gs-894	46	6	hivan	hivan	NOUN
gs-894	46	7	)	)	PUNCT
gs-894	46	8	is	be	AUX
gs-894	46	9	more	more	ADV
gs-894	46	10	common	common	ADJ
gs-894	46	11	in	in	ADP
gs-894	46	12	young	young	ADJ
gs-894	46	13	african	african	ADJ
gs-894	46	14	adults	adult	NOUN
gs-894	46	15	,	,	PUNCT
gs-894	46	16	while	while	SCONJ
gs-894	46	17	hiv	hiv	NOUN
gs-894	46	18	-	-	PUNCT
gs-894	46	19	immune	immune	ADJ
gs-894	46	20	complex	complex	ADJ
gs-894	46	21	disease	disease	NOUN
gs-894	46	22	(	(	PUNCT
gs-894	46	23	hiv	hiv	PROPN
gs-894	46	24	-	-	PUNCT
gs-894	46	25	icd	icd	PROPN
gs-894	46	26	)	)	PUNCT
gs-894	46	27	is	be	AUX
gs-894	46	28	more	more	ADV
gs-894	46	29	common	common	ADJ
gs-894	46	30	in	in	ADP
gs-894	46	31	europeans28	europeans28	NOUN
gs-894	46	32	.	.	PUNCT
gs-894	47	1	on	on	ADP
gs-894	47	2	the	the	DET
gs-894	47	3	other	other	ADJ
gs-894	47	4	hand	hand	NOUN
gs-894	47	5	hyperglycemia	hyperglycemia	NOUN
gs-894	47	6	and	and	CCONJ
gs-894	47	7	diabetes	diabetes	NOUN
gs-894	47	8	mellitus	mellitus	NOUN
gs-894	47	9	is	be	AUX
gs-894	47	10	a	a	DET
gs-894	47	11	main	main	ADJ
gs-894	47	12	cause	cause	NOUN
gs-894	47	13	of	of	ADP
gs-894	47	14	ckd	ckd	PROPN
gs-894	47	15	,	,	PUNCT
gs-894	47	16	which	which	PRON
gs-894	47	17	leads	lead	VERB
gs-894	47	18	to	to	ADP
gs-894	47	19	kidney	kidney	NOUN
gs-894	47	20	failure	failure	NOUN
gs-894	47	21	.	.	PUNCT
gs-894	48	1	studies	study	NOUN
gs-894	48	2	have	have	AUX
gs-894	48	3	shown	show	VERB
gs-894	48	4	,	,	PUNCT
gs-894	48	5	that	that	SCONJ
gs-894	48	6	one	one	NUM
gs-894	48	7	third	third	NOUN
gs-894	48	8	of	of	ADP
gs-894	48	9	ckd	ckd	PROPN
gs-894	48	10	patients	patient	NOUN
gs-894	48	11	have	have	VERB
gs-894	48	12	diabetes	diabetes	NOUN
gs-894	48	13	,	,	PUNCT
gs-894	48	14	predominantly	predominantly	ADV
gs-894	48	15	t2d29	t2d29	ADV
gs-894	48	16	.	.	PUNCT
gs-894	49	1	since	since	SCONJ
gs-894	49	2	20th	20th	ADJ
gs-894	49	3	century	century	NOUN
gs-894	49	4	,	,	PUNCT
gs-894	49	5	researchers	researcher	NOUN
gs-894	49	6	have	have	AUX
gs-894	49	7	tried	try	VERB
gs-894	49	8	to	to	PART
gs-894	49	9	find	find	VERB
gs-894	49	10	a	a	DET
gs-894	49	11	link	link	NOUN
gs-894	49	12	between	between	ADP
gs-894	49	13	t2d	t2d	NOUN
gs-894	49	14	and	and	CCONJ
gs-894	49	15	tuberculosis	tuberculosis	NOUN
gs-894	49	16	(	(	PUNCT
gs-894	49	17	tb	tb	NOUN
gs-894	49	18	)	)	PUNCT
gs-894	49	19	.	.	PUNCT
gs-894	50	1	they	they	PRON
gs-894	50	2	were	be	AUX
gs-894	50	3	unable	unable	ADJ
gs-894	50	4	to	to	PART
gs-894	50	5	distinguish	distinguish	VERB
gs-894	50	6	whether	whether	SCONJ
gs-894	50	7	t2d	t2d	NOUN
gs-894	50	8	cause	cause	VERB
gs-894	50	9	tb	tb	NOUN
gs-894	50	10	or	or	CCONJ
gs-894	50	11	vice	vice	NOUN
gs-894	50	12	versa	versa	ADV
gs-894	50	13	.	.	PUNCT
gs-894	51	1	some	some	DET
gs-894	51	2	experts	expert	NOUN
gs-894	51	3	were	be	AUX
gs-894	51	4	discussing	discuss	VERB
gs-894	51	5	merging	merge	VERB
gs-894	51	6	epidemics	epidemic	NOUN
gs-894	51	7	of	of	ADP
gs-894	51	8	tb	tb	NOUN
gs-894	51	9	and	and	CCONJ
gs-894	51	10	t2d	t2d	NUM
gs-894	51	11	30	30	NUM
gs-894	51	12	.	.	PUNCT
gs-894	52	1	people	people	NOUN
gs-894	52	2	with	with	ADP
gs-894	52	3	diabetes	diabetes	NOUN
gs-894	52	4	and	and	CCONJ
gs-894	52	5	hyperglycemia	hyperglycemia	NOUN
gs-894	52	6	are	be	AUX
gs-894	52	7	more	more	ADV
gs-894	52	8	likely	likely	ADJ
gs-894	52	9	to	to	PART
gs-894	52	10	develop	develop	VERB
gs-894	52	11	tb	tb	ADP
gs-894	52	12	,	,	PUNCT
gs-894	52	13	compared	compare	VERB
gs-894	52	14	to	to	ADP
gs-894	52	15	non	non	ADJ
gs-894	52	16	-	-	ADJ
gs-894	52	17	diabetic	diabetic	ADJ
gs-894	52	18	cohort	cohort	NOUN
gs-894	52	19	,	,	PUNCT
gs-894	52	20	due	due	ADP
gs-894	52	21	to	to	ADP
gs-894	52	22	increased	increase	VERB
gs-894	52	23	susceptibility	susceptibility	NOUN
gs-894	52	24	to	to	ADP
gs-894	52	25	infections30	infections30	NOUN
gs-894	52	26	-	-	PUNCT
gs-894	52	27	33	33	NUM
gs-894	52	28	.	.	PUNCT
gs-894	53	1	they	they	PRON
gs-894	53	2	have	have	VERB
gs-894	53	3	2.44	2.44	NUM
gs-894	53	4	to	to	PART
gs-894	53	5	8.33	8.33	NUM
gs-894	53	6	folds	fold	NOUN
gs-894	53	7	increased	increase	VERB
gs-894	53	8	risk	risk	NOUN
gs-894	53	9	of	of	ADP
gs-894	53	10	tb	tb	NOUN
gs-894	53	11	compared	compare	VERB
gs-894	53	12	to	to	ADP
gs-894	53	13	people	people	NOUN
gs-894	53	14	without	without	ADP
gs-894	53	15	diabetes	diabetes	NOUN
gs-894	53	16	mellitus	mellitus	NOUN
gs-894	53	17	(	(	PUNCT
gs-894	53	18	dm)32	dm)32	PROPN
gs-894	53	19	.	.	PUNCT
gs-894	54	1	according	accord	VERB
gs-894	54	2	to	to	ADP
gs-894	54	3	several	several	ADJ
gs-894	54	4	studies	study	NOUN
gs-894	54	5	,	,	PUNCT
gs-894	54	6	people	people	NOUN
gs-894	54	7	with	with	ADP
gs-894	54	8	hyperglycemia	hyperglycemia	NOUN
gs-894	54	9	are	be	AUX
gs-894	54	10	more	more	ADV
gs-894	54	11	prone	prone	ADJ
gs-894	54	12	to	to	PART
gs-894	54	13	acquire	acquire	VERB
gs-894	54	14	multiresistant	multiresistant	ADJ
gs-894	54	15	tb	tb	NOUN
gs-894	54	16	.	.	PUNCT
gs-894	55	1	the	the	DET
gs-894	55	2	risk	risk	NOUN
gs-894	55	3	of	of	ADP
gs-894	55	4	complications	complication	NOUN
gs-894	55	5	,	,	PUNCT
gs-894	55	6	such	such	ADJ
gs-894	55	7	as	as	ADP
gs-894	55	8	treatment	treatment	NOUN
gs-894	55	9	failures	failure	NOUN
gs-894	55	10	and	and	CCONJ
gs-894	55	11	death	death	NOUN
gs-894	55	12	are	be	AUX
gs-894	55	13	higher	high	ADJ
gs-894	55	14	in	in	ADP
gs-894	55	15	people	people	NOUN
gs-894	55	16	with	with	ADP
gs-894	55	17	diabetes	diabetes	NOUN
gs-894	55	18	mellitus	mellitus	NOUN
gs-894	55	19	.	.	PUNCT
gs-894	56	1	furthermore	furthermore	ADV
gs-894	56	2	,	,	PUNCT
gs-894	56	3	treatment	treatment	NOUN
gs-894	56	4	of	of	ADP
gs-894	56	5	tb	tb	NOUN
gs-894	56	6	,	,	PUNCT
gs-894	56	7	might	might	AUX
gs-894	56	8	affect	affect	VERB
gs-894	56	9	glycemic	glycemic	ADJ
gs-894	56	10	control	control	NOUN
gs-894	56	11	negatively30	negatively30	NOUN
gs-894	56	12	-	-	PUNCT
gs-894	56	13	33	33	NUM
gs-894	56	14	.	.	PUNCT
gs-894	57	1	patients	patient	NOUN
gs-894	57	2	should	should	AUX
gs-894	57	3	be	be	AUX
gs-894	57	4	checked	check	VERB
gs-894	57	5	annually	annually	ADV
gs-894	57	6	,	,	PUNCT
gs-894	57	7	because	because	SCONJ
gs-894	57	8	of	of	ADP
gs-894	57	9	higher	high	ADJ
gs-894	57	10	prevalence	prevalence	NOUN
gs-894	57	11	of	of	ADP
gs-894	57	12	hyperglycemia	hyperglycemia	NOUN
gs-894	57	13	and	and	CCONJ
gs-894	57	14	t2d	t2d	NOUN
gs-894	57	15	during	during	ADP
gs-894	57	16	hiv	hiv	PROPN
gs-894	57	17	.	.	PUNCT
gs-894	58	1	prevention	prevention	NOUN
gs-894	58	2	or	or	CCONJ
gs-894	58	3	early	early	ADJ
gs-894	58	4	detection	detection	NOUN
gs-894	58	5	of	of	ADP
gs-894	58	6	t2d	t2d	NOUN
gs-894	58	7	and	and	CCONJ
gs-894	58	8	timely	timely	ADJ
gs-894	58	9	management	management	NOUN
gs-894	58	10	of	of	ADP
gs-894	58	11	metabolic	metabolic	NOUN
gs-894	58	12	disturbance	disturbance	NOUN
gs-894	58	13	,	,	PUNCT
gs-894	58	14	reduce	reduce	VERB
gs-894	58	15	risk	risk	NOUN
gs-894	58	16	of	of	ADP
gs-894	58	17	morbidity	morbidity	NOUN
gs-894	58	18	and	and	CCONJ
gs-894	58	19	mortality	mortality	NOUN
gs-894	58	20	during	during	ADP
gs-894	58	21	hiv	hiv	PROPN
gs-894	58	22	5	5	NUM
gs-894	58	23	,	,	PUNCT
gs-894	58	24	7	7	NUM
gs-894	58	25	,	,	PUNCT
gs-894	58	26	8	8	NUM
gs-894	58	27	,	,	PUNCT
gs-894	58	28	17	17	NUM
gs-894	58	29	,	,	PUNCT
gs-894	58	30	19	19	NUM
gs-894	58	31	,	,	PUNCT
gs-894	58	32	34	34	NUM
gs-894	58	33	,	,	PUNCT
gs-894	58	34	35	35	NUM
gs-894	58	35	.	.	PUNCT
gs-894	59	1	the	the	DET
gs-894	59	2	prevalence	prevalence	NOUN
gs-894	59	3	of	of	ADP
gs-894	59	4	t2d	t2d	NOUN
gs-894	59	5	in	in	ADP
gs-894	59	6	plwh	plwh	NOUN
gs-894	59	7	is	be	AUX
gs-894	59	8	unknown	unknown	ADJ
gs-894	59	9	in	in	ADP
gs-894	59	10	georgia	georgia	PROPN
gs-894	59	11	.	.	PUNCT
gs-894	60	1	the	the	DET
gs-894	60	2	aim	aim	NOUN
gs-894	60	3	of	of	ADP
gs-894	60	4	the	the	DET
gs-894	60	5	study	study	NOUN
gs-894	60	6	was	be	AUX
gs-894	60	7	to	to	PART
gs-894	60	8	calculate	calculate	VERB
gs-894	60	9	the	the	DET
gs-894	60	10	prevalence	prevalence	NOUN
gs-894	60	11	of	of	ADP
gs-894	60	12	t2d	t2d	NOUN
gs-894	60	13	among	among	ADP
gs-894	60	14	people	people	NOUN
gs-894	60	15	living	live	VERB
gs-894	60	16	with	with	ADP
gs-894	60	17	hiv	hiv	PROPN
gs-894	60	18	in	in	ADP
gs-894	60	19	georgia	georgia	PROPN
gs-894	60	20	and	and	CCONJ
gs-894	60	21	find	find	VERB
gs-894	60	22	the	the	DET
gs-894	60	23	association	association	NOUN
gs-894	60	24	between	between	ADP
gs-894	60	25	diabetes	diabete	NOUN
gs-894	60	26	and	and	CCONJ
gs-894	60	27	other	other	ADJ
gs-894	60	28	comorbidities	comorbiditie	NOUN
gs-894	60	29	to	to	PART
gs-894	60	30	fill	fill	VERB
gs-894	60	31	up	up	ADP
gs-894	60	32	knowledge	knowledge	NOUN
gs-894	60	33	gap	gap	NOUN
gs-894	60	34	.	.	PUNCT
gs-894	61	1	material	material	NOUN
gs-894	61	2	and	and	CCONJ
gs-894	61	3	methods	method	NOUN
gs-894	61	4	we	we	PRON
gs-894	61	5	have	have	AUX
gs-894	61	6	conducted	conduct	VERB
gs-894	61	7	a	a	DET
gs-894	61	8	prospective	prospective	ADJ
gs-894	61	9	cohort	cohort	NOUN
gs-894	61	10	study	study	NOUN
gs-894	61	11	among	among	ADP
gs-894	61	12	plwh	plwh	NOUN
gs-894	61	13	receiving	receive	VERB
gs-894	61	14	care	care	NOUN
gs-894	61	15	at	at	ADP
gs-894	61	16	the	the	DET
gs-894	61	17	infectious	infectious	ADJ
gs-894	61	18	diseases	disease	NOUN
gs-894	61	19	,	,	PUNCT
gs-894	61	20	aids	aid	NOUN
gs-894	61	21	and	and	CCONJ
gs-894	61	22	clinical	clinical	ADJ
gs-894	61	23	immunology	immunology	NOUN
gs-894	61	24	research	research	NOUN
gs-894	61	25	center	center	NOUN
gs-894	61	26	in	in	ADP
gs-894	61	27	tbilisi	tbilisi	PROPN
gs-894	61	28	,	,	PUNCT
gs-894	61	29	georgia	georgia	PROPN
gs-894	61	30	(	(	PUNCT
gs-894	61	31	idacirc	idacirc	PROPN
gs-894	61	32	)	)	PUNCT
gs-894	61	33	.	.	PUNCT
gs-894	62	1	the	the	DET
gs-894	62	2	study	study	NOUN
gs-894	62	3	included	include	VERB
gs-894	62	4	hiv	hiv	PROPN
gs-894	62	5	positive	positive	ADJ
gs-894	62	6	adults	adult	NOUN
gs-894	62	7	(	(	PUNCT
gs-894	62	8	age	age	NOUN
gs-894	62	9	≥	≥	NUM
gs-894	62	10	18	18	NUM
gs-894	62	11	years	year	NOUN
gs-894	62	12	)	)	PUNCT
gs-894	62	13	diagnosed	diagnose	VERB
gs-894	62	14	in	in	ADP
gs-894	62	15	2012	2012	NUM
gs-894	62	16	-	-	SYM
gs-894	62	17	2018	2018	NUM
gs-894	62	18	in	in	ADP
gs-894	62	19	idacirc	idacirc	NOUN
gs-894	62	20	.	.	PUNCT
gs-894	63	1	every	every	DET
gs-894	63	2	patient	patient	NOUN
gs-894	63	3	,	,	PUNCT
gs-894	63	4	who	who	PRON
gs-894	63	5	died	die	VERB
gs-894	63	6	or	or	CCONJ
gs-894	63	7	was	be	AUX
gs-894	63	8	lost	lose	VERB
gs-894	63	9	within	within	ADP
gs-894	63	10	6	6	NUM
gs-894	63	11	months	month	NOUN
gs-894	63	12	during	during	ADP
gs-894	63	13	follow	follow	NOUN
gs-894	63	14	-	-	PUNCT
gs-894	63	15	up	up	NOUN
gs-894	63	16	were	be	AUX
gs-894	63	17	excluded	exclude	VERB
gs-894	63	18	from	from	ADP
gs-894	63	19	statistical	statistical	ADJ
gs-894	63	20	analysis	analysis	NOUN
gs-894	63	21	.	.	PUNCT
gs-894	64	1	participants	participant	NOUN
gs-894	64	2	were	be	AUX
gs-894	64	3	followed	follow	VERB
gs-894	64	4	-	-	PUNCT
gs-894	64	5	up	up	NOUN
gs-894	64	6	from	from	ADP
gs-894	64	7	aids	aid	NOUN
gs-894	64	8	diagnosis	diagnosis	NOUN
gs-894	64	9	till	till	SCONJ
gs-894	64	10	the	the	DET
gs-894	64	11	1st	1st	NOUN
gs-894	64	12	of	of	ADP
gs-894	64	13	october	october	PROPN
gs-894	64	14	2021	2021	NUM
gs-894	64	15	.	.	PUNCT
gs-894	65	1	the	the	DET
gs-894	65	2	total	total	ADJ
gs-894	65	3	number	number	NOUN
gs-894	65	4	of	of	ADP
gs-894	65	5	the	the	DET
gs-894	65	6	study	study	NOUN
gs-894	65	7	cohort	cohort	NOUN
gs-894	65	8	was	be	AUX
gs-894	65	9	2914	2914	NUM
gs-894	65	10	.	.	PUNCT
gs-894	66	1	the	the	DET
gs-894	66	2	national	national	PROPN
gs-894	66	3	aids	aids	PROPN
gs-894	66	4	health	health	PROPN
gs-894	66	5	information	information	NOUN
gs-894	66	6	system	system	NOUN
gs-894	66	7	(	(	PUNCT
gs-894	66	8	aidshis	aidshis	NOUN
gs-894	66	9	)	)	PUNCT
gs-894	66	10	,	,	PUNCT
gs-894	66	11	a	a	DET
gs-894	66	12	secure	secure	ADJ
gs-894	66	13	web	web	NOUN
gs-894	66	14	-	-	PUNCT
gs-894	66	15	based	base	VERB
gs-894	66	16	database	database	NOUN
gs-894	66	17	that	that	PRON
gs-894	66	18	collects	collect	VERB
gs-894	66	19	data	datum	NOUN
gs-894	66	20	on	on	ADP
gs-894	66	21	all	all	PRON
gs-894	66	22	confirmed	confirm	VERB
gs-894	66	23	hiv	hiv	PROPN
gs-894	66	24	cases	case	NOUN
gs-894	66	25	,	,	PUNCT
gs-894	66	26	was	be	AUX
gs-894	66	27	used	use	VERB
gs-894	66	28	to	to	PART
gs-894	66	29	retrieve	retrieve	VERB
gs-894	66	30	all	all	DET
gs-894	66	31	data	datum	NOUN
gs-894	66	32	,	,	PUNCT
gs-894	66	33	including	include	VERB
gs-894	66	34	demographic	demographic	ADJ
gs-894	66	35	,	,	PUNCT
gs-894	66	36	clinical	clinical	ADJ
gs-894	66	37	,	,	PUNCT
gs-894	66	38	and	and	CCONJ
gs-894	66	39	laboratory	laboratory	NOUN
gs-894	66	40	information	information	NOUN
gs-894	66	41	.	.	PUNCT
gs-894	67	1	georgian	georgian	ADJ
gs-894	67	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-894	67	3	მეცნიერები	მეცნიერები	VERB
gs-894	67	4	4(02	4(02	NUM
gs-894	67	5	)	)	PUNCT
gs-894	67	6	,	,	PUNCT
gs-894	67	7	2022	2022	NUM
gs-894	67	8	196	196	NUM
gs-894	67	9	national	national	PROPN
gs-894	67	10	hiv	hiv	PROPN
gs-894	67	11	guidelines	guideline	NOUN
gs-894	67	12	recommended	recommend	VERB
gs-894	67	13	screening	screen	VERB
gs-894	67	14	for	for	ADP
gs-894	67	15	glycemia	glycemia	NOUN
gs-894	67	16	at	at	ADP
gs-894	67	17	the	the	DET
gs-894	67	18	beginning	beginning	NOUN
gs-894	67	19	of	of	ADP
gs-894	67	20	hiv	hiv	PROPN
gs-894	67	21	diagnosis	diagnosis	NOUN
gs-894	67	22	and	and	CCONJ
gs-894	67	23	then	then	ADV
gs-894	67	24	annually	annually	ADV
gs-894	67	25	.	.	PUNCT
gs-894	68	1	american	american	ADJ
gs-894	68	2	diabetes	diabetes	PROPN
gs-894	68	3	association	association	PROPN
gs-894	68	4	(	(	PUNCT
gs-894	68	5	ada	ada	PROPN
gs-894	68	6	)	)	PUNCT
gs-894	68	7	guidelines	guideline	NOUN
gs-894	68	8	were	be	AUX
gs-894	68	9	used	use	VERB
gs-894	68	10	to	to	PART
gs-894	68	11	define	define	VERB
gs-894	68	12	hyperglycemia	hyperglycemia	NOUN
gs-894	68	13	and	and	CCONJ
gs-894	68	14	diabetes	diabetes	NOUN
gs-894	68	15	.	.	PUNCT
gs-894	69	1	in	in	ADP
gs-894	69	2	particular	particular	ADJ
gs-894	69	3	a	a	DET
gs-894	69	4	fasting	fast	VERB
gs-894	69	5	blood	blood	NOUN
gs-894	69	6	sugar	sugar	NOUN
gs-894	69	7	level	level	NOUN
gs-894	69	8	less	less	ADJ
gs-894	69	9	than	than	ADP
gs-894	69	10	100	100	NUM
gs-894	69	11	mg	mg	PROPN
gs-894	69	12	/	/	SYM
gs-894	69	13	dl	dl	PROPN
gs-894	69	14	(	(	PUNCT
gs-894	69	15	5.6	5.6	NUM
gs-894	69	16	mmol	mmol	NOUN
gs-894	69	17	/	/	SYM
gs-894	69	18	l	l	NOUN
gs-894	69	19	)	)	PUNCT
gs-894	69	20	is	be	AUX
gs-894	69	21	normal	normal	ADJ
gs-894	69	22	.	.	PUNCT
gs-894	70	1	a	a	DET
gs-894	70	2	fasting	fast	VERB
gs-894	70	3	blood	blood	NOUN
gs-894	70	4	sugar	sugar	NOUN
gs-894	70	5	is	be	AUX
gs-894	70	6	considered	consider	VERB
gs-894	70	7	as	as	ADP
gs-894	70	8	prediabetes	prediabete	NOUN
gs-894	70	9	if	if	SCONJ
gs-894	70	10	glucose	glucose	NOUN
gs-894	70	11	level	level	NOUN
gs-894	70	12	is	be	AUX
gs-894	70	13	from	from	ADP
gs-894	70	14	100	100	NUM
gs-894	70	15	to	to	PART
gs-894	70	16	125	125	NUM
gs-894	70	17	mg	mg	PROPN
gs-894	70	18	/	/	SYM
gs-894	70	19	dl	dl	PROPN
gs-894	70	20	(	(	PUNCT
gs-894	70	21	5.6	5.6	NUM
gs-894	70	22	to	to	PART
gs-894	70	23	6.9	6.9	NUM
gs-894	70	24	mmol	mmol	NOUN
gs-894	70	25	/	/	SYM
gs-894	70	26	l	l	NOUN
gs-894	70	27	)	)	PUNCT
gs-894	70	28	.	.	PUNCT
gs-894	71	1	if	if	SCONJ
gs-894	71	2	it	it	PRON
gs-894	71	3	's	be	AUX
gs-894	71	4	126	126	NUM
gs-894	71	5	mg	mg	PROPN
gs-894	71	6	/	/	SYM
gs-894	71	7	dl	dl	PROPN
gs-894	71	8	(	(	PUNCT
gs-894	71	9	7	7	NUM
gs-894	71	10	mmol	mmol	NOUN
gs-894	71	11	/	/	SYM
gs-894	71	12	l	l	NOUN
gs-894	71	13	)	)	PUNCT
gs-894	71	14	or	or	CCONJ
gs-894	71	15	higher	high	ADJ
gs-894	71	16	on	on	ADP
gs-894	71	17	two	two	NUM
gs-894	71	18	separate	separate	ADJ
gs-894	71	19	tests	test	NOUN
gs-894	71	20	,	,	PUNCT
gs-894	71	21	patient	patient	NOUN
gs-894	71	22	has	have	VERB
gs-894	71	23	diabetes	diabetes	NOUN
gs-894	71	24	.	.	PUNCT
gs-894	72	1	a	a	DET
gs-894	72	2	postprandial	postprandial	ADJ
gs-894	72	3	blood	blood	NOUN
gs-894	72	4	sugar	sugar	NOUN
gs-894	72	5	level	level	NOUN
gs-894	72	6	less	less	ADJ
gs-894	72	7	than	than	ADP
gs-894	72	8	140	140	NUM
gs-894	72	9	mg	mg	PROPN
gs-894	72	10	/	/	SYM
gs-894	72	11	dl	dl	PROPN
gs-894	72	12	(	(	PUNCT
gs-894	72	13	7.8	7.8	NUM
gs-894	72	14	mmol	mmol	NOUN
gs-894	72	15	/	/	SYM
gs-894	72	16	l	l	NOUN
gs-894	72	17	)	)	PUNCT
gs-894	72	18	is	be	AUX
gs-894	72	19	normal	normal	ADJ
gs-894	72	20	.	.	PUNCT
gs-894	73	1	a	a	DET
gs-894	73	2	reading	reading	NOUN
gs-894	73	3	between	between	ADP
gs-894	73	4	140	140	NUM
gs-894	73	5	and	and	CCONJ
gs-894	73	6	199	199	NUM
gs-894	73	7	mg	mg	PROPN
gs-894	73	8	/	/	SYM
gs-894	73	9	dl	dl	PROPN
gs-894	73	10	(	(	PUNCT
gs-894	73	11	7.8	7.8	NUM
gs-894	73	12	mmol	mmol	NOUN
gs-894	73	13	/	/	SYM
gs-894	73	14	l	l	NOUN
gs-894	73	15	and	and	CCONJ
gs-894	73	16	11.0	11.0	NUM
gs-894	73	17	mmol	mmol	NOUN
gs-894	73	18	/	/	SYM
gs-894	73	19	l	l	NOUN
gs-894	73	20	)	)	PUNCT
gs-894	73	21	indicates	indicate	VERB
gs-894	73	22	prediabetes	prediabete	NOUN
gs-894	73	23	.	.	PUNCT
gs-894	74	1	blood	blood	NOUN
gs-894	74	2	glucose	glucose	NOUN
gs-894	74	3	more	more	ADJ
gs-894	74	4	than	than	ADP
gs-894	74	5	200	200	NUM
gs-894	74	6	mg	mg	PROPN
gs-894	74	7	/	/	SYM
gs-894	74	8	dl	dl	PROPN
gs-894	74	9	(	(	PUNCT
gs-894	74	10	11.1	11.1	NUM
gs-894	74	11	mmol	mmol	NOUN
gs-894	74	12	/	/	SYM
gs-894	74	13	l	l	NOUN
gs-894	74	14	)	)	PUNCT
gs-894	74	15	after	after	ADP
gs-894	74	16	two	two	NUM
gs-894	74	17	hours	hour	NOUN
gs-894	74	18	indicates	indicate	VERB
gs-894	74	19	diabetes36	diabetes36	NOUN
gs-894	74	20	.	.	PUNCT
gs-894	75	1	every	every	DET
gs-894	75	2	single	single	ADJ
gs-894	75	3	patient	patient	NOUN
gs-894	75	4	who	who	PRON
gs-894	75	5	had	have	VERB
gs-894	75	6	hyperglycemia	hyperglycemia	NOUN
gs-894	75	7	even	even	ADV
gs-894	75	8	once	once	ADV
gs-894	75	9	was	be	AUX
gs-894	75	10	referred	refer	VERB
gs-894	75	11	to	to	PART
gs-894	75	12	endocrinologist	endocrinologist	VERB
gs-894	75	13	for	for	ADP
gs-894	75	14	further	further	ADJ
gs-894	75	15	diagnostics	diagnostic	NOUN
gs-894	75	16	of	of	ADP
gs-894	75	17	diabetes	diabetes	NOUN
gs-894	75	18	.	.	PUNCT
gs-894	76	1	participants	participant	NOUN
gs-894	76	2	were	be	AUX
gs-894	76	3	enrolled	enrol	VERB
gs-894	76	4	in	in	ADP
gs-894	76	5	the	the	DET
gs-894	76	6	prospective	prospective	ADJ
gs-894	76	7	study	study	NOUN
gs-894	76	8	after	after	ADP
gs-894	76	9	giving	give	VERB
gs-894	76	10	an	an	DET
gs-894	76	11	informed	informed	ADJ
gs-894	76	12	consent	consent	NOUN
gs-894	76	13	.	.	PUNCT
gs-894	77	1	additional	additional	ADJ
gs-894	77	2	diagnostic	diagnostic	ADJ
gs-894	77	3	tests	test	NOUN
gs-894	77	4	,	,	PUNCT
gs-894	77	5	in	in	ADP
gs-894	77	6	particular	particular	ADJ
gs-894	77	7	,	,	PUNCT
gs-894	77	8	oral	oral	ADJ
gs-894	77	9	glucose	glucose	NOUN
gs-894	77	10	tolerance	tolerance	NOUN
gs-894	77	11	test	test	NOUN
gs-894	77	12	(	(	PUNCT
gs-894	77	13	ogtt	ogtt	ADV
gs-894	77	14	)	)	PUNCT
gs-894	77	15	with	with	ADP
gs-894	77	16	75	75	NUM
gs-894	77	17	g	g	NOUN
gs-894	77	18	glucose	glucose	NOUN
gs-894	77	19	,	,	PUNCT
gs-894	77	20	glycated	glycate	VERB
gs-894	77	21	hemoglobin	hemoglobin	NOUN
gs-894	77	22	,	,	PUNCT
gs-894	77	23	homa	homa	PROPN
gs-894	77	24	index	index	PROPN
gs-894	77	25	,	,	PUNCT
gs-894	77	26	lipid	lipid	NOUN
gs-894	77	27	panel	panel	NOUN
gs-894	77	28	were	be	AUX
gs-894	77	29	conducted	conduct	VERB
gs-894	77	30	among	among	ADP
gs-894	77	31	the	the	DET
gs-894	77	32	participants	participant	NOUN
gs-894	77	33	.	.	PUNCT
gs-894	78	1	we	we	PRON
gs-894	78	2	have	have	AUX
gs-894	78	3	estimated	estimate	VERB
gs-894	78	4	the	the	DET
gs-894	78	5	prevalence	prevalence	NOUN
gs-894	78	6	of	of	ADP
gs-894	78	7	diabetes	diabetes	NOUN
gs-894	78	8	,	,	PUNCT
gs-894	78	9	tb	tb	NOUN
gs-894	78	10	,	,	PUNCT
gs-894	78	11	cvd	cvd	PROPN
gs-894	78	12	,	,	PUNCT
gs-894	78	13	ckd	ckd	PROPN
gs-894	78	14	and	and	CCONJ
gs-894	78	15	stroke	stroke	NOUN
gs-894	78	16	.	.	PUNCT
gs-894	79	1	the	the	DET
gs-894	79	2	association	association	NOUN
gs-894	79	3	between	between	ADP
gs-894	79	4	hyperglycemia	hyperglycemia	NOUN
gs-894	79	5	and	and	CCONJ
gs-894	79	6	tb	tb	NOUN
gs-894	79	7	,	,	PUNCT
gs-894	79	8	cvd	cvd	PROPN
gs-894	79	9	,	,	PUNCT
gs-894	79	10	ckd	ckd	PROPN
gs-894	79	11	,	,	PUNCT
gs-894	79	12	stroke	stroke	NOUN
gs-894	79	13	has	have	AUX
gs-894	79	14	been	be	AUX
gs-894	79	15	calculated	calculate	VERB
gs-894	79	16	.	.	PUNCT
gs-894	80	1	for	for	ADP
gs-894	80	2	statistical	statistical	ADJ
gs-894	80	3	analysis	analysis	NOUN
gs-894	80	4	we	we	PRON
gs-894	80	5	have	have	AUX
gs-894	80	6	performed	perform	VERB
gs-894	80	7	descriptive	descriptive	ADJ
gs-894	80	8	and	and	CCONJ
gs-894	80	9	bivariate	bivariate	ADJ
gs-894	80	10	analysis	analysis	NOUN
gs-894	80	11	,	,	PUNCT
gs-894	80	12	using	use	VERB
gs-894	80	13	sas	sas	PROPN
gs-894	80	14	9.2	9.2	NUM
gs-894	80	15	software	software	NOUN
gs-894	80	16	(	(	PUNCT
gs-894	80	17	sas	sas	PROPN
gs-894	80	18	institute	institute	PROPN
gs-894	80	19	inc	inc	PROPN
gs-894	80	20	.	.	PROPN
gs-894	80	21	,	,	PUNCT
gs-894	80	22	cary	cary	PROPN
gs-894	80	23	,	,	PUNCT
gs-894	80	24	nc	nc	PROPN
gs-894	80	25	,	,	PUNCT
gs-894	80	26	usa	usa	PROPN
gs-894	80	27	)	)	PUNCT
gs-894	80	28	.	.	PUNCT
gs-894	81	1	ethical	ethical	ADJ
gs-894	81	2	approval	approval	NOUN
gs-894	81	3	was	be	AUX
gs-894	81	4	obtained	obtain	VERB
gs-894	81	5	from	from	ADP
gs-894	81	6	the	the	DET
gs-894	81	7	ethics	ethic	NOUN
gs-894	81	8	committee	committee	PROPN
gs-894	81	9	of	of	ADP
gs-894	81	10	at	at	ADP
gs-894	81	11	infectious	infectious	ADJ
gs-894	81	12	diseases	disease	NOUN
gs-894	81	13	,	,	PUNCT
gs-894	81	14	aids	aid	NOUN
gs-894	81	15	and	and	CCONJ
gs-894	81	16	clinical	clinical	ADJ
gs-894	81	17	immunology	immunology	NOUN
gs-894	81	18	research	research	NOUN
gs-894	81	19	center	center	NOUN
gs-894	81	20	(	(	PUNCT
gs-894	81	21	n	n	ADV
gs-894	81	22	20	20	NUM
gs-894	81	23	-	-	PUNCT
gs-894	81	24	006	006	NUM
gs-894	81	25	)	)	PUNCT
gs-894	81	26	.	.	PUNCT
gs-894	82	1	results	result	NOUN
gs-894	82	2	and	and	CCONJ
gs-894	82	3	discussion	discussion	VERB
gs-894	82	4	our	our	PRON
gs-894	82	5	original	original	ADJ
gs-894	82	6	sample	sample	NOUN
gs-894	82	7	consisted	consist	VERB
gs-894	82	8	of	of	ADP
gs-894	82	9	2914	2914	NUM
gs-894	82	10	hiv	hiv	NOUN
gs-894	82	11	patients	patient	NOUN
gs-894	82	12	,	,	PUNCT
gs-894	82	13	the	the	DET
gs-894	82	14	majority	majority	NOUN
gs-894	82	15	of	of	ADP
gs-894	82	16	the	the	DET
gs-894	82	17	participants	participant	NOUN
gs-894	82	18	were	be	AUX
gs-894	82	19	male	male	ADJ
gs-894	82	20	2204	2204	NUM
gs-894	82	21	(	(	PUNCT
gs-894	82	22	75.6	75.6	NUM
gs-894	82	23	%	%	NOUN
gs-894	82	24	)	)	PUNCT
gs-894	82	25	.	.	PUNCT
gs-894	83	1	the	the	DET
gs-894	83	2	majority	majority	NOUN
gs-894	83	3	of	of	ADP
gs-894	83	4	the	the	DET
gs-894	83	5	patients	patient	NOUN
gs-894	83	6	represented	represent	VERB
gs-894	83	7	age	age	NOUN
gs-894	83	8	categories	category	NOUN
gs-894	83	9	of	of	ADP
gs-894	83	10	30	30	NUM
gs-894	83	11	-	-	SYM
gs-894	83	12	39	39	NUM
gs-894	83	13	years	year	NOUN
gs-894	83	14	old	old	ADJ
gs-894	83	15	(	(	PUNCT
gs-894	83	16	31.3	31.3	NUM
gs-894	83	17	%	%	NOUN
gs-894	83	18	)	)	PUNCT
gs-894	83	19	and	and	CCONJ
gs-894	83	20	40	40	NUM
gs-894	83	21	-	-	SYM
gs-894	83	22	49	49	NUM
gs-894	83	23	years	year	NOUN
gs-894	83	24	old	old	ADJ
gs-894	83	25	(	(	PUNCT
gs-894	83	26	29.7	29.7	NUM
gs-894	83	27	%	%	NOUN
gs-894	83	28	)	)	PUNCT
gs-894	83	29	.	.	PUNCT
gs-894	84	1	the	the	DET
gs-894	84	2	median	median	ADJ
gs-894	84	3	age	age	NOUN
gs-894	84	4	was	be	AUX
gs-894	84	5	52	52	NUM
gs-894	84	6	(	(	PUNCT
gs-894	84	7	iqr=22	iqr=22	PROPN
gs-894	84	8	-	-	PUNCT
gs-894	84	9	80	80	NUM
gs-894	84	10	)	)	PUNCT
gs-894	84	11	.	.	PUNCT
gs-894	85	1	11	11	NUM
gs-894	85	2	(	(	PUNCT
gs-894	85	3	0.4	0.4	NUM
gs-894	85	4	%	%	NOUN
gs-894	85	5	)	)	PUNCT
gs-894	86	1	patients	patient	NOUN
gs-894	86	2	did	do	AUX
gs-894	86	3	not	not	PART
gs-894	86	4	enroll	enroll	VERB
gs-894	86	5	in	in	ADP
gs-894	86	6	the	the	DET
gs-894	86	7	study	study	NOUN
gs-894	86	8	due	due	ADP
gs-894	86	9	to	to	ADP
gs-894	86	10	covid-19	covid-19	PROPN
gs-894	86	11	pandemic	pandemic	ADV
gs-894	86	12	related	relate	VERB
gs-894	86	13	situation.7.4	situation.7.4	PROPN
gs-894	86	14	%	%	NOUN
gs-894	86	15	of	of	ADP
gs-894	86	16	the	the	DET
gs-894	86	17	participants	participant	NOUN
gs-894	86	18	were	be	AUX
gs-894	86	19	lost	lose	VERB
gs-894	86	20	to	to	PART
gs-894	86	21	follow	follow	VERB
gs-894	86	22	up	up	ADP
gs-894	86	23	.	.	PUNCT
gs-894	87	1	for	for	ADP
gs-894	87	2	the	the	DET
gs-894	87	3	period	period	NOUN
gs-894	87	4	from	from	ADP
gs-894	87	5	2012	2012	NUM
gs-894	87	6	to	to	ADP
gs-894	87	7	2021	2021	NUM
gs-894	87	8	153	153	NUM
gs-894	87	9	(	(	PUNCT
gs-894	87	10	5.2	5.2	NUM
gs-894	87	11	%	%	NOUN
gs-894	87	12	)	)	PUNCT
gs-894	87	13	died	die	VERB
gs-894	87	14	.	.	PUNCT
gs-894	88	1	hyperglycemia	hyperglycemia	NOUN
gs-894	88	2	was	be	AUX
gs-894	88	3	detected	detect	VERB
gs-894	88	4	in	in	ADP
gs-894	88	5	381(13.1	381(13.1	NUM
gs-894	88	6	%	%	NOUN
gs-894	88	7	)	)	PUNCT
gs-894	88	8	hiv	hiv	PROPN
gs-894	88	9	patients	patient	NOUN
gs-894	88	10	.	.	PUNCT
gs-894	89	1	the	the	DET
gs-894	89	2	detailed	detailed	ADJ
gs-894	89	3	description	description	NOUN
gs-894	89	4	of	of	ADP
gs-894	89	5	the	the	DET
gs-894	89	6	sample	sample	NOUN
gs-894	89	7	characteristics	characteristic	NOUN
gs-894	89	8	is	be	AUX
gs-894	89	9	provided	provide	VERB
gs-894	89	10	in	in	ADP
gs-894	89	11	the	the	DET
gs-894	89	12	tables	table	NOUN
gs-894	89	13	1	1	NUM
gs-894	89	14	and	and	CCONJ
gs-894	89	15	2	2	NUM
gs-894	89	16	.	.	X
gs-894	89	17	georgian	georgian	ADJ
gs-894	89	18	scientists/ქართველი	scientists/ქართველი	PROPN
gs-894	89	19	მეცნიერები	მეცნიერები	VERB
gs-894	89	20	4(02	4(02	NUM
gs-894	89	21	)	)	PUNCT
gs-894	89	22	,	,	PUNCT
gs-894	89	23	2022	2022	NUM
gs-894	89	24	197	197	NUM
gs-894	89	25	table	table	NOUN
gs-894	89	26	1	1	NUM
gs-894	89	27	.	.	PUNCT
gs-894	89	28	sample	sample	NOUN
gs-894	89	29	characteristics	characteristic	NOUN
gs-894	89	30	of	of	ADP
gs-894	89	31	people	people	NOUN
gs-894	89	32	living	live	VERB
gs-894	89	33	with	with	ADP
gs-894	89	34	hiv	hiv	PROPN
gs-894	89	35	(	(	PUNCT
gs-894	89	36	n=2914	n=2914	PROPN
gs-894	89	37	)	)	PUNCT
gs-894	89	38	,	,	PUNCT
gs-894	89	39	georgia	georgia	PROPN
gs-894	89	40	,	,	PUNCT
gs-894	89	41	2021	2021	NUM
gs-894	89	42	variable	variable	ADJ
gs-894	89	43	total	total	NOUN
gs-894	89	44	n	n	CCONJ
gs-894	89	45	(	(	PUNCT
gs-894	89	46	%	%	INTJ
gs-894	89	47	)	)	PUNCT
gs-894	89	48	male	male	ADJ
gs-894	89	49	female	female	ADJ
gs-894	89	50	gender	gender	NOUN
gs-894	89	51	2914	2914	NUM
gs-894	89	52	(	(	PUNCT
gs-894	89	53	100	100	NUM
gs-894	89	54	%	%	NOUN
gs-894	89	55	)	)	PUNCT
gs-894	89	56	2204	2204	NUM
gs-894	89	57	(	(	PUNCT
gs-894	89	58	75.6	75.6	NUM
gs-894	89	59	%	%	NOUN
gs-894	89	60	)	)	PUNCT
gs-894	89	61	710	710	NUM
gs-894	89	62	(	(	PUNCT
gs-894	89	63	24.4	24.4	NUM
gs-894	89	64	%	%	NOUN
gs-894	89	65	)	)	PUNCT
gs-894	89	66	hyperglycemia	hyperglycemia	NOUN
gs-894	89	67	381	381	NUM
gs-894	89	68	(	(	PUNCT
gs-894	89	69	13.1	13.1	NUM
gs-894	89	70	%	%	NOUN
gs-894	89	71	)	)	PUNCT
gs-894	89	72	326	326	NUM
gs-894	89	73	(	(	PUNCT
gs-894	89	74	85.6	85.6	NUM
gs-894	89	75	%	%	NOUN
gs-894	89	76	)	)	PUNCT
gs-894	89	77	55	55	NUM
gs-894	89	78	(	(	PUNCT
gs-894	89	79	14.4	14.4	NUM
gs-894	89	80	%	%	NOUN
gs-894	89	81	)	)	PUNCT
gs-894	89	82	refused	refuse	VERB
gs-894	89	83	to	to	PART
gs-894	89	84	participate	participate	VERB
gs-894	89	85	for	for	ADP
gs-894	89	86	further	further	ADJ
gs-894	89	87	examinations	examination	NOUN
gs-894	89	88	11	11	NUM
gs-894	89	89	(	(	PUNCT
gs-894	89	90	0.4	0.4	NUM
gs-894	89	91	%	%	NOUN
gs-894	89	92	)	)	PUNCT
gs-894	89	93	9	9	NUM
gs-894	89	94	(	(	PUNCT
gs-894	89	95	0.4	0.4	NUM
gs-894	89	96	%	%	NOUN
gs-894	89	97	)	)	PUNCT
gs-894	89	98	2	2	NUM
gs-894	89	99	(	(	PUNCT
gs-894	89	100	0.3	0.3	NUM
gs-894	89	101	%	%	NOUN
gs-894	89	102	)	)	PUNCT
gs-894	89	103	loss	loss	NOUN
gs-894	89	104	to	to	PART
gs-894	89	105	follow	follow	VERB
gs-894	89	106	up	up	ADP
gs-894	89	107	(	(	PUNCT
gs-894	89	108	2012	2012	NUM
gs-894	89	109	-	-	SYM
gs-894	89	110	2021	2021	NUM
gs-894	89	111	years	year	NOUN
gs-894	89	112	)	)	PUNCT
gs-894	89	113	215	215	NUM
gs-894	89	114	(	(	PUNCT
gs-894	89	115	7.4	7.4	NUM
gs-894	89	116	%	%	NOUN
gs-894	89	117	)	)	PUNCT
gs-894	89	118	183	183	NUM
gs-894	89	119	(	(	PUNCT
gs-894	89	120	8.3	8.3	NUM
gs-894	89	121	%	%	NOUN
gs-894	89	122	)	)	PUNCT
gs-894	89	123	32	32	NUM
gs-894	89	124	(	(	PUNCT
gs-894	89	125	4.5	4.5	NUM
gs-894	89	126	%	%	NOUN
gs-894	89	127	)	)	PUNCT
gs-894	89	128	died	die	VERB
gs-894	89	129	during	during	ADP
gs-894	89	130	follow	follow	VERB
gs-894	89	131	up	up	ADP
gs-894	89	132	(	(	PUNCT
gs-894	89	133	2012	2012	NUM
gs-894	89	134	-	-	SYM
gs-894	89	135	2021	2021	NUM
gs-894	89	136	years	year	NOUN
gs-894	89	137	)	)	PUNCT
gs-894	89	138	153	153	NUM
gs-894	89	139	(	(	PUNCT
gs-894	89	140	5.2	5.2	NUM
gs-894	89	141	%	%	NOUN
gs-894	89	142	)	)	PUNCT
gs-894	89	143	130	130	NUM
gs-894	89	144	(	(	PUNCT
gs-894	89	145	5.9	5.9	NUM
gs-894	89	146	%	%	NOUN
gs-894	89	147	)	)	PUNCT
gs-894	89	148	22	22	NUM
gs-894	89	149	(	(	PUNCT
gs-894	89	150	3.1	3.1	NUM
gs-894	89	151	%	%	NOUN
gs-894	89	152	)	)	PUNCT
gs-894	89	153	performed	perform	VERB
gs-894	89	154	diagnostic	diagnostic	ADJ
gs-894	89	155	tests	test	NOUN
gs-894	89	156	(	(	PUNCT
gs-894	89	157	ogtt	ogtt	ADP
gs-894	89	158	homa	homa	PROPN
gs-894	89	159	index	index	NOUN
gs-894	89	160	lipid	lipid	NOUN
gs-894	89	161	panel	panel	NOUN
gs-894	89	162	glycated	glycate	VERB
gs-894	89	163	hemoglobin	hemoglobin	NOUN
gs-894	89	164	)	)	PUNCT
gs-894	89	165	155	155	NUM
gs-894	89	166	(	(	PUNCT
gs-894	89	167	5.3	5.3	NUM
gs-894	89	168	%	%	NOUN
gs-894	89	169	)	)	PUNCT
gs-894	89	170	145	145	NUM
gs-894	89	171	(	(	PUNCT
gs-894	89	172	6.6	6.6	NUM
gs-894	89	173	%	%	NOUN
gs-894	89	174	)	)	PUNCT
gs-894	89	175	10	10	NUM
gs-894	89	176	(	(	PUNCT
gs-894	89	177	1.4	1.4	NUM
gs-894	89	178	%	%	NOUN
gs-894	89	179	)	)	PUNCT
gs-894	89	180	table	table	NOUN
gs-894	89	181	2	2	NUM
gs-894	89	182	.	.	PUNCT
gs-894	90	1	the	the	DET
gs-894	90	2	prevalence	prevalence	NOUN
gs-894	90	3	of	of	ADP
gs-894	90	4	hyperglycemia	hyperglycemia	NOUN
gs-894	90	5	by	by	ADP
gs-894	90	6	the	the	DET
gs-894	90	7	age	age	NOUN
gs-894	90	8	and	and	CCONJ
gs-894	90	9	gender	gender	NOUN
gs-894	90	10	among	among	ADP
gs-894	90	11	people	people	NOUN
gs-894	90	12	living	live	VERB
gs-894	90	13	with	with	ADP
gs-894	90	14	hiv	hiv	PROPN
gs-894	90	15	(	(	PUNCT
gs-894	90	16	n=2914	n=2914	PROPN
gs-894	90	17	)	)	PUNCT
gs-894	90	18	,	,	PUNCT
gs-894	90	19	georgia	georgia	PROPN
gs-894	90	20	,	,	PUNCT
gs-894	90	21	2021	2021	NUM
gs-894	90	22	variable	variable	ADJ
gs-894	90	23	total	total	NOUN
gs-894	90	24	n	n	CCONJ
gs-894	90	25	(	(	PUNCT
gs-894	90	26	%	%	INTJ
gs-894	90	27	)	)	PUNCT
gs-894	90	28	normoglycemia	normoglycemia	NOUN
gs-894	90	29	hyperglycemia	hyperglycemia	VERB
gs-894	90	30	gender	gender	NOUN
gs-894	90	31	male	male	ADJ
gs-894	90	32	female	female	ADJ
gs-894	90	33	2914	2914	NUM
gs-894	90	34	(	(	PUNCT
gs-894	90	35	100	100	NUM
gs-894	90	36	%	%	NOUN
gs-894	90	37	)	)	PUNCT
gs-894	90	38	2204	2204	NUM
gs-894	90	39	(	(	PUNCT
gs-894	90	40	75.6	75.6	NUM
gs-894	90	41	%	%	NOUN
gs-894	90	42	)	)	PUNCT
gs-894	90	43	710	710	NUM
gs-894	90	44	(	(	PUNCT
gs-894	90	45	24.4	24.4	NUM
gs-894	90	46	%	%	NOUN
gs-894	90	47	)	)	PUNCT
gs-894	90	48	2533	2533	NUM
gs-894	90	49	(	(	PUNCT
gs-894	90	50	86.9	86.9	NUM
gs-894	90	51	%	%	NOUN
gs-894	90	52	)	)	PUNCT
gs-894	90	53	1878	1878	NUM
gs-894	90	54	(	(	PUNCT
gs-894	90	55	85.2	85.2	NUM
gs-894	90	56	%	%	NOUN
gs-894	90	57	)	)	PUNCT
gs-894	90	58	655	655	NUM
gs-894	90	59	(	(	PUNCT
gs-894	90	60	92.25	92.25	NUM
gs-894	90	61	%	%	NOUN
gs-894	90	62	)	)	PUNCT
gs-894	90	63	381	381	NUM
gs-894	90	64	(	(	PUNCT
gs-894	90	65	13.1	13.1	NUM
gs-894	90	66	%	%	NOUN
gs-894	90	67	)	)	PUNCT
gs-894	90	68	326	326	NUM
gs-894	90	69	(	(	PUNCT
gs-894	90	70	14.8	14.8	NUM
gs-894	90	71	%	%	NOUN
gs-894	90	72	)	)	PUNCT
gs-894	90	73	55	55	NUM
gs-894	90	74	(	(	PUNCT
gs-894	90	75	7.75	7.75	NUM
gs-894	90	76	%	%	NOUN
gs-894	90	77	)	)	PUNCT
gs-894	90	78	age	age	NOUN
gs-894	90	79	(	(	PUNCT
gs-894	90	80	years	year	NOUN
gs-894	90	81	)	)	PUNCT
gs-894	90	82	19	19	NUM
gs-894	90	83	-	-	SYM
gs-894	90	84	29	29	NUM
gs-894	90	85	30	30	NUM
gs-894	90	86	-	-	SYM
gs-894	90	87	39	39	NUM
gs-894	90	88	40	40	NUM
gs-894	90	89	-	-	SYM
gs-894	90	90	49	49	NUM
gs-894	90	91	50	50	NUM
gs-894	90	92	-	-	SYM
gs-894	90	93	64	64	NUM
gs-894	90	94	>	>	SYM
gs-894	90	95	65	65	NUM
gs-894	90	96	2914	2914	NUM
gs-894	90	97	(	(	PUNCT
gs-894	90	98	100	100	NUM
gs-894	90	99	%	%	NOUN
gs-894	90	100	)	)	PUNCT
gs-894	90	101	501	501	NUM
gs-894	90	102	(	(	PUNCT
gs-894	90	103	17.2	17.2	NUM
gs-894	90	104	%	%	NOUN
gs-894	90	105	)	)	PUNCT
gs-894	90	106	913	913	NUM
gs-894	90	107	(	(	PUNCT
gs-894	90	108	31.3	31.3	NUM
gs-894	90	109	%	%	NOUN
gs-894	90	110	)	)	PUNCT
gs-894	90	111	865	865	NUM
gs-894	90	112	(	(	PUNCT
gs-894	90	113	29.7	29.7	NUM
gs-894	90	114	%	%	NOUN
gs-894	90	115	)	)	PUNCT
gs-894	90	116	577	577	NUM
gs-894	90	117	(	(	PUNCT
gs-894	90	118	19.8	19.8	NUM
gs-894	90	119	%	%	NOUN
gs-894	90	120	)	)	PUNCT
gs-894	90	121	58	58	NUM
gs-894	90	122	(	(	PUNCT
gs-894	90	123	2.0	2.0	NUM
gs-894	90	124	%	%	NOUN
gs-894	90	125	)	)	PUNCT
gs-894	90	126	2533	2533	NUM
gs-894	90	127	(	(	PUNCT
gs-894	90	128	86.9	86.9	NUM
gs-894	90	129	%	%	NOUN
gs-894	90	130	)	)	PUNCT
gs-894	90	131	496	496	NUM
gs-894	90	132	(	(	PUNCT
gs-894	90	133	99.9	99.9	NUM
gs-894	90	134	%	%	NOUN
gs-894	90	135	)	)	PUNCT
gs-894	90	136	856	856	NUM
gs-894	90	137	(	(	PUNCT
gs-894	90	138	94.7	94.7	NUM
gs-894	90	139	%	%	NOUN
gs-894	90	140	)	)	PUNCT
gs-894	90	141	753	753	NUM
gs-894	90	142	(	(	PUNCT
gs-894	90	143	87.0	87.0	NUM
gs-894	90	144	%	%	NOUN
gs-894	90	145	)	)	PUNCT
gs-894	91	1	395(68.5	395(68.5	NUM
gs-894	91	2	%	%	NOUN
gs-894	91	3	)	)	PUNCT
gs-894	91	4	24	24	NUM
gs-894	91	5	(	(	PUNCT
gs-894	91	6	41.4	41.4	NUM
gs-894	91	7	%	%	NOUN
gs-894	91	8	)	)	PUNCT
gs-894	91	9	381	381	NUM
gs-894	91	10	(	(	PUNCT
gs-894	91	11	13.1	13.1	NUM
gs-894	91	12	%	%	NOUN
gs-894	91	13	)	)	PUNCT
gs-894	91	14	5	5	NUM
gs-894	91	15	(	(	PUNCT
gs-894	91	16	0.1	0.1	NUM
gs-894	91	17	%	%	NOUN
gs-894	91	18	)	)	PUNCT
gs-894	91	19	48	48	NUM
gs-894	91	20	(	(	PUNCT
gs-894	91	21	5.3	5.3	NUM
gs-894	91	22	%	%	NOUN
gs-894	91	23	)	)	PUNCT
gs-894	91	24	112	112	NUM
gs-894	91	25	(	(	PUNCT
gs-894	91	26	13.0	13.0	NUM
gs-894	91	27	%	%	NOUN
gs-894	91	28	)	)	PUNCT
gs-894	91	29	182	182	NUM
gs-894	91	30	(	(	PUNCT
gs-894	91	31	31.5	31.5	NUM
gs-894	91	32	%	%	NOUN
gs-894	91	33	)	)	PUNCT
gs-894	91	34	34	34	NUM
gs-894	91	35	(	(	PUNCT
gs-894	91	36	58.6	58.6	NUM
gs-894	91	37	%	%	NOUN
gs-894	91	38	)	)	PUNCT
gs-894	91	39	georgian	georgian	PROPN
gs-894	91	40	scientists/ქართველი	scientists/ქართველი	NOUN
gs-894	91	41	მეცნიერები	მეცნიერები	VERB
gs-894	91	42	4(02	4(02	NUM
gs-894	91	43	)	)	PUNCT
gs-894	91	44	,	,	PUNCT
gs-894	91	45	2022	2022	NUM
gs-894	91	46	198	198	NUM
gs-894	91	47	the	the	DET
gs-894	91	48	prevalence	prevalence	NOUN
gs-894	91	49	of	of	ADP
gs-894	91	50	hyperglycemia	hyperglycemia	NOUN
gs-894	91	51	,	,	PUNCT
gs-894	91	52	was	be	AUX
gs-894	91	53	increasing	increase	VERB
gs-894	91	54	with	with	ADP
gs-894	91	55	the	the	DET
gs-894	91	56	age	age	NOUN
gs-894	91	57	:	:	PUNCT
gs-894	91	58	5	5	NUM
gs-894	91	59	(	(	PUNCT
gs-894	91	60	1.31	1.31	NUM
gs-894	91	61	%	%	NOUN
gs-894	91	62	)	)	PUNCT
gs-894	91	63	in	in	ADP
gs-894	91	64	the	the	DET
gs-894	91	65	age	age	NOUN
gs-894	91	66	group	group	NOUN
gs-894	91	67	of	of	ADP
gs-894	91	68	19	19	NUM
gs-894	91	69	-	-	SYM
gs-894	91	70	29	29	NUM
gs-894	91	71	years	year	NOUN
gs-894	91	72	,	,	PUNCT
gs-894	91	73	48	48	NUM
gs-894	91	74	(	(	PUNCT
gs-894	91	75	12.6	12.6	NUM
gs-894	91	76	%	%	NOUN
gs-894	91	77	)	)	PUNCT
gs-894	91	78	in	in	ADP
gs-894	91	79	30	30	NUM
gs-894	91	80	-	-	SYM
gs-894	91	81	39	39	NUM
gs-894	91	82	years	year	NOUN
gs-894	91	83	,	,	PUNCT
gs-894	91	84	112	112	NUM
gs-894	91	85	(	(	PUNCT
gs-894	91	86	29.4	29.4	NUM
gs-894	91	87	%	%	NOUN
gs-894	91	88	)	)	PUNCT
gs-894	91	89	in	in	ADP
gs-894	91	90	40	40	NUM
gs-894	91	91	-	-	SYM
gs-894	91	92	49	49	NUM
gs-894	91	93	years	year	NOUN
gs-894	91	94	,	,	PUNCT
gs-894	91	95	182	182	NUM
gs-894	91	96	(	(	PUNCT
gs-894	91	97	47.8	47.8	NUM
gs-894	91	98	%	%	NOUN
gs-894	91	99	)	)	PUNCT
gs-894	91	100	in	in	ADP
gs-894	91	101	50	50	NUM
gs-894	91	102	-	-	SYM
gs-894	91	103	64	64	NUM
gs-894	91	104	years	year	NOUN
gs-894	91	105	and	and	CCONJ
gs-894	91	106	34	34	NUM
gs-894	91	107	(	(	PUNCT
gs-894	91	108	8.9	8.9	NUM
gs-894	91	109	%	%	NOUN
gs-894	91	110	)	)	PUNCT
gs-894	91	111	in	in	ADP
gs-894	91	112	older	old	ADJ
gs-894	91	113	than	than	ADP
gs-894	91	114	65	65	NUM
gs-894	91	115	years	year	NOUN
gs-894	91	116	(	(	PUNCT
gs-894	91	117	p	p	NOUN
gs-894	91	118	value	value	NOUN
gs-894	91	119	<	<	X
gs-894	91	120	0.0001	0.0001	NUM
gs-894	91	121	)	)	PUNCT
gs-894	91	122	(	(	PUNCT
gs-894	91	123	table	table	NOUN
gs-894	91	124	3	3	NUM
gs-894	91	125	)	)	PUNCT
gs-894	91	126	.	.	PUNCT
gs-894	92	1	table	table	NOUN
gs-894	92	2	3	3	NUM
gs-894	92	3	.	.	PUNCT
gs-894	93	1	the	the	DET
gs-894	93	2	prevalence	prevalence	NOUN
gs-894	93	3	and	and	CCONJ
gs-894	93	4	distribution	distribution	NOUN
gs-894	93	5	of	of	ADP
gs-894	93	6	hyperglycemia	hyperglycemia	NOUN
gs-894	93	7	by	by	ADP
gs-894	93	8	age	age	NOUN
gs-894	93	9	among	among	ADP
gs-894	93	10	people	people	NOUN
gs-894	93	11	living	live	VERB
gs-894	93	12	with	with	ADP
gs-894	93	13	hiv	hiv	PROPN
gs-894	93	14	(	(	PUNCT
gs-894	93	15	n=2914	n=2914	PROPN
gs-894	93	16	)	)	PUNCT
gs-894	93	17	,	,	PUNCT
gs-894	93	18	georgia	georgia	PROPN
gs-894	93	19	,	,	PUNCT
gs-894	93	20	2021	2021	NUM
gs-894	93	21	prevalence	prevalence	NOUN
gs-894	93	22	of	of	ADP
gs-894	93	23	hyperglycemia	hyperglycemia	NOUN
gs-894	93	24	by	by	ADP
gs-894	93	25	age	age	NOUN
gs-894	93	26	total	total	NOUN
gs-894	93	27	sample	sample	NOUN
gs-894	93	28	(	(	PUNCT
gs-894	93	29	n=381	n=381	NOUN
gs-894	93	30	)	)	PUNCT
gs-894	93	31	13.1	13.1	NUM
gs-894	93	32	%	%	NOUN
gs-894	93	33	p	p	NOUN
gs-894	93	34	value	value	NOUN
gs-894	93	35	median	median	NOUN
gs-894	93	36	(	(	PUNCT
gs-894	93	37	iqr	iqr	NOUN
gs-894	93	38	)	)	PUNCT
gs-894	93	39	19	19	NUM
gs-894	93	40	-	-	SYM
gs-894	93	41	29	29	NUM
gs-894	93	42	30	30	NUM
gs-894	93	43	-	-	SYM
gs-894	93	44	39	39	NUM
gs-894	93	45	40	40	NUM
gs-894	93	46	-	-	SYM
gs-894	93	47	49	49	NUM
gs-894	93	48	50	50	NUM
gs-894	93	49	-	-	SYM
gs-894	93	50	64	64	NUM
gs-894	93	51	>	>	SYM
gs-894	93	52	65	65	NUM
gs-894	93	53	52	52	NUM
gs-894	93	54	(	(	PUNCT
gs-894	93	55	2280	2280	NUM
gs-894	93	56	)	)	PUNCT
gs-894	93	57	5	5	NUM
gs-894	93	58	(	(	PUNCT
gs-894	93	59	1.31	1.31	NUM
gs-894	93	60	%	%	NOUN
gs-894	93	61	)	)	PUNCT
gs-894	93	62	48	48	NUM
gs-894	93	63	(	(	PUNCT
gs-894	93	64	12.6	12.6	NUM
gs-894	93	65	%	%	NOUN
gs-894	93	66	)	)	PUNCT
gs-894	93	67	112	112	NUM
gs-894	93	68	(	(	PUNCT
gs-894	93	69	29.4	29.4	NUM
gs-894	93	70	%	%	NOUN
gs-894	93	71	)	)	PUNCT
gs-894	93	72	182	182	NUM
gs-894	93	73	(	(	PUNCT
gs-894	93	74	47.8	47.8	NUM
gs-894	93	75	%	%	NOUN
gs-894	93	76	)	)	PUNCT
gs-894	93	77	34	34	NUM
gs-894	93	78	(	(	PUNCT
gs-894	93	79	8.9	8.9	NUM
gs-894	93	80	%	%	NOUN
gs-894	93	81	)	)	PUNCT
gs-894	94	1	<	<	X
gs-894	94	2	0.0001	0.0001	NUM
gs-894	94	3	additional	additional	ADJ
gs-894	94	4	tests	test	NOUN
gs-894	94	5	(	(	PUNCT
gs-894	94	6	ogtt	ogtt	ADV
gs-894	94	7	,	,	PUNCT
gs-894	94	8	homa	homa	PROPN
gs-894	94	9	index	index	PROPN
gs-894	94	10	,	,	PUNCT
gs-894	94	11	lipid	lipid	NOUN
gs-894	94	12	panel	panel	NOUN
gs-894	94	13	,	,	PUNCT
gs-894	94	14	glycated	glycate	VERB
gs-894	94	15	hemoglobin	hemoglobin	NOUN
gs-894	94	16	)	)	PUNCT
gs-894	94	17	hava	hava	PROPN
gs-894	94	18	been	be	AUX
gs-894	94	19	conducted	conduct	VERB
gs-894	94	20	in	in	ADP
gs-894	94	21	155	155	NUM
gs-894	94	22	(	(	PUNCT
gs-894	94	23	5.3	5.3	NUM
gs-894	94	24	%	%	NOUN
gs-894	94	25	)	)	PUNCT
gs-894	94	26	study	study	NOUN
gs-894	94	27	participants	participant	NOUN
gs-894	94	28	.	.	PUNCT
gs-894	95	1	from	from	ADP
gs-894	95	2	2914	2914	NUM
gs-894	95	3	hiv	hiv	NOUN
gs-894	95	4	infected	infect	VERB
gs-894	95	5	persons	person	NOUN
gs-894	95	6	4.47	4.47	NUM
gs-894	95	7	%	%	NOUN
gs-894	95	8	(	(	PUNCT
gs-894	95	9	95	95	NUM
gs-894	95	10	%	%	NOUN
gs-894	95	11	ci	ci	NOUN
gs-894	95	12	:	:	PUNCT
gs-894	95	13	3.77	3.77	NUM
gs-894	95	14	5.27	5.27	NUM
gs-894	95	15	)	)	PUNCT
gs-894	95	16	had	have	VERB
gs-894	95	17	metabolic	metabolic	NOUN
gs-894	95	18	syndrome	syndrome	NOUN
gs-894	95	19	and	and	CCONJ
gs-894	95	20	2.65	2.65	NUM
gs-894	95	21	%	%	NOUN
gs-894	95	22	(	(	PUNCT
gs-894	95	23	95	95	NUM
gs-894	95	24	%	%	NOUN
gs-894	95	25	ci	ci	NOUN
gs-894	95	26	:	:	PUNCT
gs-894	95	27	2.11	2.11	NUM
gs-894	95	28	3.28	3.28	NUM
gs-894	95	29	)	)	PUNCT
gs-894	95	30	t2d	t2d	NOUN
gs-894	95	31	.	.	PUNCT
gs-894	96	1	from	from	ADP
gs-894	96	2	381	381	NUM
gs-894	96	3	hyperglycemic	hyperglycemic	ADJ
gs-894	96	4	participants	participant	NOUN
gs-894	96	5	33.7	33.7	NUM
gs-894	96	6	%	%	NOUN
gs-894	96	7	(	(	PUNCT
gs-894	96	8	29.0	29.0	NUM
gs-894	96	9	–	–	PUNCT
gs-894	96	10	38.5	38.5	NUM
gs-894	96	11	)	)	PUNCT
gs-894	96	12	had	have	VERB
gs-894	96	13	metabolic	metabolic	NOUN
gs-894	96	14	syndrome	syndrome	NOUN
gs-894	96	15	and	and	CCONJ
gs-894	96	16	19.9	19.9	NUM
gs-894	96	17	%	%	NOUN
gs-894	96	18	(	(	PUNCT
gs-894	96	19	16.0	16.0	NUM
gs-894	96	20	–	–	PUNCT
gs-894	96	21	24.3	24.3	NUM
gs-894	96	22	)	)	PUNCT
gs-894	96	23	t2d	t2d	NOUN
gs-894	96	24	.	.	PUNCT
gs-894	97	1	from	from	ADP
gs-894	97	2	examined	examine	VERB
gs-894	97	3	cohort	cohort	NOUN
gs-894	97	4	(	(	PUNCT
gs-894	97	5	n=155	n=155	NUM
gs-894	97	6	)	)	PUNCT
gs-894	97	7	metabolic	metabolic	NOUN
gs-894	97	8	syndrome	syndrome	NOUN
gs-894	97	9	was	be	AUX
gs-894	97	10	detected	detect	VERB
gs-894	97	11	in	in	ADP
gs-894	97	12	82.2	82.2	NUM
gs-894	97	13	%	%	NOUN
gs-894	97	14	(	(	PUNCT
gs-894	97	15	95	95	NUM
gs-894	97	16	%	%	NOUN
gs-894	97	17	ci	ci	NOUN
gs-894	97	18	:	:	PUNCT
gs-894	97	19	76.2	76.2	NUM
gs-894	97	20	–	–	PUNCT
gs-894	97	21	88.2	88.2	NUM
gs-894	97	22	)	)	PUNCT
gs-894	97	23	and	and	CCONJ
gs-894	97	24	t2d	t2d	NOUN
gs-894	97	25	in	in	ADP
gs-894	97	26	48.4	48.4	NUM
gs-894	97	27	%	%	NOUN
gs-894	97	28	(	(	PUNCT
gs-894	97	29	95	95	NUM
gs-894	97	30	%	%	NOUN
gs-894	97	31	ci	ci	NOUN
gs-894	97	32	:	:	PUNCT
gs-894	97	33	40.5	40.5	NUM
gs-894	97	34	–	–	PUNCT
gs-894	97	35	56.2	56.2	NUM
gs-894	97	36	)	)	PUNCT
gs-894	97	37	cases	case	NOUN
gs-894	97	38	(	(	PUNCT
gs-894	97	39	table	table	NOUN
gs-894	97	40	4	4	NUM
gs-894	97	41	)	)	PUNCT
gs-894	97	42	.	.	PUNCT
gs-894	98	1	table	table	NOUN
gs-894	98	2	4	4	NUM
gs-894	98	3	.	.	PUNCT
gs-894	99	1	the	the	DET
gs-894	99	2	prevalence	prevalence	NOUN
gs-894	99	3	of	of	ADP
gs-894	99	4	type	type	NOUN
gs-894	99	5	2	2	NUM
gs-894	99	6	diabetes	diabetes	NOUN
gs-894	99	7	and	and	CCONJ
gs-894	99	8	metabolic	metabolic	NOUN
gs-894	99	9	syndrome	syndrome	NOUN
gs-894	99	10	among	among	ADP
gs-894	99	11	people	people	NOUN
gs-894	99	12	living	live	VERB
gs-894	99	13	with	with	ADP
gs-894	99	14	hiv	hiv	PROPN
gs-894	99	15	(	(	PUNCT
gs-894	99	16	n=2914	n=2914	PROPN
gs-894	99	17	)	)	PUNCT
gs-894	99	18	,	,	PUNCT
gs-894	99	19	georgia	georgia	PROPN
gs-894	99	20	,	,	PUNCT
gs-894	99	21	2021	2021	NUM
gs-894	99	22	variable	variable	ADJ
gs-894	99	23	metabolic	metabolic	NOUN
gs-894	99	24	syndrome	syndrome	NOUN
gs-894	99	25	(	(	PUNCT
gs-894	99	26	n=	n=	ADJ
gs-894	99	27	130	130	NUM
gs-894	99	28	)	)	PUNCT
gs-894	99	29	95	95	NUM
gs-894	99	30	%	%	NOUN
gs-894	99	31	confidence	confidence	NOUN
gs-894	99	32	interval	interval	NOUN
gs-894	99	33	(	(	PUNCT
gs-894	99	34	ci	ci	NOUN
gs-894	99	35	)	)	PUNCT
gs-894	99	36	type	type	NOUN
gs-894	99	37	2	2	NUM
gs-894	99	38	diabetes	diabetes	NOUN
gs-894	99	39	(	(	PUNCT
gs-894	99	40	n=	n=	ADJ
gs-894	99	41	65	65	NUM
gs-894	99	42	)	)	SYM
gs-894	99	43	95	95	NUM
gs-894	99	44	%	%	NOUN
gs-894	99	45	confidence	confidence	NOUN
gs-894	99	46	interval	interval	NOUN
gs-894	99	47	(	(	PUNCT
gs-894	99	48	ci	ci	NOUN
gs-894	99	49	)	)	PUNCT
gs-894	99	50	total	total	NOUN
gs-894	99	51	(	(	PUNCT
gs-894	99	52	n	n	NOUN
gs-894	99	53	=	=	SYM
gs-894	99	54	2194	2194	NUM
gs-894	99	55	)	)	PUNCT
gs-894	99	56	4.47	4.47	NUM
gs-894	99	57	%	%	NOUN
gs-894	99	58	3.77	3.77	NUM
gs-894	99	59	5.27	5.27	NUM
gs-894	99	60	2.65	2.65	NUM
gs-894	99	61	%	%	NOUN
gs-894	99	62	2.11	2.11	NUM
gs-894	99	63	3.28	3.28	NUM
gs-894	99	64	hyperglycemia	hyperglycemia	NOUN
gs-894	99	65	(	(	PUNCT
gs-894	99	66	n=	n=	ADJ
gs-894	99	67	381	381	NUM
gs-894	99	68	)	)	PUNCT
gs-894	99	69	33.7	33.7	NUM
gs-894	99	70	%	%	NOUN
gs-894	99	71	29.0	29.0	NUM
gs-894	99	72	–	–	PUNCT
gs-894	99	73	38.5	38.5	NUM
gs-894	99	74	19.9	19.9	NUM
gs-894	99	75	%	%	NOUN
gs-894	99	76	16.0	16.0	NUM
gs-894	99	77	–	–	PUNCT
gs-894	99	78	24.3	24.3	NUM
gs-894	99	79	examined	examine	VERB
gs-894	99	80	cohort	cohort	NOUN
gs-894	99	81	(	(	PUNCT
gs-894	99	82	n=155	n=155	NUM
gs-894	99	83	)	)	PUNCT
gs-894	99	84	(	(	PUNCT
gs-894	99	85	ogtt	ogtt	CCONJ
gs-894	99	86	homa	homa	PROPN
gs-894	99	87	index	index	NOUN
gs-894	99	88	lipid	lipid	NOUN
gs-894	99	89	panel	panel	NOUN
gs-894	99	90	glycated	glycate	VERB
gs-894	99	91	hemoglobin	hemoglobin	NOUN
gs-894	99	92	)	)	PUNCT
gs-894	99	93	82.2	82.2	NUM
gs-894	99	94	%	%	NOUN
gs-894	99	95	76.2	76.2	NUM
gs-894	99	96	–	–	PUNCT
gs-894	99	97	88.2	88.2	NUM
gs-894	99	98	48.4	48.4	NUM
gs-894	99	99	%	%	NOUN
gs-894	99	100	40.5	40.5	NUM
gs-894	99	101	–	–	PUNCT
gs-894	99	102	56.2	56.2	NUM
gs-894	99	103	georgian	georgian	ADJ
gs-894	99	104	scientists/ქართველი	scientists/ქართველი	NOUN
gs-894	99	105	მეცნიერები	მეცნიერები	VERB
gs-894	99	106	4(02	4(02	NUM
gs-894	99	107	)	)	PUNCT
gs-894	99	108	,	,	PUNCT
gs-894	99	109	2022	2022	NUM
gs-894	99	110	199	199	NUM
gs-894	99	111	in	in	ADP
gs-894	99	112	total	total	ADJ
gs-894	99	113	171	171	NUM
gs-894	99	114	(	(	PUNCT
gs-894	99	115	5.87	5.87	NUM
gs-894	99	116	%	%	NOUN
gs-894	99	117	)	)	PUNCT
gs-894	99	118	participants	participant	NOUN
gs-894	99	119	had	have	VERB
gs-894	99	120	tb	tb	NOUN
gs-894	99	121	.	.	PUNCT
gs-894	99	122	hyperglycemia	hyperglycemia	NOUN
gs-894	99	123	and	and	CCONJ
gs-894	99	124	tb	tb	NOUN
gs-894	99	125	together	together	ADV
gs-894	99	126	was	be	AUX
gs-894	99	127	detected	detect	VERB
gs-894	99	128	in	in	ADP
gs-894	99	129	48.5	48.5	NUM
gs-894	99	130	%	%	NOUN
gs-894	99	131	(	(	PUNCT
gs-894	99	132	83	83	NUM
gs-894	99	133	)	)	PUNCT
gs-894	99	134	of	of	ADP
gs-894	99	135	all	all	PRON
gs-894	99	136	tb	tb	ADP
gs-894	99	137	patients	patient	NOUN
gs-894	99	138	.	.	PUNCT
gs-894	100	1	relative	relative	ADJ
gs-894	100	2	risk	risk	NOUN
gs-894	100	3	(	(	PUNCT
gs-894	100	4	rr	rr	NOUN
gs-894	100	5	)	)	PUNCT
gs-894	100	6	of	of	ADP
gs-894	100	7	tb	tb	PROPN
gs-894	100	8	was	be	AUX
gs-894	100	9	0.94	0.94	NUM
gs-894	100	10	(	(	PUNCT
gs-894	100	11	95	95	NUM
gs-894	100	12	%	%	NOUN
gs-894	100	13	ci	ci	NOUN
gs-894	100	14	:	:	PUNCT
gs-894	100	15	0.85	0.85	NUM
gs-894	100	16	-	-	SYM
gs-894	100	17	1.56	1.56	NUM
gs-894	100	18	)	)	PUNCT
gs-894	100	19	.	.	PUNCT
gs-894	101	1	32	32	NUM
gs-894	101	2	participants	participant	NOUN
gs-894	101	3	had	have	VERB
gs-894	101	4	ckd	ckd	PROPN
gs-894	101	5	,	,	PUNCT
gs-894	101	6	50	50	NUM
gs-894	101	7	%	%	NOUN
gs-894	101	8	(	(	PUNCT
gs-894	101	9	p=0.08	p=0.08	NOUN
gs-894	101	10	)	)	PUNCT
gs-894	101	11	had	have	VERB
gs-894	101	12	hyperglycemia	hyperglycemia	NOUN
gs-894	101	13	.	.	PUNCT
gs-894	102	1	cvd	cvd	PROPN
gs-894	102	2	was	be	AUX
gs-894	102	3	detected	detect	VERB
gs-894	102	4	in	in	ADP
gs-894	102	5	92	92	NUM
gs-894	102	6	participants	participant	NOUN
gs-894	102	7	,	,	PUNCT
gs-894	102	8	44.6	44.6	NUM
gs-894	102	9	%	%	NOUN
gs-894	102	10	(	(	PUNCT
gs-894	102	11	p=0.07	p=0.07	X
gs-894	102	12	)	)	PUNCT
gs-894	102	13	was	be	AUX
gs-894	102	14	hyperglycemic.16	hyperglycemic.16	ADJ
gs-894	102	15	patients	patient	NOUN
gs-894	102	16	had	have	VERB
gs-894	102	17	a	a	DET
gs-894	102	18	stroke	stroke	NOUN
gs-894	102	19	,	,	PUNCT
gs-894	102	20	from	from	ADP
gs-894	102	21	which	which	PRON
gs-894	102	22	11	11	NUM
gs-894	102	23	(	(	PUNCT
gs-894	102	24	68.8	68.8	NUM
gs-894	102	25	%	%	NOUN
gs-894	102	26	)	)	PUNCT
gs-894	102	27	had	have	VERB
gs-894	102	28	hyperglycemia	hyperglycemia	NOUN
gs-894	102	29	.	.	PUNCT
gs-894	103	1	the	the	DET
gs-894	103	2	rr	rr	PROPN
gs-894	103	3	of	of	ADP
gs-894	103	4	stroke	stroke	NOUN
gs-894	103	5	=	=	NOUN
gs-894	103	6	1.8	1.8	NUM
gs-894	103	7	(	(	PUNCT
gs-894	103	8	95	95	NUM
gs-894	103	9	%	%	NOUN
gs-894	103	10	ci	ci	NOUN
gs-894	103	11	:	:	PUNCT
gs-894	103	12	1.454.76	1.454.76	NUM
gs-894	103	13	)	)	PUNCT
gs-894	103	14	.	.	PUNCT
gs-894	104	1	550	550	NUM
gs-894	104	2	(	(	PUNCT
gs-894	104	3	18.9	18.9	NUM
gs-894	104	4	%	%	NOUN
gs-894	104	5	)	)	PUNCT
gs-894	104	6	patients	patient	NOUN
gs-894	104	7	had	have	VERB
gs-894	104	8	high	high	ADJ
gs-894	104	9	total	total	ADJ
gs-894	104	10	cholesterol	cholesterol	NOUN
gs-894	104	11	and	and	CCONJ
gs-894	104	12	ldl	ldl	NOUN
gs-894	104	13	level	level	NOUN
gs-894	104	14	,	,	PUNCT
gs-894	104	15	195	195	NUM
gs-894	104	16	(	(	PUNCT
gs-894	104	17	35	35	NUM
gs-894	104	18	%	%	NOUN
gs-894	104	19	)	)	PUNCT
gs-894	104	20	had	have	VERB
gs-894	104	21	hyperglycemia	hyperglycemia	NOUN
gs-894	104	22	.	.	PUNCT
gs-894	105	1	in	in	ADP
gs-894	105	2	our	our	PRON
gs-894	105	3	study	study	NOUN
gs-894	105	4	the	the	DET
gs-894	105	5	prevalence	prevalence	NOUN
gs-894	105	6	of	of	ADP
gs-894	105	7	hyperglycemia	hyperglycemia	NOUN
gs-894	105	8	was	be	AUX
gs-894	105	9	significantly	significantly	ADV
gs-894	105	10	higher	high	ADJ
gs-894	105	11	in	in	ADP
gs-894	105	12	male	male	PROPN
gs-894	105	13	hiv	hiv	PROPN
gs-894	105	14	infected	infect	VERB
gs-894	105	15	participants	participant	NOUN
gs-894	105	16	,	,	PUNCT
gs-894	105	17	compared	compare	VERB
gs-894	105	18	to	to	ADP
gs-894	105	19	the	the	DET
gs-894	105	20	female	female	ADJ
gs-894	105	21	hiv	hiv	PROPN
gs-894	105	22	infected	infect	VERB
gs-894	105	23	persons	person	NOUN
gs-894	105	24	.	.	PUNCT
gs-894	106	1	similar	similar	ADJ
gs-894	106	2	results	result	NOUN
gs-894	106	3	have	have	AUX
gs-894	106	4	been	be	AUX
gs-894	106	5	reported	report	VERB
gs-894	106	6	from	from	ADP
gs-894	106	7	china	china	PROPN
gs-894	106	8	(	(	PUNCT
gs-894	106	9	shen	shen	PROPN
gs-894	106	10	et	et	PROPN
gs-894	106	11	al	al	PROPN
gs-894	106	12	.	.	PROPN
gs-894	106	13	2016)1	2016)1	NUM
gs-894	106	14	in	in	ADP
gs-894	106	15	contrast	contrast	NOUN
gs-894	106	16	to	to	ADP
gs-894	106	17	spanish	spanish	ADJ
gs-894	106	18	study	study	NOUN
gs-894	106	19	(	(	PUNCT
gs-894	106	20	alvaro	alvaro	PROPN
gs-894	106	21	-	-	PUNCT
gs-894	106	22	meca	meca	PROPN
gs-894	106	23	et	et	PROPN
gs-894	106	24	al	al	PROPN
gs-894	106	25	.	.	PROPN
gs-894	106	26	2016	2016	NUM
gs-894	106	27	)	)	PUNCT
gs-894	106	28	.	.	PUNCT
gs-894	107	1	spanish	spanish	ADJ
gs-894	107	2	study	study	NOUN
gs-894	107	3	outlined	outline	VERB
gs-894	107	4	,	,	PUNCT
gs-894	107	5	that	that	DET
gs-894	107	6	hyperglycemia	hyperglycemia	NOUN
gs-894	107	7	was	be	AUX
gs-894	107	8	more	more	ADV
gs-894	107	9	prevalent	prevalent	ADJ
gs-894	107	10	in	in	ADP
gs-894	107	11	female	female	ADJ
gs-894	107	12	hiv	hiv	PROPN
gs-894	107	13	patients	patient	NOUN
gs-894	107	14	37	37	NUM
gs-894	107	15	.	.	PUNCT
gs-894	108	1	our	our	PRON
gs-894	108	2	research	research	NOUN
gs-894	108	3	demonstrates	demonstrate	VERB
gs-894	108	4	that	that	SCONJ
gs-894	108	5	the	the	DET
gs-894	108	6	prevalence	prevalence	NOUN
gs-894	108	7	of	of	ADP
gs-894	108	8	hyperglycemia	hyperglycemia	NOUN
gs-894	108	9	increases	increase	NOUN
gs-894	108	10	by	by	ADP
gs-894	108	11	the	the	DET
gs-894	108	12	age	age	NOUN
gs-894	108	13	.	.	PUNCT
gs-894	109	1	results	result	NOUN
gs-894	109	2	are	be	AUX
gs-894	109	3	not	not	PART
gs-894	109	4	surprising	surprising	ADJ
gs-894	109	5	,	,	PUNCT
gs-894	109	6	because	because	SCONJ
gs-894	109	7	,	,	PUNCT
gs-894	109	8	similar	similar	ADJ
gs-894	109	9	results	result	NOUN
gs-894	109	10	have	have	AUX
gs-894	109	11	been	be	AUX
gs-894	109	12	reported	report	VERB
gs-894	109	13	in	in	ADP
gs-894	109	14	other	other	ADJ
gs-894	109	15	studies	study	NOUN
gs-894	109	16	about	about	ADP
gs-894	109	17	plwh5	plwh5	NOUN
gs-894	109	18	,	,	PUNCT
gs-894	109	19	15	15	NUM
gs-894	109	20	,	,	PUNCT
gs-894	109	21	38	38	NUM
gs-894	109	22	,	,	PUNCT
gs-894	109	23	39and	39and	PRON
gs-894	109	24	general	general	ADJ
gs-894	109	25	population36	population36	NOUN
gs-894	109	26	.	.	PUNCT
gs-894	110	1	factors	factor	NOUN
gs-894	110	2	such	such	ADJ
gs-894	110	3	as	as	ADP
gs-894	110	4	a	a	DET
gs-894	110	5	family	family	NOUN
gs-894	110	6	history	history	NOUN
gs-894	110	7	of	of	ADP
gs-894	110	8	diabetes	diabetes	NOUN
gs-894	110	9	,	,	PUNCT
gs-894	110	10	weight	weight	NOUN
gs-894	110	11	gain	gain	NOUN
gs-894	110	12	,	,	PUNCT
gs-894	110	13	obesity	obesity	NOUN
gs-894	110	14	and	and	CCONJ
gs-894	110	15	insulin	insulin	NOUN
gs-894	110	16	resistance	resistance	NOUN
gs-894	110	17	can	can	AUX
gs-894	110	18	lead	lead	VERB
gs-894	110	19	increased	increase	VERB
gs-894	110	20	blood	blood	NOUN
gs-894	110	21	glucose	glucose	NOUN
gs-894	110	22	levels11	levels11	NOUN
gs-894	110	23	.	.	PUNCT
gs-894	111	1	furthermore	furthermore	ADV
gs-894	111	2	,	,	PUNCT
gs-894	111	3	some	some	DET
gs-894	111	4	antiretroviral	antiretroviral	ADJ
gs-894	111	5	drugs	drug	NOUN
gs-894	111	6	,	,	PUNCT
gs-894	111	7	such	such	ADJ
gs-894	111	8	as	as	ADP
gs-894	111	9	pi	pi	PROPN
gs-894	111	10	’s	’s	PART
gs-894	111	11	and	and	CCONJ
gs-894	111	12	nrti	nrti	PROPN
gs-894	111	13	’s	’	VERB
gs-894	111	14	were	be	AUX
gs-894	111	15	related	relate	VERB
gs-894	111	16	to	to	ADP
gs-894	111	17	the	the	DET
gs-894	111	18	higher	high	ADJ
gs-894	111	19	risk	risk	NOUN
gs-894	111	20	of	of	ADP
gs-894	111	21	t2d	t2d	NOUN
gs-894	111	22	.	.	PUNCT
gs-894	112	1	longer	long	ADJ
gs-894	112	2	art	art	NOUN
gs-894	112	3	exposure	exposure	NOUN
gs-894	112	4	was	be	AUX
gs-894	112	5	shown	show	VERB
gs-894	112	6	to	to	PART
gs-894	112	7	be	be	AUX
gs-894	112	8	responsible	responsible	ADJ
gs-894	112	9	for	for	ADP
gs-894	112	10	increased	increase	VERB
gs-894	112	11	risk	risk	NOUN
gs-894	112	12	of	of	ADP
gs-894	112	13	hyperglycemia	hyperglycemia	NOUN
gs-894	112	14	and	and	CCONJ
gs-894	112	15	diabetes	diabetes	NOUN
gs-894	112	16	mellitus	mellitus	NOUN
gs-894	112	17	1	1	NUM
gs-894	112	18	,	,	PUNCT
gs-894	112	19	3	3	NUM
gs-894	112	20	,	,	PUNCT
gs-894	112	21	4	4	NUM
gs-894	112	22	,	,	PUNCT
gs-894	112	23	11	11	NUM
gs-894	112	24	.	.	PUNCT
gs-894	113	1	in	in	ADP
gs-894	113	2	addition	addition	NOUN
gs-894	113	3	,	,	PUNCT
gs-894	113	4	there	there	PRON
gs-894	113	5	are	be	VERB
gs-894	113	6	a	a	DET
gs-894	113	7	lot	lot	NOUN
gs-894	113	8	of	of	ADP
gs-894	113	9	discussions	discussion	NOUN
gs-894	113	10	whether	whether	SCONJ
gs-894	113	11	or	or	CCONJ
gs-894	113	12	not	not	PART
gs-894	113	13	hiv	hiv	PROPN
gs-894	113	14	infection	infection	NOUN
gs-894	113	15	alone	alone	ADV
gs-894	113	16	can	can	AUX
gs-894	113	17	promote	promote	VERB
gs-894	113	18	to	to	ADP
gs-894	113	19	the	the	DET
gs-894	113	20	development	development	NOUN
gs-894	113	21	of	of	ADP
gs-894	113	22	t2d	t2d	NOUN
gs-894	113	23	.	.	PUNCT
gs-894	114	1	for	for	ADP
gs-894	114	2	example	example	NOUN
gs-894	114	3	,	,	PUNCT
gs-894	114	4	a	a	DET
gs-894	114	5	study	study	NOUN
gs-894	114	6	of	of	ADP
gs-894	114	7	2009	2009	NUM
gs-894	114	8	-	-	SYM
gs-894	114	9	2012	2012	NUM
gs-894	114	10	years	year	NOUN
gs-894	114	11	in	in	ADP
gs-894	114	12	china	china	PROPN
gs-894	114	13	,	,	PUNCT
gs-894	114	14	conducted	conduct	VERB
gs-894	114	15	among	among	ADP
gs-894	114	16	newly	newly	ADV
gs-894	114	17	diagnosed	diagnose	VERB
gs-894	114	18	hiv	hiv	NOUN
gs-894	114	19	patients	patient	NOUN
gs-894	114	20	who	who	PRON
gs-894	114	21	were	be	AUX
gs-894	114	22	not	not	PART
gs-894	114	23	taking	take	VERB
gs-894	114	24	antiretroviral	antiretroviral	ADJ
gs-894	114	25	drugs	drug	NOUN
gs-894	114	26	,	,	PUNCT
gs-894	114	27	found	find	VERB
gs-894	114	28	a	a	DET
gs-894	114	29	significant	significant	ADJ
gs-894	114	30	association	association	NOUN
gs-894	114	31	between	between	ADP
gs-894	114	32	hiv	hiv	PROPN
gs-894	114	33	and	and	CCONJ
gs-894	114	34	t2d	t2d	NOUN
gs-894	114	35	,	,	PUNCT
gs-894	114	36	suggesting	suggest	VERB
gs-894	114	37	that	that	PRON
gs-894	114	38	hyperglycemia	hyperglycemia	NOUN
gs-894	114	39	in	in	ADP
gs-894	114	40	hiv	hiv	PROPN
gs-894	114	41	patients	patient	NOUN
gs-894	114	42	might	might	AUX
gs-894	114	43	be	be	AUX
gs-894	114	44	explained	explain	VERB
gs-894	114	45	by	by	ADP
gs-894	114	46	not	not	PART
gs-894	114	47	only	only	ADV
gs-894	114	48	art	art	NOUN
gs-894	114	49	use	use	NOUN
gs-894	114	50	,	,	PUNCT
gs-894	114	51	but	but	CCONJ
gs-894	114	52	by	by	ADP
gs-894	114	53	hiv	hiv	PROPN
gs-894	114	54	infection	infection	NOUN
gs-894	114	55	itself	itself	PRON
gs-894	114	56	40	40	NUM
gs-894	114	57	.	.	PUNCT
gs-894	115	1	unfortunately	unfortunately	ADV
gs-894	115	2	,	,	PUNCT
gs-894	115	3	association	association	NOUN
gs-894	115	4	between	between	ADP
gs-894	115	5	art	art	NOUN
gs-894	115	6	and	and	CCONJ
gs-894	115	7	diabetes	diabetes	NOUN
gs-894	115	8	or	or	CCONJ
gs-894	115	9	hyperglycemia	hyperglycemia	NOUN
gs-894	115	10	could	could	AUX
gs-894	115	11	not	not	PART
gs-894	115	12	be	be	AUX
gs-894	115	13	examined	examine	VERB
gs-894	115	14	in	in	ADP
gs-894	115	15	our	our	PRON
gs-894	115	16	study	study	NOUN
gs-894	115	17	as	as	SCONJ
gs-894	115	18	all	all	DET
gs-894	115	19	the	the	DET
gs-894	115	20	patients	patient	NOUN
gs-894	115	21	diagnosed	diagnose	VERB
gs-894	115	22	with	with	ADP
gs-894	115	23	hiv	hiv	PROPN
gs-894	115	24	in	in	ADP
gs-894	115	25	our	our	PRON
gs-894	115	26	cohort	cohort	NOUN
gs-894	115	27	received	receive	VERB
gs-894	115	28	art	art	NOUN
gs-894	115	29	immediately	immediately	ADV
gs-894	115	30	after	after	ADP
gs-894	115	31	the	the	DET
gs-894	115	32	diagnosis	diagnosis	NOUN
gs-894	115	33	.	.	PUNCT
gs-894	116	1	our	our	PRON
gs-894	116	2	study	study	NOUN
gs-894	116	3	found	find	VERB
gs-894	116	4	out	out	ADP
gs-894	116	5	that	that	SCONJ
gs-894	116	6	the	the	DET
gs-894	116	7	prevalence	prevalence	NOUN
gs-894	116	8	of	of	ADP
gs-894	116	9	t2d	t2d	NOUN
gs-894	116	10	in	in	ADP
gs-894	116	11	total	total	ADJ
gs-894	116	12	cohort	cohort	NOUN
gs-894	116	13	was	be	AUX
gs-894	116	14	2.65	2.65	NUM
gs-894	116	15	%	%	NOUN
gs-894	116	16	.	.	PUNCT
gs-894	117	1	similar	similar	ADJ
gs-894	117	2	results	result	NOUN
gs-894	117	3	have	have	AUX
gs-894	117	4	been	be	AUX
gs-894	117	5	reported	report	VERB
gs-894	117	6	from	from	ADP
gs-894	117	7	denmark	denmark	PROPN
gs-894	117	8	(	(	PUNCT
gs-894	117	9	rasmussen	rasmussen	PROPN
gs-894	117	10	et	et	PROPN
gs-894	117	11	al	al	PROPN
gs-894	117	12	.	.	PROPN
gs-894	117	13	2012	2012	NUM
gs-894	117	14	,	,	PUNCT
gs-894	117	15	worm	worm	NOUN
gs-894	117	16	et	et	PROPN
gs-894	117	17	al	al	PROPN
gs-894	117	18	.2009)41	.2009)41	PROPN
gs-894	117	19	,	,	PUNCT
gs-894	117	20	42	42	NUM
gs-894	117	21	in	in	ADP
gs-894	117	22	contrast	contrast	NOUN
gs-894	117	23	to	to	ADP
gs-894	117	24	researches	research	NOUN
gs-894	117	25	in	in	ADP
gs-894	117	26	china	china	PROPN
gs-894	117	27	and	and	CCONJ
gs-894	117	28	the	the	DET
gs-894	117	29	usa	usa	PROPN
gs-894	117	30	,	,	PUNCT
gs-894	117	31	where	where	SCONJ
gs-894	117	32	prevalence	prevalence	NOUN
gs-894	117	33	of	of	ADP
gs-894	117	34	t2d	t2d	NUM
gs-894	117	35	was	be	AUX
gs-894	117	36	9.7	9.7	NUM
gs-894	117	37	%	%	NOUN
gs-894	117	38	and	and	CCONJ
gs-894	117	39	10.3	10.3	NUM
gs-894	117	40	%	%	NOUN
gs-894	117	41	respectively1	respectively1	PROPN
gs-894	117	42	,	,	PUNCT
gs-894	117	43	5	5	NUM
gs-894	117	44	.	.	PUNCT
gs-894	118	1	it	it	PRON
gs-894	118	2	should	should	AUX
gs-894	118	3	be	be	AUX
gs-894	118	4	taken	take	VERB
gs-894	118	5	into	into	ADP
gs-894	118	6	account	account	NOUN
gs-894	118	7	that	that	PRON
gs-894	118	8	study	study	NOUN
gs-894	118	9	cohort	cohort	NOUN
gs-894	118	10	age	age	NOUN
gs-894	118	11	was	be	AUX
gs-894	118	12	young	young	ADJ
gs-894	118	13	(	(	PUNCT
gs-894	118	14	about	about	ADP
gs-894	118	15	40	40	NUM
gs-894	118	16	years	year	NOUN
gs-894	118	17	old	old	ADJ
gs-894	118	18	)	)	PUNCT
gs-894	118	19	.	.	PUNCT
gs-894	119	1	t2d	t2d	NUM
gs-894	119	2	is	be	AUX
gs-894	119	3	more	more	ADV
gs-894	119	4	common	common	ADJ
gs-894	119	5	in	in	ADP
gs-894	119	6	people	people	NOUN
gs-894	119	7	above	above	ADP
gs-894	119	8	40	40	NUM
gs-894	119	9	years	year	NOUN
gs-894	119	10	old	old	ADJ
gs-894	119	11	,	,	PUNCT
gs-894	119	12	so	so	ADV
gs-894	119	13	theoretically	theoretically	ADV
gs-894	119	14	it	it	PRON
gs-894	119	15	’s	’	VERB
gs-894	119	16	possible	possible	ADJ
gs-894	119	17	,	,	PUNCT
gs-894	119	18	that	that	SCONJ
gs-894	119	19	young	young	ADJ
gs-894	119	20	participants	participant	NOUN
gs-894	119	21	might	might	AUX
gs-894	119	22	decrease	decrease	VERB
gs-894	119	23	the	the	DET
gs-894	119	24	prevalence	prevalence	NOUN
gs-894	119	25	of	of	ADP
gs-894	119	26	diabetes	diabetes	NOUN
gs-894	119	27	in	in	ADP
gs-894	119	28	the	the	DET
gs-894	119	29	total	total	ADJ
gs-894	119	30	cohort	cohort	NOUN
gs-894	119	31	.	.	PUNCT
gs-894	120	1	age	age	NOUN
gs-894	120	2	distribution	distribution	NOUN
gs-894	120	3	of	of	ADP
gs-894	120	4	hyperglycemia	hyperglycemia	NOUN
gs-894	120	5	proved	prove	VERB
gs-894	120	6	the	the	DET
gs-894	120	7	same	same	ADJ
gs-894	120	8	as	as	SCONJ
gs-894	120	9	it	it	PRON
gs-894	120	10	was	be	AUX
gs-894	120	11	the	the	DET
gs-894	120	12	highest	high	ADJ
gs-894	120	13	in	in	ADP
gs-894	120	14	people	people	NOUN
gs-894	120	15	aged	age	VERB
gs-894	120	16	40	40	NUM
gs-894	120	17	-	-	SYM
gs-894	120	18	65	65	NUM
gs-894	120	19	+	+	NOUN
gs-894	120	20	.	.	PUNCT
gs-894	121	1	a	a	DET
gs-894	121	2	similar	similar	ADJ
gs-894	121	3	association	association	NOUN
gs-894	121	4	between	between	ADP
gs-894	121	5	increasing	increase	VERB
gs-894	121	6	age	age	NOUN
gs-894	121	7	and	and	CCONJ
gs-894	121	8	prevalence	prevalence	NOUN
gs-894	121	9	of	of	ADP
gs-894	121	10	t2d	t2d	NOUN
gs-894	121	11	among	among	ADP
gs-894	121	12	plwh	plwh	NOUN
gs-894	121	13	found	find	VERB
gs-894	121	14	in	in	ADP
gs-894	121	15	many	many	ADJ
gs-894	121	16	other	other	ADJ
gs-894	121	17	studies5	studies5	PROPN
gs-894	121	18	,	,	PUNCT
gs-894	121	19	38	38	NUM
gs-894	121	20	,	,	PUNCT
gs-894	121	21	39	39	NUM
gs-894	121	22	.	.	PUNCT
gs-894	122	1	our	our	PRON
gs-894	122	2	study	study	NOUN
gs-894	122	3	found	find	VERB
gs-894	122	4	that	that	SCONJ
gs-894	122	5	the	the	DET
gs-894	122	6	prevalence	prevalence	NOUN
gs-894	122	7	of	of	ADP
gs-894	122	8	tuberculosis	tuberculosis	NOUN
gs-894	122	9	was	be	AUX
gs-894	122	10	5.87	5.87	NUM
gs-894	122	11	%	%	NOUN
gs-894	122	12	among	among	ADP
gs-894	122	13	people	people	NOUN
gs-894	122	14	living	live	VERB
gs-894	122	15	with	with	ADP
gs-894	122	16	hiv	hiv	PROPN
gs-894	122	17	.	.	PUNCT
gs-894	123	1	based	base	VERB
gs-894	123	2	on	on	ADP
gs-894	123	3	our	our	PRON
gs-894	123	4	results	result	NOUN
gs-894	123	5	the	the	DET
gs-894	123	6	prevalence	prevalence	NOUN
gs-894	123	7	of	of	ADP
gs-894	123	8	tb	tb	NOUN
gs-894	123	9	with	with	ADP
gs-894	123	10	and	and	CCONJ
gs-894	123	11	without	without	ADP
gs-894	123	12	hyperglycemia	hyperglycemia	NOUN
gs-894	123	13	did	do	AUX
gs-894	123	14	not	not	PART
gs-894	123	15	differ	differ	VERB
gs-894	123	16	significantly	significantly	ADV
gs-894	123	17	.	.	PUNCT
gs-894	124	1	similar	similar	ADJ
gs-894	124	2	results	result	NOUN
gs-894	124	3	have	have	AUX
gs-894	124	4	been	be	AUX
gs-894	124	5	found	find	VERB
gs-894	124	6	in	in	ADP
gs-894	124	7	uk	uk	PROPN
gs-894	124	8	by	by	ADP
gs-894	124	9	pealing	peal	VERB
gs-894	124	10	et	et	NOUN
gs-894	124	11	al	al	PROPN
gs-894	124	12	43	43	PROPN
gs-894	124	13	.	.	PUNCT
gs-894	125	1	other	other	ADJ
gs-894	125	2	studies	study	NOUN
gs-894	125	3	revealed	reveal	VERB
gs-894	125	4	different	different	ADJ
gs-894	125	5	results	result	NOUN
gs-894	125	6	and	and	CCONJ
gs-894	125	7	showed	show	VERB
gs-894	125	8	,	,	PUNCT
gs-894	125	9	that	that	PRON
gs-894	125	10	diabetes	diabetes	NOUN
gs-894	125	11	and	and	CCONJ
gs-894	125	12	hyperglycemia	hyperglycemia	NOUN
gs-894	125	13	were	be	AUX
gs-894	125	14	significantly	significantly	ADV
gs-894	125	15	associated	associate	VERB
gs-894	125	16	with	with	ADP
gs-894	125	17	increased	increase	VERB
gs-894	125	18	risk	risk	NOUN
gs-894	125	19	of	of	ADP
gs-894	125	20	tb30	tb30	PROPN
gs-894	125	21	,	,	PUNCT
gs-894	125	22	32	32	NUM
gs-894	125	23	,	,	PUNCT
gs-894	125	24	33	33	NUM
gs-894	125	25	.	.	PUNCT
gs-894	126	1	according	accord	VERB
gs-894	126	2	to	to	ADP
gs-894	126	3	,	,	PUNCT
gs-894	126	4	the	the	DET
gs-894	126	5	study	study	NOUN
gs-894	126	6	in	in	ADP
gs-894	126	7	sounth	sounth	ADJ
gs-894	126	8	africa	africa	PROPN
gs-894	126	9	by	by	ADP
gs-894	126	10	oni	oni	PROPN
gs-894	126	11	et	et	NOUN
gs-894	126	12	al	al	PROPN
gs-894	126	13	tb	tb	PROPN
gs-894	126	14	in	in	ADP
gs-894	126	15	hyperglycemic	hyperglycemic	ADJ
gs-894	126	16	patients	patient	NOUN
gs-894	126	17	were	be	AUX
gs-894	126	18	2.4	2.4	NUM
gs-894	126	19	fold	fold	ADV
gs-894	126	20	higher	higher	ADV
gs-894	126	21	,	,	PUNCT
gs-894	126	22	compared	compare	VERB
gs-894	126	23	to	to	ADP
gs-894	126	24	georgian	georgian	ADJ
gs-894	126	25	scientists/ქართველი	scientists/ქართველი	PROPN
gs-894	126	26	მეცნიერები	მეცნიერები	NOUN
gs-894	126	27	4(02	4(02	NUM
gs-894	126	28	)	)	PUNCT
gs-894	126	29	,	,	PUNCT
gs-894	126	30	2022	2022	NUM
gs-894	126	31	200	200	NUM
gs-894	126	32	normoglycemic	normoglycemic	ADJ
gs-894	126	33	cohort33	cohort33	NOUN
gs-894	126	34	.	.	PUNCT
gs-894	127	1	other	other	ADJ
gs-894	127	2	studies	study	NOUN
gs-894	127	3	suggested	suggest	VERB
gs-894	127	4	,	,	PUNCT
gs-894	127	5	that	that	DET
gs-894	127	6	hyperglycemia	hyperglycemia	NOUN
gs-894	127	7	is	be	AUX
gs-894	127	8	associated	associate	VERB
gs-894	127	9	with	with	ADP
gs-894	127	10	higher	high	ADJ
gs-894	127	11	mortality	mortality	NOUN
gs-894	127	12	rates	rate	NOUN
gs-894	127	13	in	in	ADP
gs-894	127	14	tb	tb	ADP
gs-894	127	15	patients19	patients19	PROPN
gs-894	127	16	,	,	PUNCT
gs-894	127	17	44	44	NUM
gs-894	127	18	,	,	PUNCT
gs-894	127	19	45	45	NUM
gs-894	127	20	.	.	PUNCT
gs-894	128	1	in	in	ADP
gs-894	128	2	our	our	PRON
gs-894	128	3	research	research	NOUN
gs-894	128	4	,	,	PUNCT
gs-894	128	5	the	the	DET
gs-894	128	6	most	most	ADV
gs-894	128	7	common	common	ADJ
gs-894	128	8	complication	complication	NOUN
gs-894	128	9	was	be	AUX
gs-894	128	10	dyslipidemia	dyslipidemia	NOUN
gs-894	128	11	.	.	PUNCT
gs-894	129	1	we	we	PRON
gs-894	129	2	found	find	VERB
gs-894	129	3	out	out	ADP
gs-894	129	4	that	that	SCONJ
gs-894	129	5	1/5	1/5	NUM
gs-894	129	6	of	of	ADP
gs-894	129	7	our	our	PRON
gs-894	129	8	cohort	cohort	NOUN
gs-894	129	9	had	have	VERB
gs-894	129	10	a	a	DET
gs-894	129	11	high	high	ADJ
gs-894	129	12	cholesterol	cholesterol	NOUN
gs-894	129	13	level	level	NOUN
gs-894	129	14	.	.	PUNCT
gs-894	130	1	as	as	SCONJ
gs-894	130	2	we	we	PRON
gs-894	130	3	mentioned	mention	VERB
gs-894	130	4	hiv	hiv	PROPN
gs-894	130	5	and	and	CCONJ
gs-894	130	6	art	art	NOUN
gs-894	130	7	are	be	AUX
gs-894	130	8	key	key	ADJ
gs-894	130	9	factors	factor	NOUN
gs-894	130	10	in	in	ADP
gs-894	130	11	disease	disease	NOUN
gs-894	130	12	development8	development8	NOUN
gs-894	130	13	,	,	PUNCT
gs-894	130	14	16	16	NUM
gs-894	130	15	,	,	PUNCT
gs-894	130	16	23	23	NUM
gs-894	130	17	,	,	PUNCT
gs-894	130	18	34	34	NUM
gs-894	130	19	,	,	PUNCT
gs-894	130	20	46	46	NUM
gs-894	130	21	-	-	SYM
gs-894	130	22	48	48	NUM
gs-894	130	23	.	.	PUNCT
gs-894	131	1	in	in	ADP
gs-894	131	2	addition	addition	NOUN
gs-894	131	3	,	,	PUNCT
gs-894	131	4	well	well	ADV
gs-894	131	5	know	know	VERB
gs-894	131	6	factors	factor	NOUN
gs-894	131	7	such	such	ADJ
gs-894	131	8	as	as	ADP
gs-894	131	9	an	an	DET
gs-894	131	10	unhealthy	unhealthy	ADJ
gs-894	131	11	diet	diet	NOUN
gs-894	131	12	,	,	PUNCT
gs-894	131	13	low	low	ADJ
gs-894	131	14	physical	physical	ADJ
gs-894	131	15	activity	activity	NOUN
gs-894	131	16	and	and	CCONJ
gs-894	131	17	cigarette	cigarette	NOUN
gs-894	131	18	smoking	smoking	NOUN
gs-894	131	19	increase	increase	NOUN
gs-894	131	20	risk	risk	NOUN
gs-894	131	21	of	of	ADP
gs-894	131	22	dyslipidemia	dyslipidemia	NOUN
gs-894	131	23	.	.	PUNCT
gs-894	132	1	if	if	SCONJ
gs-894	132	2	dyslipidemia	dyslipidemia	NOUN
gs-894	132	3	is	be	AUX
gs-894	132	4	untreated	untreated	ADJ
gs-894	132	5	,	,	PUNCT
gs-894	132	6	it	it	PRON
gs-894	132	7	leads	lead	VERB
gs-894	132	8	to	to	ADP
gs-894	132	9	serious	serious	ADJ
gs-894	132	10	health	health	NOUN
gs-894	132	11	complications	complication	NOUN
gs-894	132	12	and	and	CCONJ
gs-894	132	13	cvd	cvd	PROPN
gs-894	132	14	.	.	PUNCT
gs-894	133	1	cvd	cvd	PROPN
gs-894	133	2	was	be	AUX
gs-894	133	3	detected	detect	VERB
gs-894	133	4	in	in	ADP
gs-894	133	5	92	92	NUM
gs-894	133	6	participants	participant	NOUN
gs-894	133	7	,	,	PUNCT
gs-894	133	8	44.6	44.6	NUM
gs-894	133	9	%	%	NOUN
gs-894	133	10	had	have	VERB
gs-894	133	11	hyperglycemia	hyperglycemia	NOUN
gs-894	133	12	.	.	PUNCT
gs-894	134	1	based	base	VERB
gs-894	134	2	on	on	ADP
gs-894	134	3	rr	rr	PROPN
gs-894	134	4	normoglycemic	normoglycemic	PROPN
gs-894	134	5	and	and	CCONJ
gs-894	134	6	hyperglycemic	hyperglycemic	ADJ
gs-894	134	7	cohort	cohort	NOUN
gs-894	134	8	did	do	AUX
gs-894	134	9	not	not	PART
gs-894	134	10	differ	differ	VERB
gs-894	134	11	significantly	significantly	ADV
gs-894	134	12	.	.	PUNCT
gs-894	135	1	it	it	PRON
gs-894	135	2	might	might	AUX
gs-894	135	3	be	be	AUX
gs-894	135	4	explained	explain	VERB
gs-894	135	5	by	by	ADP
gs-894	135	6	the	the	DET
gs-894	135	7	fact	fact	NOUN
gs-894	135	8	,	,	PUNCT
gs-894	135	9	that	that	SCONJ
gs-894	135	10	our	our	PRON
gs-894	135	11	general	general	ADJ
gs-894	135	12	cohort	cohort	NOUN
gs-894	135	13	was	be	AUX
gs-894	135	14	young	young	ADJ
gs-894	135	15	and	and	CCONJ
gs-894	135	16	the	the	DET
gs-894	135	17	risk	risk	NOUN
gs-894	135	18	of	of	ADP
gs-894	135	19	cvd	cvd	PROPN
gs-894	135	20	is	be	AUX
gs-894	135	21	increasing	increase	VERB
gs-894	135	22	with	with	ADP
gs-894	135	23	the	the	DET
gs-894	135	24	age	age	NOUN
gs-894	135	25	.	.	PUNCT
gs-894	136	1	the	the	DET
gs-894	136	2	higher	high	ADJ
gs-894	136	3	prevalence	prevalence	NOUN
gs-894	136	4	of	of	ADP
gs-894	136	5	cvd	cvd	PROPN
gs-894	136	6	was	be	AUX
gs-894	136	7	reported	report	VERB
gs-894	136	8	in	in	ADP
gs-894	136	9	general	general	ADJ
gs-894	136	10	population	population	NOUN
gs-894	136	11	georgia	georgia	PROPN
gs-894	136	12	,	,	PUNCT
gs-894	136	13	compared	compare	VERB
gs-894	136	14	to	to	ADP
gs-894	136	15	people	people	NOUN
gs-894	136	16	living	live	VERB
gs-894	136	17	with	with	ADP
gs-894	136	18	hiv	hiv	PROPN
gs-894	136	19	(	(	PUNCT
gs-894	136	20	15.3	15.3	NUM
gs-894	136	21	vs	vs	ADP
gs-894	136	22	3.1	3.1	NUM
gs-894	136	23	respectively	respectively	ADV
gs-894	136	24	)	)	PUNCT
gs-894	136	25	.	.	PUNCT
gs-894	137	1	our	our	PRON
gs-894	137	2	study	study	NOUN
gs-894	137	3	demonstrated	demonstrate	VERB
gs-894	137	4	that	that	SCONJ
gs-894	137	5	the	the	DET
gs-894	137	6	risk	risk	NOUN
gs-894	137	7	of	of	ADP
gs-894	137	8	stroke	stroke	NOUN
gs-894	137	9	was	be	AUX
gs-894	137	10	2.2	2.2	NUM
gs-894	137	11	times	time	NOUN
gs-894	137	12	higher	high	ADJ
gs-894	137	13	in	in	ADP
gs-894	137	14	hyperglicemic	hyperglicemic	ADJ
gs-894	137	15	cohort	cohort	NOUN
gs-894	137	16	,	,	PUNCT
gs-894	137	17	compared	compare	VERB
gs-894	137	18	to	to	ADP
gs-894	137	19	people	people	NOUN
gs-894	137	20	with	with	ADP
gs-894	137	21	normoglycemia	normoglycemia	NOUN
gs-894	137	22	.	.	PUNCT
gs-894	138	1	similar	similar	ADJ
gs-894	138	2	results	result	NOUN
gs-894	138	3	have	have	AUX
gs-894	138	4	been	be	AUX
gs-894	138	5	reported	report	VERB
gs-894	138	6	from	from	ADP
gs-894	138	7	another	another	DET
gs-894	138	8	study	study	NOUN
gs-894	138	9	by	by	ADP
gs-894	138	10	michael	michael	PROPN
gs-894	138	11	d	d	PROPN
gs-894	138	12	hill	hill	PROPN
gs-894	138	13	in	in	ADP
gs-894	138	14	201449	201449	NUM
gs-894	138	15	.	.	PUNCT
gs-894	139	1	nearly	nearly	ADV
gs-894	139	2	30	30	NUM
gs-894	139	3	-	-	SYM
gs-894	139	4	40	40	NUM
gs-894	139	5	%	%	NOUN
gs-894	139	6	of	of	ADP
gs-894	139	7	acute	acute	ADJ
gs-894	139	8	ischemic	ischemic	ADJ
gs-894	139	9	stroke	stroke	NOUN
gs-894	139	10	patients	patient	NOUN
gs-894	139	11	have	have	VERB
gs-894	139	12	hyperglycemia	hyperglycemia	NOUN
gs-894	139	13	.	.	PUNCT
gs-894	140	1	it	it	PRON
gs-894	140	2	has	have	AUX
gs-894	140	3	been	be	AUX
gs-894	140	4	reported	report	VERB
gs-894	140	5	,	,	PUNCT
gs-894	140	6	that	that	DET
gs-894	140	7	hyperglycemia	hyperglycemia	NOUN
gs-894	140	8	increases	increase	VERB
gs-894	140	9	mortality	mortality	NOUN
gs-894	140	10	rate	rate	NOUN
gs-894	140	11	significantly	significantly	ADV
gs-894	140	12	in	in	ADP
gs-894	140	13	patients	patient	NOUN
gs-894	140	14	with	with	ADP
gs-894	140	15	acute	acute	ADJ
gs-894	140	16	ischemic	ischemic	ADJ
gs-894	140	17	stroke50	stroke50	NOUN
gs-894	140	18	.	.	PUNCT
gs-894	141	1	in	in	ADP
gs-894	141	2	our	our	PRON
gs-894	141	3	research	research	NOUN
gs-894	141	4	32	32	NUM
gs-894	141	5	participants	participant	NOUN
gs-894	141	6	had	have	VERB
gs-894	141	7	cdk	cdk	NOUN
gs-894	141	8	and	and	CCONJ
gs-894	141	9	half	half	NOUN
gs-894	141	10	of	of	ADP
gs-894	141	11	them	they	PRON
gs-894	141	12	had	have	VERB
gs-894	141	13	hyperglycemia	hyperglycemia	NOUN
gs-894	141	14	.	.	PUNCT
gs-894	142	1	it	it	PRON
gs-894	142	2	is	be	AUX
gs-894	142	3	well	well	ADV
gs-894	142	4	known	know	VERB
gs-894	142	5	,	,	PUNCT
gs-894	142	6	that	that	PRON
gs-894	142	7	diabetes	diabete	NOUN
gs-894	142	8	damages	damage	VERB
gs-894	142	9	kidneys	kidney	NOUN
gs-894	142	10	and	and	CCONJ
gs-894	142	11	causes	cause	VERB
gs-894	142	12	diabetic	diabetic	ADJ
gs-894	142	13	nephropathy.diabetic	nephropathy.diabetic	ADJ
gs-894	142	14	nephropathy	nephropathy	NOUN
gs-894	142	15	is	be	AUX
gs-894	142	16	a	a	DET
gs-894	142	17	major	major	ADJ
gs-894	142	18	cause	cause	NOUN
gs-894	142	19	of	of	ADP
gs-894	142	20	ckd	ckd	PROPN
gs-894	142	21	and	and	CCONJ
gs-894	142	22	renal	renal	ADJ
gs-894	142	23	failure29	failure29	PROPN
gs-894	142	24	,	,	PUNCT
gs-894	142	25	51	51	NUM
gs-894	142	26	.	.	PUNCT
gs-894	143	1	additional	additional	ADJ
gs-894	143	2	risk	risk	NOUN
gs-894	143	3	factors	factor	NOUN
gs-894	143	4	of	of	ADP
gs-894	143	5	ckd	ckd	PROPN
gs-894	143	6	are	be	AUX
gs-894	143	7	hiv	hiv	PROPN
gs-894	143	8	and	and	CCONJ
gs-894	143	9	art	art	NOUN
gs-894	143	10	by	by	ADP
gs-894	143	11	itself28	itself28	ADJ
gs-894	143	12	,	,	PUNCT
gs-894	143	13	29	29	NUM
gs-894	143	14	,	,	PUNCT
gs-894	143	15	51	51	NUM
gs-894	143	16	,	,	PUNCT
gs-894	143	17	52	52	NUM
gs-894	143	18	.	.	PUNCT
gs-894	144	1	based	base	VERB
gs-894	144	2	on	on	ADP
gs-894	144	3	our	our	PRON
gs-894	144	4	results	result	NOUN
gs-894	144	5	the	the	DET
gs-894	144	6	rate	rate	NOUN
gs-894	144	7	of	of	ADP
gs-894	144	8	ckd	ckd	PROPN
gs-894	144	9	in	in	ADP
gs-894	144	10	hyperglycemic	hyperglycemic	ADJ
gs-894	144	11	and	and	CCONJ
gs-894	144	12	normoglycemic	normoglycemic	ADJ
gs-894	144	13	cohort	cohort	NOUN
gs-894	144	14	,	,	PUNCT
gs-894	144	15	did	do	AUX
gs-894	144	16	not	not	PART
gs-894	144	17	differ	differ	VERB
gs-894	144	18	significantly	significantly	ADV
gs-894	144	19	.	.	PUNCT
gs-894	145	1	hyperglycemia	hyperglycemia	NOUN
gs-894	145	2	and	and	CCONJ
gs-894	145	3	other	other	ADJ
gs-894	145	4	non	non	ADJ
gs-894	145	5	communicable	communicable	NOUN
gs-894	145	6	diseases	disease	NOUN
gs-894	145	7	should	should	AUX
gs-894	145	8	be	be	AUX
gs-894	145	9	monitored	monitor	VERB
gs-894	145	10	annually	annually	ADV
gs-894	145	11	among	among	ADP
gs-894	145	12	people	people	NOUN
gs-894	145	13	living	live	VERB
gs-894	145	14	with	with	ADP
gs-894	145	15	hiv	hiv	PROPN
gs-894	145	16	to	to	PART
gs-894	145	17	decrease	decrease	VERB
gs-894	145	18	morbidity	morbidity	NOUN
gs-894	145	19	and	and	CCONJ
gs-894	145	20	mortality	mortality	NOUN
gs-894	145	21	rate	rate	NOUN
gs-894	145	22	.	.	PUNCT
gs-894	146	1	prevention	prevention	NOUN
gs-894	146	2	and	and	CCONJ
gs-894	146	3	early	early	ADJ
gs-894	146	4	detection	detection	NOUN
gs-894	146	5	of	of	ADP
gs-894	146	6	noncommunicable	noncommunicable	ADJ
gs-894	146	7	diseases	disease	NOUN
gs-894	146	8	among	among	ADP
gs-894	146	9	plwh	plwh	NOUN
gs-894	146	10	will	will	AUX
gs-894	146	11	increase	increase	VERB
gs-894	146	12	life	life	NOUN
gs-894	146	13	expectancy	expectancy	NOUN
gs-894	146	14	and	and	CCONJ
gs-894	146	15	improve	improve	VERB
gs-894	146	16	quality	quality	NOUN
gs-894	146	17	of	of	ADP
gs-894	146	18	life	life	NOUN
gs-894	146	19	.	.	PUNCT
gs-894	147	1	conclusions	conclusion	NOUN
gs-894	147	2	noncommunicable	noncommunicable	ADJ
gs-894	147	3	diseases	disease	NOUN
gs-894	147	4	among	among	ADP
gs-894	147	5	plwh	plwh	NOUN
gs-894	147	6	,	,	PUNCT
gs-894	147	7	in	in	ADP
gs-894	147	8	particular	particular	ADJ
gs-894	147	9	hyperglycemia	hyperglycemia	NOUN
gs-894	147	10	and	and	CCONJ
gs-894	147	11	t2d	t2d	NOUN
gs-894	147	12	is	be	AUX
gs-894	147	13	a	a	DET
gs-894	147	14	growing	grow	VERB
gs-894	147	15	problem	problem	NOUN
gs-894	147	16	around	around	ADP
gs-894	147	17	the	the	DET
gs-894	147	18	world	world	NOUN
gs-894	147	19	.	.	PUNCT
gs-894	148	1	our	our	PRON
gs-894	148	2	research	research	NOUN
gs-894	148	3	addressed	address	VERB
gs-894	148	4	an	an	DET
gs-894	148	5	issue	issue	NOUN
gs-894	148	6	.	.	PUNCT
gs-894	149	1	the	the	DET
gs-894	149	2	prevalence	prevalence	NOUN
gs-894	149	3	of	of	ADP
gs-894	149	4	t2d	t2d	NOUN
gs-894	149	5	and	and	CCONJ
gs-894	149	6	metabolic	metabolic	NOUN
gs-894	149	7	syndroime	syndroime	NOUN
gs-894	149	8	has	have	AUX
gs-894	149	9	never	never	ADV
gs-894	149	10	been	be	AUX
gs-894	149	11	calculated	calculate	VERB
gs-894	149	12	in	in	ADP
gs-894	149	13	georgia	georgia	PROPN
gs-894	149	14	before	before	ADV
gs-894	149	15	.	.	PUNCT
gs-894	150	1	we	we	PRON
gs-894	150	2	found	find	VERB
gs-894	150	3	out	out	ADP
gs-894	150	4	that	that	SCONJ
gs-894	150	5	the	the	DET
gs-894	150	6	prevalence	prevalence	NOUN
gs-894	150	7	of	of	ADP
gs-894	150	8	t2d	t2d	NUM
gs-894	150	9	is	be	AUX
gs-894	150	10	2.65	2.65	NUM
gs-894	150	11	%	%	NOUN
gs-894	150	12	and	and	CCONJ
gs-894	150	13	is	be	AUX
gs-894	150	14	not	not	PART
gs-894	150	15	higher	high	ADJ
gs-894	150	16	,	,	PUNCT
gs-894	150	17	than	than	ADP
gs-894	150	18	prevalence	prevalence	NOUN
gs-894	150	19	in	in	ADP
gs-894	150	20	general	general	ADJ
gs-894	150	21	population	population	NOUN
gs-894	150	22	in	in	ADP
gs-894	150	23	georgia	georgia	PROPN
gs-894	150	24	.	.	PUNCT
gs-894	151	1	we	we	PRON
gs-894	151	2	think	think	VERB
gs-894	151	3	that	that	SCONJ
gs-894	151	4	further	further	ADJ
gs-894	151	5	studies	study	NOUN
gs-894	151	6	are	be	AUX
gs-894	151	7	needed	need	VERB
gs-894	151	8	to	to	PART
gs-894	151	9	clarify	clarify	VERB
gs-894	151	10	an	an	DET
gs-894	151	11	issue	issue	NOUN
gs-894	151	12	.	.	PUNCT
gs-894	152	1	prevention	prevention	NOUN
gs-894	152	2	or	or	CCONJ
gs-894	152	3	early	early	ADJ
gs-894	152	4	detection	detection	NOUN
gs-894	152	5	of	of	ADP
gs-894	152	6	t2d	t2d	NOUN
gs-894	152	7	and	and	CCONJ
gs-894	152	8	timely	timely	ADJ
gs-894	152	9	management	management	NOUN
gs-894	152	10	of	of	ADP
gs-894	152	11	metabolic	metabolic	NOUN
gs-894	152	12	disturbance	disturbance	NOUN
gs-894	152	13	reduces	reduce	VERB
gs-894	152	14	risk	risk	NOUN
gs-894	152	15	of	of	ADP
gs-894	152	16	morbidity	morbidity	NOUN
gs-894	152	17	and	and	CCONJ
gs-894	152	18	mortality	mortality	NOUN
gs-894	152	19	during	during	ADP
gs-894	152	20	hiv	hiv	PROPN
gs-894	152	21	.	.	PUNCT
gs-894	153	1	screening	screening	NOUN
gs-894	153	2	and	and	CCONJ
gs-894	153	3	management	management	NOUN
gs-894	153	4	of	of	ADP
gs-894	153	5	hyperglycemia	hyperglycemia	NOUN
gs-894	153	6	should	should	AUX
gs-894	153	7	be	be	AUX
gs-894	153	8	part	part	NOUN
gs-894	153	9	of	of	ADP
gs-894	153	10	the	the	DET
gs-894	153	11	routine	routine	ADJ
gs-894	153	12	hiv	hiv	PROPN
gs-894	153	13	clinical	clinical	ADJ
gs-894	153	14	services	service	NOUN
gs-894	153	15	.	.	PUNCT
gs-894	154	1	georgian	georgian	ADJ
gs-894	154	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-894	154	3	მეცნიერები	მეცნიერები	VERB
gs-894	154	4	4(02	4(02	NUM
gs-894	154	5	)	)	PUNCT
gs-894	154	6	,	,	PUNCT
gs-894	154	7	2022	2022	NUM
gs-894	154	8	201	201	NUM
gs-894	154	9	references	reference	NOUN
gs-894	154	10	1	1	NUM
gs-894	154	11	.	.	PUNCT
gs-894	155	1	shen	shen	PROPN
gs-894	155	2	y	y	PROPN
gs-894	155	3	,	,	PUNCT
gs-894	155	4	wang	wang	PROPN
gs-894	155	5	z	z	PROPN
gs-894	155	6	,	,	PUNCT
gs-894	155	7	liu	liu	PROPN
gs-894	155	8	l	l	PROPN
gs-894	155	9	,	,	PUNCT
gs-894	155	10	zhang	zhang	PROPN
gs-894	155	11	r	r	PROPN
gs-894	155	12	,	,	PUNCT
gs-894	155	13	zheng	zheng	PROPN
gs-894	155	14	y	y	PROPN
gs-894	155	15	and	and	CCONJ
gs-894	155	16	lu	lu	PROPN
gs-894	155	17	h.	h.	PROPN
gs-894	155	18	prevalence	prevalence	NOUN
gs-894	155	19	of	of	ADP
gs-894	155	20	hyperglycemia	hyperglycemia	NOUN
gs-894	155	21	among	among	ADP
gs-894	155	22	adults	adult	NOUN
gs-894	155	23	with	with	ADP
gs-894	155	24	newly	newly	ADV
gs-894	155	25	diagnosed	diagnose	VERB
gs-894	155	26	hiv	hiv	PROPN
gs-894	155	27	/	/	SYM
gs-894	155	28	aids	aids	PROPN
gs-894	155	29	in	in	ADP
gs-894	155	30	china	china	PROPN
gs-894	155	31	.	.	PUNCT
gs-894	156	1	bmc	bmc	VERB
gs-894	156	2	infectious	infectious	ADJ
gs-894	156	3	diseases	disease	NOUN
gs-894	156	4	.	.	PUNCT
gs-894	157	1	2013	2013	NUM
gs-894	157	2	;	;	PUNCT
gs-894	157	3	13	13	NUM
gs-894	157	4	:	:	SYM
gs-894	157	5	79	79	NUM
gs-894	157	6	.	.	X
gs-894	157	7	2	2	X
gs-894	157	8	.	.	X
gs-894	157	9	wandeler	wandeler	NOUN
gs-894	157	10	g	g	PROPN
gs-894	157	11	,	,	PUNCT
gs-894	157	12	johnson	johnson	PROPN
gs-894	157	13	lf	lf	PROPN
gs-894	157	14	and	and	CCONJ
gs-894	157	15	egger	egger	NOUN
gs-894	157	16	m.	m.	NOUN
gs-894	157	17	trends	trend	NOUN
gs-894	157	18	in	in	ADP
gs-894	157	19	life	life	NOUN
gs-894	157	20	expectancy	expectancy	NOUN
gs-894	157	21	of	of	ADP
gs-894	157	22	hiv	hiv	PROPN
gs-894	157	23	-	-	PUNCT
gs-894	157	24	positive	positive	ADJ
gs-894	157	25	adults	adult	NOUN
gs-894	157	26	on	on	ADP
gs-894	157	27	antiretroviral	antiretroviral	ADJ
gs-894	157	28	therapy	therapy	NOUN
gs-894	157	29	across	across	ADP
gs-894	157	30	the	the	DET
gs-894	157	31	globe	globe	NOUN
gs-894	157	32	:	:	PUNCT
gs-894	157	33	comparisons	comparison	NOUN
gs-894	157	34	with	with	ADP
gs-894	157	35	general	general	ADJ
gs-894	157	36	population	population	NOUN
gs-894	157	37	.	.	PUNCT
gs-894	158	1	current	current	ADJ
gs-894	158	2	opinion	opinion	NOUN
gs-894	158	3	in	in	ADP
gs-894	158	4	hiv	hiv	PROPN
gs-894	158	5	and	and	CCONJ
gs-894	158	6	aids	aids	PROPN
gs-894	158	7	.	.	PUNCT
gs-894	159	1	2016	2016	NUM
gs-894	159	2	;	;	PUNCT
gs-894	159	3	11	11	NUM
gs-894	159	4	:	:	SYM
gs-894	159	5	492	492	NUM
gs-894	159	6	-	-	SYM
gs-894	159	7	500	500	NUM
gs-894	159	8	.	.	PUNCT
gs-894	160	1	3	3	X
gs-894	160	2	.	.	X
gs-894	160	3	brown	brown	PROPN
gs-894	160	4	tt	tt	PROPN
gs-894	160	5	,	,	PUNCT
gs-894	160	6	tassiopoulos	tassiopoulos	PROPN
gs-894	160	7	k	k	PROPN
gs-894	160	8	,	,	PUNCT
gs-894	160	9	bosch	bosch	PROPN
gs-894	160	10	rj	rj	PROPN
gs-894	160	11	,	,	PUNCT
gs-894	160	12	shikuma	shikuma	PROPN
gs-894	160	13	c	c	PROPN
gs-894	160	14	and	and	CCONJ
gs-894	160	15	mccomsey	mccomsey	PROPN
gs-894	160	16	ga	ga	PROPN
gs-894	160	17	.	.	PROPN
gs-894	160	18	association	association	PROPN
gs-894	160	19	between	between	ADP
gs-894	160	20	systemic	systemic	ADJ
gs-894	160	21	inflammation	inflammation	NOUN
gs-894	160	22	and	and	CCONJ
gs-894	160	23	incident	incident	NOUN
gs-894	160	24	diabetes	diabetes	NOUN
gs-894	160	25	in	in	ADP
gs-894	160	26	hiv	hiv	PROPN
gs-894	160	27	-	-	PUNCT
gs-894	160	28	infected	infect	VERB
gs-894	160	29	patients	patient	NOUN
gs-894	160	30	after	after	ADP
gs-894	160	31	initiation	initiation	NOUN
gs-894	160	32	of	of	ADP
gs-894	160	33	antiretroviral	antiretroviral	ADJ
gs-894	160	34	therapy	therapy	NOUN
gs-894	160	35	.	.	PUNCT
gs-894	161	1	diabetes	diabetes	NOUN
gs-894	161	2	care	care	NOUN
gs-894	161	3	.	.	PUNCT
gs-894	162	1	2010	2010	NUM
gs-894	162	2	;	;	PUNCT
gs-894	162	3	33	33	NUM
gs-894	162	4	:	:	SYM
gs-894	162	5	2244	2244	NUM
gs-894	162	6	-	-	SYM
gs-894	162	7	9	9	NUM
gs-894	162	8	.	.	NOUN
gs-894	162	9	4	4	NUM
gs-894	162	10	.	.	X
gs-894	162	11	coelho	coelho	PROPN
gs-894	162	12	ar	ar	PROPN
gs-894	162	13	,	,	PUNCT
gs-894	162	14	moreira	moreira	PROPN
gs-894	162	15	fa	fa	PROPN
gs-894	162	16	,	,	PUNCT
gs-894	162	17	santos	santos	PROPN
gs-894	162	18	ac	ac	PROPN
gs-894	162	19	,	,	PUNCT
gs-894	162	20	et	et	PROPN
gs-894	162	21	al	al	PROPN
gs-894	162	22	.	.	PROPN
gs-894	163	1	diabetes	diabete	VERB
gs-894	163	2	mellitus	mellitus	NOUN
gs-894	163	3	in	in	ADP
gs-894	163	4	hiv	hiv	PROPN
gs-894	163	5	-	-	PUNCT
gs-894	163	6	infected	infect	VERB
gs-894	163	7	patients	patient	NOUN
gs-894	163	8	:	:	PUNCT
gs-894	163	9	fasting	fast	VERB
gs-894	163	10	glucose	glucose	NOUN
gs-894	163	11	,	,	PUNCT
gs-894	163	12	a1c	a1c	PROPN
gs-894	163	13	,	,	PUNCT
gs-894	163	14	or	or	CCONJ
gs-894	163	15	oral	oral	ADJ
gs-894	163	16	glucose	glucose	NOUN
gs-894	163	17	tolerance	tolerance	NOUN
gs-894	163	18	test	test	NOUN
gs-894	163	19	–	–	PUNCT
gs-894	163	20	which	which	PRON
gs-894	163	21	method	method	NOUN
gs-894	163	22	to	to	PART
gs-894	163	23	choose	choose	VERB
gs-894	163	24	for	for	ADP
gs-894	163	25	the	the	DET
gs-894	163	26	diagnosis	diagnosis	NOUN
gs-894	163	27	?	?	PUNCT
gs-894	164	1	bmc	bmc	ADJ
gs-894	164	2	infectious	infectious	ADJ
gs-894	164	3	diseases	disease	NOUN
gs-894	164	4	.	.	PUNCT
gs-894	164	5	2018	2018	NUM
gs-894	164	6	;	;	PUNCT
gs-894	164	7	18	18	NUM
gs-894	164	8	.	.	NOUN
gs-894	164	9	5	5	NUM
gs-894	164	10	.	.	PUNCT
gs-894	164	11	hernandez	hernandez	PROPN
gs-894	164	12	-	-	PUNCT
gs-894	164	13	romieu	romieu	PROPN
gs-894	164	14	ac	ac	PROPN
gs-894	164	15	,	,	PUNCT
gs-894	164	16	garg	garg	PROPN
gs-894	164	17	s	s	PROPN
gs-894	164	18	,	,	PUNCT
gs-894	164	19	rosenberg	rosenberg	PROPN
gs-894	164	20	es	es	PROPN
gs-894	164	21	,	,	PUNCT
gs-894	164	22	thompson	thompson	PROPN
gs-894	164	23	-	-	PUNCT
gs-894	164	24	paul	paul	PROPN
gs-894	164	25	am	am	NOUN
gs-894	164	26	and	and	CCONJ
gs-894	164	27	skarbinski	skarbinski	VERB
gs-894	164	28	j.	j.	PROPN
gs-894	164	29	is	be	AUX
gs-894	164	30	diabetes	diabetes	NOUN
gs-894	164	31	prevalence	prevalence	NOUN
gs-894	164	32	higher	higher	ADV
gs-894	164	33	among	among	ADP
gs-894	164	34	hiv	hiv	PROPN
gs-894	164	35	-	-	PUNCT
gs-894	164	36	infected	infect	VERB
gs-894	164	37	individuals	individual	NOUN
gs-894	164	38	compared	compare	VERB
gs-894	164	39	with	with	ADP
gs-894	164	40	the	the	DET
gs-894	164	41	general	general	ADJ
gs-894	164	42	population	population	NOUN
gs-894	164	43	?	?	PUNCT
gs-894	165	1	evidence	evidence	NOUN
gs-894	165	2	from	from	ADP
gs-894	165	3	mmp	mmp	PROPN
gs-894	165	4	and	and	CCONJ
gs-894	165	5	nhanes	nhane	NOUN
gs-894	165	6	2009–2010	2009–2010	NUM
gs-894	165	7	.	.	PUNCT
gs-894	166	1	bmj	bmj	PROPN
gs-894	166	2	open	open	ADJ
gs-894	166	3	diabetes	diabetes	NOUN
gs-894	166	4	research	research	NOUN
gs-894	166	5	&	&	CCONJ
gs-894	166	6	care	care	PROPN
gs-894	166	7	.	.	PUNCT
gs-894	167	1	2017	2017	NUM
gs-894	167	2	;	;	PUNCT
gs-894	167	3	5	5	NUM
gs-894	167	4	.	.	NOUN
gs-894	167	5	6	6	NUM
gs-894	167	6	.	.	X
gs-894	168	1	pelchen	pelchen	NOUN
gs-894	168	2	-	-	PUNCT
gs-894	168	3	matthews	matthews	PROPN
gs-894	168	4	a	a	PRON
gs-894	168	5	,	,	PUNCT
gs-894	168	6	ryom	ryom	NOUN
gs-894	168	7	l	l	NOUN
gs-894	168	8	,	,	PUNCT
gs-894	168	9	borges	borges	X
gs-894	168	10	á	á	PROPN
gs-894	168	11	h	h	NOUN
gs-894	168	12	,	,	PUNCT
gs-894	168	13	et	et	PROPN
gs-894	168	14	al	al	PROPN
gs-894	168	15	.	.	PROPN
gs-894	168	16	aging	aging	NOUN
gs-894	168	17	and	and	CCONJ
gs-894	168	18	the	the	DET
gs-894	168	19	evolution	evolution	NOUN
gs-894	168	20	of	of	ADP
gs-894	168	21	comorbidities	comorbiditie	NOUN
gs-894	168	22	among	among	ADP
gs-894	168	23	hiv	hiv	PROPN
gs-894	168	24	-	-	PUNCT
gs-894	168	25	positive	positive	ADJ
gs-894	168	26	individuals	individual	NOUN
gs-894	168	27	in	in	ADP
gs-894	168	28	a	a	DET
gs-894	168	29	european	european	ADJ
gs-894	168	30	cohort	cohort	NOUN
gs-894	168	31	.	.	PUNCT
gs-894	169	1	aids	aids	PROPN
gs-894	169	2	(	(	PUNCT
gs-894	169	3	london	london	PROPN
gs-894	169	4	,	,	PUNCT
gs-894	169	5	england	england	PROPN
gs-894	169	6	)	)	PUNCT
gs-894	169	7	.	.	PUNCT
gs-894	170	1	2018	2018	NUM
gs-894	170	2	;	;	PUNCT
gs-894	170	3	32	32	NUM
gs-894	170	4	:	:	PUNCT
gs-894	170	5	2405	2405	NUM
gs-894	170	6	-	-	SYM
gs-894	170	7	16	16	NUM
gs-894	170	8	.	.	PUNCT
gs-894	171	1	7	7	X
gs-894	171	2	.	.	X
gs-894	171	3	duncan	duncan	PROPN
gs-894	171	4	ad	ad	NOUN
gs-894	171	5	,	,	PUNCT
gs-894	171	6	goff	goff	PROPN
gs-894	171	7	lm	lm	PROPN
gs-894	171	8	and	and	CCONJ
gs-894	171	9	peters	peters	PROPN
gs-894	171	10	bs	bs	PROPN
gs-894	171	11	.	.	PUNCT
gs-894	171	12	type	type	NOUN
gs-894	171	13	2	2	NUM
gs-894	171	14	diabetes	diabetes	NOUN
gs-894	171	15	prevalence	prevalence	NOUN
gs-894	171	16	and	and	CCONJ
gs-894	171	17	its	its	PRON
gs-894	171	18	risk	risk	NOUN
gs-894	171	19	factors	factor	NOUN
gs-894	171	20	in	in	ADP
gs-894	171	21	hiv	hiv	PROPN
gs-894	171	22	:	:	PUNCT
gs-894	171	23	a	a	DET
gs-894	171	24	cross	cross	ADJ
gs-894	171	25	-	-	ADJ
gs-894	171	26	sectional	sectional	ADJ
gs-894	171	27	study	study	NOUN
gs-894	171	28	.	.	PUNCT
gs-894	172	1	plos	plos	PROPN
gs-894	172	2	one	one	NUM
gs-894	172	3	.	.	PUNCT
gs-894	172	4	2018	2018	NUM
gs-894	172	5	;	;	PUNCT
gs-894	172	6	13	13	NUM
gs-894	172	7	.	.	NOUN
gs-894	172	8	8	8	NUM
gs-894	172	9	.	.	PUNCT
gs-894	173	1	husain	husain	PROPN
gs-894	173	2	ne	ne	PROPN
gs-894	173	3	,	,	PUNCT
gs-894	173	4	noor	noor	PROPN
gs-894	173	5	sk	sk	PROPN
gs-894	173	6	,	,	PUNCT
gs-894	173	7	elmadhoun	elmadhoun	PROPN
gs-894	173	8	wm	wm	PROPN
gs-894	173	9	,	,	PUNCT
gs-894	173	10	et	et	PROPN
gs-894	173	11	al	al	PROPN
gs-894	173	12	.	.	PROPN
gs-894	173	13	diabetes	diabetes	NOUN
gs-894	173	14	,	,	PUNCT
gs-894	173	15	metabolic	metabolic	NOUN
gs-894	173	16	syndrome	syndrome	NOUN
gs-894	173	17	and	and	CCONJ
gs-894	173	18	dyslipidemia	dyslipidemia	NOUN
gs-894	173	19	in	in	ADP
gs-894	173	20	people	people	NOUN
gs-894	173	21	living	live	VERB
gs-894	173	22	with	with	ADP
gs-894	173	23	hiv	hiv	PROPN
gs-894	173	24	in	in	ADP
gs-894	173	25	africa	africa	PROPN
gs-894	173	26	:	:	PUNCT
gs-894	173	27	re	re	VERB
gs-894	173	28	-	-	VERB
gs-894	173	29	emerging	emerge	VERB
gs-894	173	30	challenges	challenge	NOUN
gs-894	173	31	not	not	PART
gs-894	173	32	to	to	PART
gs-894	173	33	be	be	AUX
gs-894	173	34	forgotten	forget	VERB
gs-894	173	35	.	.	PUNCT
gs-894	174	1	hiv	hiv	PROPN
gs-894	174	2	/	/	SYM
gs-894	174	3	aids	aids	PROPN
gs-894	174	4	(	(	PUNCT
gs-894	174	5	auckland	auckland	PROPN
gs-894	174	6	,	,	PUNCT
gs-894	174	7	nz	nz	PROPN
gs-894	174	8	)	)	PUNCT
gs-894	174	9	.	.	PUNCT
gs-894	175	1	2017	2017	NUM
gs-894	175	2	;	;	PUNCT
gs-894	175	3	9	9	NUM
gs-894	175	4	:	:	SYM
gs-894	175	5	193	193	NUM
gs-894	175	6	-	-	SYM
gs-894	175	7	202	202	NUM
gs-894	175	8	.	.	NOUN
gs-894	176	1	9	9	NUM
gs-894	176	2	.	.	X
gs-894	176	3	suligoi	suligoi	PROPN
gs-894	176	4	b	b	PROPN
gs-894	176	5	,	,	PUNCT
gs-894	176	6	virdone	virdone	NOUN
gs-894	176	7	s	s	NOUN
gs-894	176	8	,	,	PUNCT
gs-894	176	9	taborelli	taborelli	PROPN
gs-894	176	10	m	m	PROPN
gs-894	176	11	,	,	PUNCT
gs-894	176	12	et	et	PROPN
gs-894	176	13	al	al	PROPN
gs-894	176	14	.	.	PUNCT
gs-894	177	1	excess	excess	ADJ
gs-894	177	2	mortality	mortality	NOUN
gs-894	177	3	related	relate	VERB
gs-894	177	4	to	to	ADP
gs-894	177	5	circulatory	circulatory	ADJ
gs-894	177	6	system	system	NOUN
gs-894	177	7	diseases	disease	NOUN
gs-894	177	8	and	and	CCONJ
gs-894	177	9	diabetes	diabetes	NOUN
gs-894	177	10	mellitus	mellitus	NOUN
gs-894	177	11	among	among	ADP
gs-894	177	12	italian	italian	ADJ
gs-894	177	13	aids	aid	NOUN
gs-894	177	14	patients	patient	NOUN
gs-894	177	15	vs.	vs.	ADP
gs-894	177	16	non	non	ADJ
gs-894	177	17	-	-	ADJ
gs-894	177	18	aids	aids	ADJ
gs-894	177	19	population	population	NOUN
gs-894	177	20	:	:	PUNCT
gs-894	177	21	a	a	DET
gs-894	177	22	population	population	NOUN
gs-894	177	23	-	-	PUNCT
gs-894	177	24	based	base	VERB
gs-894	177	25	cohort	cohort	NOUN
gs-894	177	26	study	study	NOUN
gs-894	177	27	using	use	VERB
gs-894	177	28	the	the	DET
gs-894	177	29	multiple	multiple	ADJ
gs-894	177	30	causes	cause	NOUN
gs-894	177	31	-	-	PUNCT
gs-894	177	32	of	of	ADP
gs-894	177	33	-	-	PUNCT
gs-894	177	34	death	death	NOUN
gs-894	177	35	approach	approach	NOUN
gs-894	177	36	.	.	PUNCT
gs-894	178	1	bmc	bmc	ADJ
gs-894	178	2	infectious	infectious	ADJ
gs-894	178	3	diseases	disease	NOUN
gs-894	178	4	.	.	PUNCT
gs-894	178	5	2018	2018	NUM
gs-894	178	6	;	;	PUNCT
gs-894	178	7	18	18	NUM
gs-894	178	8	:	:	SYM
gs-894	178	9	428	428	NUM
gs-894	178	10	.	.	NOUN
gs-894	178	11	10	10	NUM
gs-894	178	12	.	.	PUNCT
gs-894	179	1	teeraananchai	teeraananchai	PROPN
gs-894	179	2	s	s	PROPN
gs-894	179	3	,	,	PUNCT
gs-894	179	4	kerr	kerr	PROPN
gs-894	179	5	sj	sj	PROPN
gs-894	179	6	,	,	PUNCT
gs-894	179	7	amin	amin	PROPN
gs-894	179	8	j	j	PROPN
gs-894	179	9	,	,	PUNCT
gs-894	179	10	ruxrungtham	ruxrungtham	PROPN
gs-894	179	11	k	k	PROPN
gs-894	179	12	and	and	CCONJ
gs-894	179	13	law	law	PROPN
gs-894	179	14	mg	mg	PROPN
gs-894	179	15	.	.	PUNCT
gs-894	180	1	life	life	NOUN
gs-894	180	2	expectancy	expectancy	NOUN
gs-894	180	3	of	of	ADP
gs-894	180	4	hiv	hiv	PROPN
gs-894	180	5	-	-	PUNCT
gs-894	180	6	positive	positive	ADJ
gs-894	180	7	people	people	NOUN
gs-894	180	8	after	after	ADP
gs-894	180	9	starting	start	VERB
gs-894	180	10	combination	combination	NOUN
gs-894	180	11	antiretroviral	antiretroviral	ADJ
gs-894	180	12	therapy	therapy	NOUN
gs-894	180	13	:	:	PUNCT
gs-894	180	14	a	a	DET
gs-894	180	15	meta	meta	ADJ
gs-894	180	16	-	-	PUNCT
gs-894	180	17	analysis	analysis	NOUN
gs-894	180	18	.	.	PUNCT
gs-894	181	1	hiv	hiv	PROPN
gs-894	181	2	medicine	medicine	NOUN
gs-894	181	3	.	.	PUNCT
gs-894	182	1	2017	2017	NUM
gs-894	182	2	;	;	PUNCT
gs-894	182	3	18	18	NUM
gs-894	182	4	:	:	SYM
gs-894	182	5	25666	25666	NUM
gs-894	182	6	.	.	PUNCT
gs-894	183	1	11	11	NUM
gs-894	183	2	.	.	PUNCT
gs-894	184	1	kalra	kalra	PROPN
gs-894	184	2	s	s	PROPN
gs-894	184	3	,	,	PUNCT
gs-894	184	4	kalra	kalra	NOUN
gs-894	184	5	b	b	PROPN
gs-894	184	6	,	,	PUNCT
gs-894	184	7	agrawal	agrawal	PROPN
gs-894	184	8	n	n	ADJ
gs-894	184	9	and	and	CCONJ
gs-894	184	10	unnikrishnan	unnikrishnan	PROPN
gs-894	184	11	a.	a.	NOUN
gs-894	184	12	understanding	understanding	PROPN
gs-894	184	13	diabetes	diabetes	NOUN
gs-894	184	14	in	in	ADP
gs-894	184	15	patients	patient	NOUN
gs-894	184	16	with	with	ADP
gs-894	184	17	hiv	hiv	PROPN
gs-894	184	18	/	/	SYM
gs-894	184	19	aids	aids	PROPN
gs-894	184	20	.	.	PUNCT
gs-894	185	1	diabetology	diabetology	PROPN
gs-894	185	2	&	&	CCONJ
gs-894	185	3	metabolic	metabolic	PROPN
gs-894	185	4	syndrome	syndrome	NOUN
gs-894	185	5	.	.	PUNCT
gs-894	186	1	2011	2011	NUM
gs-894	186	2	;	;	PUNCT
gs-894	186	3	3	3	NUM
gs-894	186	4	:	:	SYM
gs-894	186	5	2	2	NUM
gs-894	186	6	.	.	NUM
gs-894	186	7	12	12	NUM
gs-894	186	8	.	.	PUNCT
gs-894	187	1	kumar	kumar	PROPN
gs-894	187	2	s	s	PROPN
gs-894	187	3	and	and	CCONJ
gs-894	187	4	samaras	samaras	PROPN
gs-894	187	5	k.	k.	PROPN
gs-894	188	1	the	the	DET
gs-894	188	2	impact	impact	NOUN
gs-894	188	3	of	of	ADP
gs-894	188	4	weight	weight	NOUN
gs-894	188	5	gain	gain	NOUN
gs-894	188	6	during	during	ADP
gs-894	188	7	hiv	hiv	PROPN
gs-894	188	8	treatment	treatment	NOUN
gs-894	188	9	on	on	ADP
gs-894	188	10	risk	risk	NOUN
gs-894	188	11	of	of	ADP
gs-894	188	12	prediabetes	prediabete	NOUN
gs-894	188	13	,	,	PUNCT
gs-894	188	14	diabetes	diabetes	NOUN
gs-894	188	15	mellitus	mellitus	NOUN
gs-894	188	16	,	,	PUNCT
gs-894	188	17	cardiovascular	cardiovascular	ADJ
gs-894	188	18	disease	disease	NOUN
gs-894	188	19	,	,	PUNCT
gs-894	188	20	and	and	CCONJ
gs-894	188	21	mortality	mortality	NOUN
gs-894	188	22	.	.	PUNCT
gs-894	189	1	frontiers	frontier	NOUN
gs-894	189	2	in	in	ADP
gs-894	189	3	endocrinology	endocrinology	NOUN
gs-894	189	4	.	.	PUNCT
gs-894	189	5	2018	2018	NUM
gs-894	189	6	;	;	PUNCT
gs-894	189	7	9	9	NUM
gs-894	189	8	:	:	SYM
gs-894	189	9	705	705	NUM
gs-894	189	10	.	.	NOUN
gs-894	189	11	13	13	NUM
gs-894	189	12	.	.	PUNCT
gs-894	189	13	saeedi	saeedi	NOUN
gs-894	189	14	p	p	NOUN
gs-894	189	15	,	,	PUNCT
gs-894	189	16	petersohn	petersohn	PROPN
gs-894	189	17	i	i	PROPN
gs-894	189	18	,	,	PUNCT
gs-894	189	19	salpea	salpea	NOUN
gs-894	189	20	p	p	NOUN
gs-894	189	21	,	,	PUNCT
gs-894	189	22	et	et	PROPN
gs-894	189	23	al	al	PROPN
gs-894	189	24	.	.	PROPN
gs-894	190	1	global	global	ADJ
gs-894	190	2	and	and	CCONJ
gs-894	190	3	regional	regional	ADJ
gs-894	190	4	diabetes	diabetes	NOUN
gs-894	190	5	prevalence	prevalence	NOUN
gs-894	190	6	estimates	estimate	NOUN
gs-894	190	7	for	for	ADP
gs-894	190	8	2019	2019	NUM
gs-894	190	9	and	and	CCONJ
gs-894	190	10	projections	projection	NOUN
gs-894	190	11	for	for	ADP
gs-894	190	12	2030	2030	NUM
gs-894	190	13	and	and	CCONJ
gs-894	190	14	2045	2045	NUM
gs-894	190	15	:	:	PUNCT
gs-894	190	16	results	result	NOUN
gs-894	190	17	from	from	ADP
gs-894	190	18	the	the	DET
gs-894	190	19	international	international	ADJ
gs-894	190	20	diabetes	diabetes	NOUN
gs-894	190	21	federation	federation	PROPN
gs-894	190	22	diabetes	diabetes	PROPN
gs-894	190	23	atlas	atlas	PROPN
gs-894	190	24	,	,	PUNCT
gs-894	190	25	9(th	9(th	NOUN
gs-894	190	26	)	)	PUNCT
gs-894	190	27	edition	edition	NOUN
gs-894	190	28	.	.	PUNCT
gs-894	191	1	diabetes	diabetes	NOUN
gs-894	191	2	research	research	NOUN
gs-894	191	3	and	and	CCONJ
gs-894	191	4	clinical	clinical	ADJ
gs-894	191	5	practice	practice	NOUN
gs-894	191	6	.	.	PUNCT
gs-894	192	1	2019	2019	NUM
gs-894	192	2	;	;	PUNCT
gs-894	192	3	157	157	NUM
gs-894	192	4	:	:	SYM
gs-894	192	5	107843	107843	NUM
gs-894	192	6	.	.	PUNCT
gs-894	193	1	georgian	georgian	ADJ
gs-894	193	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-894	193	3	მეცნიერები	მეცნიერები	VERB
gs-894	193	4	4(02	4(02	NUM
gs-894	193	5	)	)	PUNCT
gs-894	193	6	,	,	PUNCT
gs-894	193	7	2022	2022	NUM
gs-894	193	8	202	202	NUM
gs-894	193	9	14	14	NUM
gs-894	193	10	.	.	PUNCT
gs-894	194	1	spollett	spollett	PROPN
gs-894	194	2	gr	gr	PROPN
gs-894	194	3	.	.	PUNCT
gs-894	194	4	hyperglycemia	hyperglycemia	NOUN
gs-894	194	5	in	in	ADP
gs-894	194	6	hiv	hiv	PROPN
gs-894	194	7	/	/	SYM
gs-894	194	8	aids	aids	PROPN
gs-894	194	9	.	.	PUNCT
gs-894	195	1	diabetes	diabetes	NOUN
gs-894	195	2	spectrum	spectrum	NOUN
gs-894	195	3	.	.	PUNCT
gs-894	196	1	2006	2006	NUM
gs-894	196	2	;	;	PUNCT
gs-894	196	3	19	19	NUM
gs-894	196	4	:	:	SYM
gs-894	196	5	163	163	NUM
gs-894	196	6	-	-	SYM
gs-894	196	7	6	6	NUM
gs-894	196	8	.	.	NOUN
gs-894	196	9	15	15	NUM
gs-894	196	10	.	.	PUNCT
gs-894	196	11	tien	tien	PROPN
gs-894	196	12	pc	pc	PROPN
gs-894	196	13	,	,	PUNCT
gs-894	196	14	schneider	schneider	NOUN
gs-894	196	15	mf	mf	PROPN
gs-894	196	16	,	,	PUNCT
gs-894	196	17	cox	cox	PROPN
gs-894	196	18	c	c	AUX
gs-894	196	19	,	,	PUNCT
gs-894	196	20	et	et	PROPN
gs-894	196	21	al	al	PROPN
gs-894	196	22	.	.	PROPN
gs-894	196	23	association	association	PROPN
gs-894	196	24	of	of	ADP
gs-894	196	25	hiv	hiv	PROPN
gs-894	196	26	infection	infection	NOUN
gs-894	196	27	with	with	ADP
gs-894	196	28	incident	incident	NOUN
gs-894	196	29	diabetes	diabetes	NOUN
gs-894	196	30	mellitus	mellitus	NOUN
gs-894	196	31	:	:	PUNCT
gs-894	196	32	impact	impact	NOUN
gs-894	196	33	of	of	ADP
gs-894	196	34	using	use	VERB
gs-894	196	35	hemoglobin	hemoglobin	NOUN
gs-894	196	36	a1c	a1c	PROPN
gs-894	196	37	as	as	ADP
gs-894	196	38	a	a	DET
gs-894	196	39	criterion	criterion	NOUN
gs-894	196	40	for	for	ADP
gs-894	196	41	diabetes	diabetes	NOUN
gs-894	196	42	.	.	PUNCT
gs-894	197	1	journal	journal	NOUN
gs-894	197	2	of	of	ADP
gs-894	197	3	acquired	acquire	VERB
gs-894	197	4	immune	immune	ADJ
gs-894	197	5	deficiency	deficiency	NOUN
gs-894	197	6	syndromes	syndrome	NOUN
gs-894	197	7	(	(	PUNCT
gs-894	197	8	1999	1999	NUM
gs-894	197	9	)	)	PUNCT
gs-894	197	10	.	.	PUNCT
gs-894	198	1	2012	2012	NUM
gs-894	198	2	;	;	PUNCT
gs-894	198	3	61	61	NUM
gs-894	198	4	:	:	SYM
gs-894	198	5	334	334	NUM
gs-894	198	6	-	-	SYM
gs-894	198	7	40	40	NUM
gs-894	198	8	.	.	PUNCT
gs-894	199	1	16	16	NUM
gs-894	199	2	.	.	PUNCT
gs-894	200	1	fleischman	fleischman	PROPN
gs-894	200	2	a	a	PROPN
gs-894	200	3	,	,	PUNCT
gs-894	200	4	johnsen	johnsen	PROPN
gs-894	200	5	s	s	PROPN
gs-894	200	6	,	,	PUNCT
gs-894	200	7	systrom	systrom	ADJ
gs-894	200	8	dm	dm	PROPN
gs-894	200	9	,	,	PUNCT
gs-894	200	10	et	et	PROPN
gs-894	200	11	al	al	PROPN
gs-894	200	12	.	.	PUNCT
gs-894	200	13	effects	effect	NOUN
gs-894	200	14	of	of	ADP
gs-894	200	15	a	a	DET
gs-894	200	16	nucleoside	nucleoside	ADJ
gs-894	200	17	reverse	reverse	ADJ
gs-894	200	18	transcriptase	transcriptase	NOUN
gs-894	200	19	inhibitor	inhibitor	NOUN
gs-894	200	20	,	,	PUNCT
gs-894	200	21	stavudine	stavudine	ADJ
gs-894	200	22	,	,	PUNCT
gs-894	200	23	on	on	ADP
gs-894	200	24	glucose	glucose	NOUN
gs-894	200	25	disposal	disposal	NOUN
gs-894	200	26	and	and	CCONJ
gs-894	200	27	mitochondrial	mitochondrial	ADJ
gs-894	200	28	function	function	NOUN
gs-894	200	29	in	in	ADP
gs-894	200	30	muscle	muscle	NOUN
gs-894	200	31	of	of	ADP
gs-894	200	32	healthy	healthy	ADJ
gs-894	200	33	adults	adult	NOUN
gs-894	200	34	.	.	PUNCT
gs-894	201	1	american	american	ADJ
gs-894	201	2	journal	journal	PROPN
gs-894	201	3	of	of	ADP
gs-894	201	4	physiology	physiology	NOUN
gs-894	201	5	endocrinology	endocrinology	NOUN
gs-894	201	6	and	and	CCONJ
gs-894	201	7	metabolism	metabolism	NOUN
gs-894	201	8	.	.	PUNCT
gs-894	202	1	2007	2007	NUM
gs-894	202	2	;	;	PUNCT
gs-894	202	3	292	292	NUM
gs-894	202	4	:	:	PUNCT
gs-894	202	5	e1666	e1666	NUM
gs-894	202	6	-	-	PUNCT
gs-894	202	7	73	73	NUM
gs-894	202	8	.	.	PUNCT
gs-894	203	1	17	17	NUM
gs-894	203	2	.	.	PUNCT
gs-894	204	1	haguihara	haguihara	PROPN
gs-894	204	2	t	t	PROPN
gs-894	204	3	,	,	PUNCT
gs-894	204	4	silva	silva	PROPN
gs-894	204	5	mdo	mdo	PROPN
gs-894	204	6	,	,	PUNCT
gs-894	204	7	rebouças	rebouças	PROPN
gs-894	204	8	mc	mc	PROPN
gs-894	204	9	,	,	PUNCT
gs-894	204	10	martins	martin	VERB
gs-894	204	11	netto	netto	NOUN
gs-894	204	12	e	e	PROPN
gs-894	204	13	and	and	CCONJ
gs-894	204	14	brites	brites	PROPN
gs-894	204	15	c.	c.	PROPN
gs-894	204	16	factors	factor	NOUN
gs-894	204	17	associated	associate	VERB
gs-894	204	18	with	with	ADP
gs-894	204	19	mortality	mortality	NOUN
gs-894	204	20	in	in	ADP
gs-894	204	21	hiv	hiv	PROPN
gs-894	204	22	patients	patient	NOUN
gs-894	204	23	failing	fail	VERB
gs-894	204	24	antiretroviral	antiretroviral	ADJ
gs-894	204	25	therapy	therapy	NOUN
gs-894	204	26	,	,	PUNCT
gs-894	204	27	in	in	ADP
gs-894	204	28	salvador	salvador	PROPN
gs-894	204	29	,	,	PUNCT
gs-894	204	30	brazil	brazil	PROPN
gs-894	204	31	.	.	PUNCT
gs-894	205	1	the	the	DET
gs-894	205	2	brazilian	brazilian	ADJ
gs-894	205	3	journal	journal	NOUN
gs-894	205	4	of	of	ADP
gs-894	205	5	infectious	infectious	ADJ
gs-894	205	6	diseases	disease	NOUN
gs-894	205	7	:	:	PUNCT
gs-894	205	8	an	an	DET
gs-894	205	9	official	official	ADJ
gs-894	205	10	publication	publication	NOUN
gs-894	205	11	of	of	ADP
gs-894	205	12	the	the	DET
gs-894	205	13	brazilian	brazilian	ADJ
gs-894	205	14	society	society	NOUN
gs-894	205	15	of	of	ADP
gs-894	205	16	infectious	infectious	ADJ
gs-894	205	17	diseases	disease	NOUN
gs-894	205	18	.	.	PUNCT
gs-894	205	19	2019	2019	NUM
gs-894	205	20	;	;	PUNCT
gs-894	205	21	23	23	NUM
gs-894	205	22	:	:	SYM
gs-894	205	23	160	160	NUM
gs-894	205	24	-	-	SYM
gs-894	205	25	3	3	NUM
gs-894	205	26	.	.	NOUN
gs-894	205	27	18	18	NUM
gs-894	205	28	.	.	PUNCT
gs-894	206	1	karamchand	karamchand	PROPN
gs-894	206	2	s	s	PROPN
gs-894	206	3	,	,	PUNCT
gs-894	206	4	leisegang	leisegang	ADJ
gs-894	206	5	r	r	NOUN
gs-894	206	6	,	,	PUNCT
gs-894	206	7	schomaker	schomaker	NOUN
gs-894	206	8	m	m	PROPN
gs-894	206	9	,	,	PUNCT
gs-894	206	10	et	et	PROPN
gs-894	206	11	al	al	PROPN
gs-894	206	12	.	.	PUNCT
gs-894	207	1	risk	risk	NOUN
gs-894	207	2	factors	factor	NOUN
gs-894	207	3	for	for	ADP
gs-894	207	4	incident	incident	NOUN
gs-894	207	5	diabetes	diabetes	NOUN
gs-894	207	6	in	in	ADP
gs-894	207	7	a	a	DET
gs-894	207	8	cohort	cohort	NOUN
gs-894	207	9	taking	take	VERB
gs-894	207	10	first	first	ADJ
gs-894	207	11	-	-	PUNCT
gs-894	207	12	line	line	NOUN
gs-894	207	13	nonnucleoside	nonnucleoside	ADV
gs-894	207	14	reverse	reverse	ADJ
gs-894	207	15	transcriptase	transcriptase	NOUN
gs-894	207	16	inhibitor	inhibitor	NOUN
gs-894	207	17	-	-	PUNCT
gs-894	207	18	based	base	VERB
gs-894	207	19	antiretroviral	antiretroviral	ADJ
gs-894	207	20	therapy	therapy	NOUN
gs-894	207	21	.	.	PUNCT
gs-894	208	1	medicine	medicine	NOUN
gs-894	208	2	.	.	PUNCT
gs-894	209	1	2016	2016	NUM
gs-894	209	2	;	;	PUNCT
gs-894	209	3	95	95	NUM
gs-894	209	4	.	.	NOUN
gs-894	210	1	19	19	NUM
gs-894	210	2	.	.	PUNCT
gs-894	211	1	kyaw	kyaw	PROPN
gs-894	211	2	ntt	ntt	PROPN
gs-894	211	3	,	,	PUNCT
gs-894	211	4	satyanarayana	satyanarayana	PROPN
gs-894	211	5	s	s	PROPN
gs-894	211	6	,	,	PUNCT
gs-894	211	7	oo	oo	INTJ
gs-894	211	8	hn	hn	PROPN
gs-894	211	9	,	,	PUNCT
gs-894	211	10	et	et	PROPN
gs-894	211	11	al	al	PROPN
gs-894	211	12	.	.	PROPN
gs-894	211	13	hyperglycemia	hyperglycemia	NOUN
gs-894	211	14	and	and	CCONJ
gs-894	211	15	risk	risk	NOUN
gs-894	211	16	of	of	ADP
gs-894	211	17	all	all	DET
gs-894	211	18	-	-	PUNCT
gs-894	211	19	cause	cause	NOUN
gs-894	211	20	mortality	mortality	NOUN
gs-894	211	21	among	among	ADP
gs-894	211	22	people	people	NOUN
gs-894	211	23	living	live	VERB
gs-894	211	24	with	with	ADP
gs-894	211	25	hiv	hiv	PROPN
gs-894	211	26	with	with	ADP
gs-894	211	27	and	and	CCONJ
gs-894	211	28	without	without	ADP
gs-894	211	29	tuberculosis	tuberculosis	NOUN
gs-894	211	30	disease	disease	NOUN
gs-894	211	31	in	in	ADP
gs-894	211	32	myanmar	myanmar	PROPN
gs-894	211	33	(	(	PUNCT
gs-894	211	34	2011–2017	2011–2017	NUM
gs-894	211	35	)	)	PUNCT
gs-894	211	36	.	.	PUNCT
gs-894	212	1	open	open	ADJ
gs-894	212	2	forum	forum	PROPN
gs-894	212	3	infectious	infectious	ADJ
gs-894	212	4	diseases	disease	NOUN
gs-894	212	5	.	.	PUNCT
gs-894	213	1	2019	2019	NUM
gs-894	213	2	;	;	PUNCT
gs-894	213	3	6	6	NUM
gs-894	213	4	.	.	NOUN
gs-894	213	5	20	20	NUM
gs-894	213	6	.	.	PUNCT
gs-894	214	1	patel	patel	PROPN
gs-894	214	2	p	p	PROPN
gs-894	214	3	,	,	PUNCT
gs-894	214	4	rose	rise	VERB
gs-894	214	5	ce	ce	PROPN
gs-894	214	6	,	,	PUNCT
gs-894	214	7	collins	collins	PROPN
gs-894	214	8	py	py	PROPN
gs-894	214	9	,	,	PUNCT
gs-894	214	10	et	et	PROPN
gs-894	214	11	al	al	PROPN
gs-894	214	12	.	.	PUNCT
gs-894	215	1	noncommunicable	noncommunicable	ADJ
gs-894	215	2	diseases	disease	NOUN
gs-894	215	3	among	among	ADP
gs-894	215	4	hiv	hiv	PROPN
gs-894	215	5	-	-	PUNCT
gs-894	215	6	infected	infect	VERB
gs-894	215	7	persons	person	NOUN
gs-894	215	8	in	in	ADP
gs-894	215	9	low	low	ADJ
gs-894	215	10	-	-	PUNCT
gs-894	215	11	income	income	NOUN
gs-894	215	12	and	and	CCONJ
gs-894	215	13	middle	middle	ADJ
gs-894	215	14	-	-	PUNCT
gs-894	215	15	income	income	NOUN
gs-894	215	16	countries	country	NOUN
gs-894	215	17	:	:	PUNCT
gs-894	215	18	a	a	DET
gs-894	215	19	systematic	systematic	ADJ
gs-894	215	20	review	review	NOUN
gs-894	215	21	and	and	CCONJ
gs-894	215	22	meta	meta	ADJ
gs-894	215	23	-	-	PUNCT
gs-894	215	24	analysis	analysis	NOUN
gs-894	215	25	.	.	PUNCT
gs-894	216	1	aids	aids	PROPN
gs-894	216	2	(	(	PUNCT
gs-894	216	3	london	london	PROPN
gs-894	216	4	,	,	PUNCT
gs-894	216	5	england	england	PROPN
gs-894	216	6	)	)	PUNCT
gs-894	216	7	.	.	PUNCT
gs-894	217	1	2018	2018	NUM
gs-894	217	2	;	;	PUNCT
gs-894	217	3	32	32	NUM
gs-894	217	4	suppl	suppl	ADJ
gs-894	217	5	1	1	NUM
gs-894	217	6	:	:	PUNCT
gs-894	217	7	s5	s5	NOUN
gs-894	217	8	-	-	PUNCT
gs-894	217	9	s20	s20	NOUN
gs-894	217	10	.	.	PUNCT
gs-894	217	11	21	21	NUM
gs-894	217	12	.	.	PUNCT
gs-894	218	1	rajpal	rajpal	PROPN
gs-894	218	2	a	a	DET
gs-894	218	3	,	,	PUNCT
gs-894	218	4	rahimi	rahimi	ADJ
gs-894	218	5	l	l	NOUN
gs-894	218	6	and	and	CCONJ
gs-894	218	7	ismail	ismail	PROPN
gs-894	218	8	-	-	PUNCT
gs-894	218	9	beigi	beigi	PROPN
gs-894	218	10	f.	f.	PROPN
gs-894	218	11	factors	factor	NOUN
gs-894	218	12	leading	lead	VERB
gs-894	218	13	to	to	ADP
gs-894	218	14	high	high	ADJ
gs-894	218	15	morbidity	morbidity	NOUN
gs-894	218	16	and	and	CCONJ
gs-894	218	17	mortality	mortality	NOUN
gs-894	218	18	of	of	ADP
gs-894	218	19	covid-19	covid-19	PROPN
gs-894	218	20	in	in	ADP
gs-894	218	21	patients	patient	NOUN
gs-894	218	22	with	with	ADP
gs-894	218	23	type	type	NOUN
gs-894	218	24	2	2	NUM
gs-894	218	25	diabetes	diabetes	NOUN
gs-894	218	26	.	.	PUNCT
gs-894	219	1	journal	journal	NOUN
gs-894	219	2	of	of	ADP
gs-894	219	3	diabetes	diabetes	NOUN
gs-894	219	4	.	.	PUNCT
gs-894	220	1	2020	2020	NUM
gs-894	220	2	;	;	PUNCT
gs-894	220	3	12	12	NUM
gs-894	220	4	:	:	SYM
gs-894	220	5	895	895	NUM
gs-894	220	6	-	-	SYM
gs-894	220	7	908	908	NUM
gs-894	220	8	.	.	PUNCT
gs-894	221	1	22	22	NUM
gs-894	221	2	.	.	PUNCT
gs-894	222	1	third	third	ADJ
gs-894	222	2	report	report	NOUN
gs-894	222	3	of	of	ADP
gs-894	222	4	the	the	DET
gs-894	222	5	national	national	ADJ
gs-894	222	6	cholesterol	cholesterol	PROPN
gs-894	222	7	education	education	NOUN
gs-894	222	8	program	program	NOUN
gs-894	222	9	(	(	PUNCT
gs-894	222	10	ncep	ncep	NOUN
gs-894	222	11	)	)	PUNCT
gs-894	222	12	expert	expert	NOUN
gs-894	222	13	panel	panel	NOUN
gs-894	222	14	on	on	ADP
gs-894	222	15	detection	detection	NOUN
gs-894	222	16	,	,	PUNCT
gs-894	222	17	evaluation	evaluation	NOUN
gs-894	222	18	,	,	PUNCT
gs-894	222	19	and	and	CCONJ
gs-894	222	20	treatment	treatment	NOUN
gs-894	222	21	of	of	ADP
gs-894	222	22	high	high	ADJ
gs-894	222	23	blood	blood	NOUN
gs-894	222	24	cholesterol	cholesterol	NOUN
gs-894	222	25	in	in	ADP
gs-894	222	26	adults	adult	NOUN
gs-894	222	27	(	(	PUNCT
gs-894	222	28	adult	adult	NOUN
gs-894	222	29	treatment	treatment	NOUN
gs-894	222	30	panel	panel	NOUN
gs-894	222	31	iii	iii	NOUN
gs-894	222	32	)	)	PUNCT
gs-894	222	33	final	final	ADJ
gs-894	222	34	report	report	NOUN
gs-894	222	35	.	.	PUNCT
gs-894	223	1	circulation	circulation	NOUN
gs-894	223	2	.	.	PUNCT
gs-894	224	1	2002	2002	NUM
gs-894	224	2	;	;	PUNCT
gs-894	224	3	106	106	NUM
gs-894	224	4	:	:	PUNCT
gs-894	224	5	3143	3143	NUM
gs-894	224	6	-	-	SYM
gs-894	224	7	421	421	NUM
gs-894	224	8	.	.	PUNCT
gs-894	225	1	23	23	NUM
gs-894	225	2	.	.	PUNCT
gs-894	226	1	nix	nix	PROPN
gs-894	226	2	lm	lm	PROPN
gs-894	226	3	and	and	CCONJ
gs-894	226	4	tien	tien	PROPN
gs-894	226	5	pc	pc	PROPN
gs-894	226	6	.	.	PUNCT
gs-894	226	7	metabolic	metabolic	NOUN
gs-894	226	8	syndrome	syndrome	NOUN
gs-894	226	9	,	,	PUNCT
gs-894	226	10	diabetes	diabetes	NOUN
gs-894	226	11	,	,	PUNCT
gs-894	226	12	and	and	CCONJ
gs-894	226	13	cardiovascular	cardiovascular	ADJ
gs-894	226	14	risk	risk	NOUN
gs-894	226	15	in	in	ADP
gs-894	226	16	hiv	hiv	PROPN
gs-894	226	17	.	.	PUNCT
gs-894	227	1	current	current	ADJ
gs-894	227	2	hiv	hiv	PROPN
gs-894	227	3	/	/	SYM
gs-894	227	4	aids	aids	PROPN
gs-894	227	5	reports	report	NOUN
gs-894	227	6	.	.	PUNCT
gs-894	228	1	2014	2014	NUM
gs-894	228	2	;	;	PUNCT
gs-894	228	3	11	11	NUM
gs-894	228	4	:	:	PUNCT
gs-894	228	5	271	271	NUM
gs-894	228	6	-	-	SYM
gs-894	228	7	8	8	NUM
gs-894	228	8	.	.	NUM
gs-894	229	1	24	24	NUM
gs-894	229	2	.	.	PUNCT
gs-894	230	1	law	law	PROPN
gs-894	230	2	mg	mg	PROPN
gs-894	230	3	,	,	PUNCT
gs-894	230	4	friis	friis	NOUN
gs-894	230	5	-	-	PUNCT
gs-894	230	6	møller	møller	NOUN
gs-894	230	7	n	n	CCONJ
gs-894	230	8	,	,	PUNCT
gs-894	230	9	el	el	PROPN
gs-894	230	10	-	-	PROPN
gs-894	230	11	sadr	sadr	PROPN
gs-894	230	12	wm	wm	PROPN
gs-894	230	13	,	,	PUNCT
gs-894	230	14	et	et	PROPN
gs-894	230	15	al	al	PROPN
gs-894	230	16	.	.	PUNCT
gs-894	231	1	the	the	DET
gs-894	231	2	use	use	NOUN
gs-894	231	3	of	of	ADP
gs-894	231	4	the	the	DET
gs-894	231	5	framingham	framingham	PROPN
gs-894	231	6	equation	equation	NOUN
gs-894	231	7	to	to	PART
gs-894	231	8	predict	predict	VERB
gs-894	231	9	myocardial	myocardial	ADJ
gs-894	231	10	infarctions	infarction	NOUN
gs-894	231	11	in	in	ADP
gs-894	231	12	hiv	hiv	PROPN
gs-894	231	13	-	-	PUNCT
gs-894	231	14	infected	infect	VERB
gs-894	231	15	patients	patient	NOUN
gs-894	231	16	:	:	PUNCT
gs-894	231	17	comparison	comparison	NOUN
gs-894	231	18	with	with	ADP
gs-894	231	19	observed	observed	ADJ
gs-894	231	20	events	event	NOUN
gs-894	231	21	in	in	ADP
gs-894	231	22	the	the	DET
gs-894	231	23	d	d	NOUN
gs-894	231	24	:	:	PUNCT
gs-894	231	25	a	a	DET
gs-894	231	26	:	:	PUNCT
gs-894	231	27	d	d	X
gs-894	231	28	study	study	NOUN
gs-894	231	29	.	.	PUNCT
gs-894	232	1	hiv	hiv	PROPN
gs-894	232	2	medicine	medicine	NOUN
gs-894	232	3	.	.	PUNCT
gs-894	233	1	2006	2006	NUM
gs-894	233	2	;	;	PUNCT
gs-894	233	3	7	7	NUM
gs-894	233	4	:	:	SYM
gs-894	233	5	218	218	NUM
gs-894	233	6	-	-	SYM
gs-894	233	7	30	30	NUM
gs-894	233	8	.	.	PUNCT
gs-894	234	1	25	25	NUM
gs-894	234	2	.	.	PUNCT
gs-894	234	3	davidson	davidson	PROPN
gs-894	234	4	ja	ja	PROPN
gs-894	234	5	and	and	CCONJ
gs-894	234	6	parkin	parkin	ADJ
gs-894	234	7	cg	cg	NOUN
gs-894	234	8	.	.	PUNCT
gs-894	235	1	is	be	AUX
gs-894	235	2	hyperglycemia	hyperglycemia	NOUN
gs-894	235	3	a	a	DET
gs-894	235	4	causal	causal	ADJ
gs-894	235	5	factor	factor	NOUN
gs-894	235	6	in	in	ADP
gs-894	235	7	cardiovascular	cardiovascular	ADJ
gs-894	235	8	disease	disease	NOUN
gs-894	235	9	?	?	PUNCT
gs-894	236	1	does	do	AUX
gs-894	236	2	proving	prove	VERB
gs-894	236	3	this	this	DET
gs-894	236	4	relationship	relationship	NOUN
gs-894	236	5	really	really	ADV
gs-894	236	6	matter	matter	ADV
gs-894	236	7	?	?	PUNCT
gs-894	237	1	yes	yes	INTJ
gs-894	237	2	.	.	PUNCT
gs-894	238	1	diabetes	diabetes	NOUN
gs-894	238	2	care	care	NOUN
gs-894	238	3	.	.	PUNCT
gs-894	239	1	2009	2009	NUM
gs-894	239	2	;	;	PUNCT
gs-894	239	3	32	32	NUM
gs-894	239	4	suppl	suppl	NOUN
gs-894	239	5	2	2	NUM
gs-894	239	6	:	:	PUNCT
gs-894	239	7	s331	s331	NUM
gs-894	239	8	-	-	SYM
gs-894	239	9	3	3	NUM
gs-894	239	10	.	.	NOUN
gs-894	239	11	26	26	NUM
gs-894	239	12	.	.	PUNCT
gs-894	240	1	stettler	stettler	PROPN
gs-894	240	2	c	c	PROPN
gs-894	240	3	,	,	PUNCT
gs-894	240	4	allemann	allemann	PROPN
gs-894	240	5	s	s	PROPN
gs-894	240	6	,	,	PUNCT
gs-894	240	7	jüni	jüni	NOUN
gs-894	240	8	p	p	NOUN
gs-894	240	9	,	,	PUNCT
gs-894	240	10	et	et	PROPN
gs-894	240	11	al	al	PROPN
gs-894	240	12	.	.	PUNCT
gs-894	241	1	glycemic	glycemic	ADJ
gs-894	241	2	control	control	NOUN
gs-894	241	3	and	and	CCONJ
gs-894	241	4	macrovascular	macrovascular	ADJ
gs-894	241	5	disease	disease	NOUN
gs-894	241	6	in	in	ADP
gs-894	241	7	types	type	NOUN
gs-894	241	8	1	1	NUM
gs-894	241	9	and	and	CCONJ
gs-894	241	10	2	2	NUM
gs-894	241	11	diabetes	diabetes	NOUN
gs-894	241	12	mellitus	mellitus	NOUN
gs-894	241	13	:	:	PUNCT
gs-894	242	1	meta	meta	ADJ
gs-894	242	2	-	-	PUNCT
gs-894	242	3	analysis	analysis	NOUN
gs-894	242	4	of	of	ADP
gs-894	242	5	randomized	randomized	ADJ
gs-894	242	6	trials	trial	NOUN
gs-894	242	7	.	.	PUNCT
gs-894	243	1	american	american	ADJ
gs-894	243	2	heart	heart	PROPN
gs-894	243	3	journal	journal	PROPN
gs-894	243	4	.	.	PUNCT
gs-894	244	1	2006	2006	NUM
gs-894	244	2	;	;	PUNCT
gs-894	244	3	152	152	NUM
gs-894	244	4	:	:	SYM
gs-894	244	5	27	27	NUM
gs-894	244	6	-	-	SYM
gs-894	244	7	38	38	NUM
gs-894	244	8	.	.	PUNCT
gs-894	245	1	27	27	NUM
gs-894	245	2	.	.	PUNCT
gs-894	246	1	gerich	gerich	PROPN
gs-894	246	2	je	je	PROPN
gs-894	246	3	.	.	PUNCT
gs-894	246	4	clinical	clinical	ADJ
gs-894	246	5	significance	significance	NOUN
gs-894	246	6	,	,	PUNCT
gs-894	246	7	pathogenesis	pathogenesis	NOUN
gs-894	246	8	,	,	PUNCT
gs-894	246	9	and	and	CCONJ
gs-894	246	10	management	management	NOUN
gs-894	246	11	of	of	ADP
gs-894	246	12	postprandial	postprandial	ADJ
gs-894	246	13	hyperglycemia	hyperglycemia	NOUN
gs-894	246	14	.	.	PUNCT
gs-894	247	1	archives	archive	NOUN
gs-894	247	2	of	of	ADP
gs-894	247	3	internal	internal	ADJ
gs-894	247	4	medicine	medicine	NOUN
gs-894	247	5	.	.	PUNCT
gs-894	248	1	2003	2003	NUM
gs-894	248	2	;	;	PUNCT
gs-894	248	3	163	163	NUM
gs-894	248	4	:	:	PUNCT
gs-894	248	5	1306	1306	NUM
gs-894	248	6	-	-	SYM
gs-894	248	7	16	16	NUM
gs-894	248	8	.	.	PUNCT
gs-894	249	1	28	28	NUM
gs-894	249	2	.	.	PUNCT
gs-894	250	1	naicker	naicker	PROPN
gs-894	250	2	s	s	PROPN
gs-894	250	3	,	,	PUNCT
gs-894	250	4	rahmanian	rahmanian	PROPN
gs-894	250	5	s	s	PART
gs-894	250	6	and	and	CCONJ
gs-894	250	7	kopp	kopp	PROPN
gs-894	250	8	jb	jb	PROPN
gs-894	250	9	.	.	PUNCT
gs-894	251	1	hiv	hiv	PROPN
gs-894	251	2	and	and	CCONJ
gs-894	251	3	chronic	chronic	ADJ
gs-894	251	4	kidney	kidney	NOUN
gs-894	251	5	disease	disease	NOUN
gs-894	251	6	.	.	PUNCT
gs-894	252	1	clinical	clinical	ADJ
gs-894	252	2	nephrology	nephrology	NOUN
gs-894	252	3	.	.	PUNCT
gs-894	253	1	2015	2015	NUM
gs-894	253	2	;	;	PUNCT
gs-894	253	3	83	83	NUM
gs-894	253	4	:	:	SYM
gs-894	253	5	32	32	NUM
gs-894	253	6	-	-	SYM
gs-894	253	7	8	8	NUM
gs-894	253	8	.	.	PUNCT
gs-894	254	1	georgian	georgian	ADJ
gs-894	254	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-894	254	3	მეცნიერები	მეცნიერები	VERB
gs-894	254	4	4(02	4(02	NUM
gs-894	254	5	)	)	PUNCT
gs-894	254	6	,	,	PUNCT
gs-894	254	7	2022	2022	NUM
gs-894	254	8	203	203	NUM
gs-894	254	9	29	29	NUM
gs-894	254	10	.	.	PUNCT
gs-894	255	1	sampanis	sampanis	PROPN
gs-894	255	2	c.	c.	PROPN
gs-894	255	3	management	management	NOUN
gs-894	255	4	of	of	ADP
gs-894	255	5	hyperglycemia	hyperglycemia	NOUN
gs-894	255	6	in	in	ADP
gs-894	255	7	patients	patient	NOUN
gs-894	255	8	with	with	ADP
gs-894	255	9	diabetes	diabetes	NOUN
gs-894	255	10	mellitus	mellitus	NOUN
gs-894	255	11	and	and	CCONJ
gs-894	255	12	chronic	chronic	ADJ
gs-894	255	13	renal	renal	ADJ
gs-894	255	14	failure	failure	NOUN
gs-894	255	15	.	.	PUNCT
gs-894	256	1	hippokratia	hippokratia	NOUN
gs-894	256	2	.	.	PUNCT
gs-894	257	1	2008	2008	NUM
gs-894	257	2	;	;	PUNCT
gs-894	257	3	12	12	NUM
gs-894	257	4	:	:	SYM
gs-894	257	5	22	22	NUM
gs-894	257	6	-	-	SYM
gs-894	257	7	7	7	NUM
gs-894	257	8	.	.	NOUN
gs-894	257	9	30	30	NUM
gs-894	257	10	.	.	PUNCT
gs-894	258	1	jeon	jeon	PROPN
gs-894	258	2	cy	cy	PROPN
gs-894	258	3	and	and	CCONJ
gs-894	258	4	murray	murray	PROPN
gs-894	258	5	mb	mb	PROPN
gs-894	258	6	.	.	PROPN
gs-894	258	7	diabetes	diabete	NOUN
gs-894	258	8	mellitus	mellitus	NOUN
gs-894	258	9	increases	increase	VERB
gs-894	258	10	the	the	DET
gs-894	258	11	risk	risk	NOUN
gs-894	258	12	of	of	ADP
gs-894	258	13	active	active	ADJ
gs-894	258	14	tuberculosis	tuberculosis	NOUN
gs-894	258	15	:	:	PUNCT
gs-894	258	16	a	a	DET
gs-894	258	17	systematic	systematic	ADJ
gs-894	258	18	review	review	NOUN
gs-894	258	19	of	of	ADP
gs-894	258	20	13	13	NUM
gs-894	258	21	observational	observational	ADJ
gs-894	258	22	studies	study	NOUN
gs-894	258	23	.	.	PUNCT
gs-894	259	1	plos	plos	PROPN
gs-894	259	2	medicine	medicine	PROPN
gs-894	259	3	.	.	PUNCT
gs-894	260	1	2008	2008	NUM
gs-894	260	2	;	;	PUNCT
gs-894	260	3	5	5	NUM
gs-894	260	4	:	:	PUNCT
gs-894	260	5	e152	e152	PROPN
gs-894	260	6	.	.	PROPN
gs-894	261	1	31	31	NUM
gs-894	261	2	.	.	PUNCT
gs-894	262	1	casqueiro	casqueiro	PROPN
gs-894	262	2	j	j	PROPN
gs-894	262	3	,	,	PUNCT
gs-894	262	4	casqueiro	casqueiro	PROPN
gs-894	262	5	j	j	PROPN
gs-894	262	6	and	and	CCONJ
gs-894	262	7	alves	alves	PROPN
gs-894	262	8	c.	c.	PROPN
gs-894	262	9	infections	infection	NOUN
gs-894	262	10	in	in	ADP
gs-894	262	11	patients	patient	NOUN
gs-894	262	12	with	with	ADP
gs-894	262	13	diabetes	diabetes	NOUN
gs-894	262	14	mellitus	mellitus	NOUN
gs-894	262	15	:	:	PUNCT
gs-894	262	16	a	a	DET
gs-894	262	17	review	review	NOUN
gs-894	262	18	of	of	ADP
gs-894	262	19	pathogenesis	pathogenesis	NOUN
gs-894	262	20	.	.	PUNCT
gs-894	263	1	indian	indian	ADJ
gs-894	263	2	journal	journal	PROPN
gs-894	263	3	of	of	ADP
gs-894	263	4	endocrinology	endocrinology	NOUN
gs-894	263	5	and	and	CCONJ
gs-894	263	6	metabolism	metabolism	NOUN
gs-894	263	7	.	.	PUNCT
gs-894	264	1	2012	2012	NUM
gs-894	264	2	;	;	PUNCT
gs-894	264	3	16	16	NUM
gs-894	264	4	:	:	PUNCT
gs-894	264	5	s27	s27	PROPN
gs-894	264	6	-	-	PROPN
gs-894	264	7	36	36	NUM
gs-894	264	8	.	.	PUNCT
gs-894	265	1	32	32	NUM
gs-894	265	2	.	.	PUNCT
gs-894	266	1	dooley	dooley	PROPN
gs-894	266	2	ke	ke	PROPN
gs-894	266	3	and	and	CCONJ
gs-894	266	4	chaisson	chaisson	NOUN
gs-894	266	5	re	re	PROPN
gs-894	266	6	.	.	PUNCT
gs-894	267	1	tuberculosis	tuberculosis	NOUN
gs-894	267	2	and	and	CCONJ
gs-894	267	3	diabetes	diabetes	NOUN
gs-894	267	4	mellitus	mellitus	NOUN
gs-894	267	5	:	:	PUNCT
gs-894	267	6	convergence	convergence	NOUN
gs-894	267	7	of	of	ADP
gs-894	267	8	two	two	NUM
gs-894	267	9	epidemics	epidemic	NOUN
gs-894	267	10	.	.	PUNCT
gs-894	268	1	the	the	DET
gs-894	268	2	lancet	lancet	ADJ
gs-894	268	3	infectious	infectious	ADJ
gs-894	268	4	diseases	disease	NOUN
gs-894	268	5	.	.	PUNCT
gs-894	268	6	2009	2009	NUM
gs-894	268	7	;	;	PUNCT
gs-894	268	8	9	9	NUM
gs-894	268	9	:	:	SYM
gs-894	268	10	737	737	NUM
gs-894	268	11	-	-	SYM
gs-894	268	12	46	46	NUM
gs-894	268	13	.	.	PUNCT
gs-894	268	14	33	33	NUM
gs-894	268	15	.	.	PUNCT
gs-894	269	1	oni	oni	PROPN
gs-894	269	2	t	t	PROPN
gs-894	269	3	,	,	PUNCT
gs-894	269	4	berkowitz	berkowitz	PROPN
gs-894	269	5	n	n	CCONJ
gs-894	269	6	,	,	PUNCT
gs-894	269	7	kubjane	kubjane	PROPN
gs-894	269	8	m	m	PROPN
gs-894	269	9	,	,	PUNCT
gs-894	269	10	goliath	goliath	PROPN
gs-894	269	11	r	r	PROPN
gs-894	269	12	,	,	PUNCT
gs-894	269	13	levitt	levitt	PROPN
gs-894	269	14	ns	ns	PROPN
gs-894	269	15	and	and	CCONJ
gs-894	269	16	wilkinson	wilkinson	PROPN
gs-894	269	17	rj	rj	PROPN
gs-894	269	18	.	.	PUNCT
gs-894	269	19	trilateral	trilateral	ADJ
gs-894	269	20	overlap	overlap	NOUN
gs-894	269	21	of	of	ADP
gs-894	269	22	tuberculosis	tuberculosis	NOUN
gs-894	269	23	,	,	PUNCT
gs-894	269	24	diabetes	diabetes	NOUN
gs-894	269	25	and	and	CCONJ
gs-894	269	26	hiv-1	hiv-1	PUNCT
gs-894	269	27	in	in	ADP
gs-894	269	28	a	a	DET
gs-894	269	29	high	high	ADJ
gs-894	269	30	-	-	PUNCT
gs-894	269	31	burden	burden	NOUN
gs-894	269	32	african	african	ADJ
gs-894	269	33	setting	setting	NOUN
gs-894	269	34	:	:	PUNCT
gs-894	269	35	implications	implication	NOUN
gs-894	269	36	for	for	ADP
gs-894	269	37	tb	tb	ADP
gs-894	269	38	control	control	NOUN
gs-894	269	39	.	.	PUNCT
gs-894	270	1	the	the	DET
gs-894	270	2	european	european	ADJ
gs-894	270	3	respiratory	respiratory	ADJ
gs-894	270	4	journal	journal	NOUN
gs-894	270	5	.	.	PUNCT
gs-894	271	1	2017	2017	NUM
gs-894	271	2	;	;	PUNCT
gs-894	271	3	50	50	NUM
gs-894	271	4	.	.	X
gs-894	272	1	34	34	NUM
gs-894	272	2	.	.	PUNCT
gs-894	273	1	achwoka	achwoka	PROPN
gs-894	273	2	d	d	PROPN
gs-894	273	3	,	,	PUNCT
gs-894	273	4	waruru	waruru	X
gs-894	273	5	a	a	X
gs-894	273	6	,	,	PUNCT
gs-894	273	7	chen	chen	PROPN
gs-894	273	8	th	th	PROPN
gs-894	273	9	,	,	PUNCT
gs-894	273	10	et	et	PROPN
gs-894	273	11	al	al	PROPN
gs-894	273	12	.	.	PUNCT
gs-894	274	1	noncommunicable	noncommunicable	ADJ
gs-894	274	2	disease	disease	NOUN
gs-894	274	3	burden	burden	NOUN
gs-894	274	4	among	among	ADP
gs-894	274	5	hiv	hiv	PROPN
gs-894	274	6	patients	patient	NOUN
gs-894	274	7	in	in	ADP
gs-894	274	8	care	care	NOUN
gs-894	274	9	:	:	PUNCT
gs-894	274	10	a	a	DET
gs-894	274	11	national	national	ADJ
gs-894	274	12	retrospective	retrospective	ADJ
gs-894	274	13	longitudinal	longitudinal	ADJ
gs-894	274	14	analysis	analysis	NOUN
gs-894	274	15	of	of	ADP
gs-894	274	16	hiv	hiv	NOUN
gs-894	274	17	-	-	PUNCT
gs-894	274	18	treatment	treatment	NOUN
gs-894	274	19	outcomes	outcome	NOUN
gs-894	274	20	in	in	ADP
gs-894	274	21	kenya	kenya	PROPN
gs-894	274	22	,	,	PUNCT
gs-894	274	23	2003	2003	NUM
gs-894	274	24	-	-	SYM
gs-894	274	25	2013	2013	NUM
gs-894	274	26	.	.	PUNCT
gs-894	275	1	bmc	bmc	ADJ
gs-894	275	2	public	public	ADJ
gs-894	275	3	health	health	NOUN
gs-894	275	4	.	.	PUNCT
gs-894	276	1	2019	2019	NUM
gs-894	276	2	;	;	PUNCT
gs-894	276	3	19	19	NUM
gs-894	276	4	.	.	NOUN
gs-894	276	5	35	35	NUM
gs-894	276	6	.	.	PUNCT
gs-894	277	1	han	han	PROPN
gs-894	277	2	jh	jh	PROPN
gs-894	277	3	,	,	PUNCT
gs-894	277	4	crane	crane	PROPN
gs-894	277	5	hm	hm	PROPN
gs-894	277	6	,	,	PUNCT
gs-894	277	7	bellamy	bellamy	PROPN
gs-894	277	8	sl	sl	PROPN
gs-894	277	9	,	,	PUNCT
gs-894	277	10	frank	frank	PROPN
gs-894	277	11	i	i	PROPN
gs-894	277	12	,	,	PUNCT
gs-894	277	13	cardillo	cardillo	PROPN
gs-894	277	14	s	s	PROPN
gs-894	277	15	and	and	CCONJ
gs-894	277	16	bisson	bisson	PROPN
gs-894	277	17	gp	gp	PROPN
gs-894	277	18	.	.	PUNCT
gs-894	278	1	hiv	hiv	PROPN
gs-894	278	2	infection	infection	NOUN
gs-894	278	3	and	and	CCONJ
gs-894	278	4	glycemic	glycemic	ADJ
gs-894	278	5	response	response	NOUN
gs-894	278	6	to	to	ADP
gs-894	278	7	newly	newly	ADV
gs-894	278	8	initiated	initiate	VERB
gs-894	278	9	diabetic	diabetic	ADJ
gs-894	278	10	medical	medical	ADJ
gs-894	278	11	therapy	therapy	NOUN
gs-894	278	12	.	.	PUNCT
gs-894	279	1	aids	aids	PROPN
gs-894	279	2	(	(	PUNCT
gs-894	279	3	london	london	PROPN
gs-894	279	4	,	,	PUNCT
gs-894	279	5	england	england	PROPN
gs-894	279	6	)	)	PUNCT
gs-894	279	7	.	.	PUNCT
gs-894	280	1	2012	2012	NUM
gs-894	280	2	;	;	PUNCT
gs-894	280	3	26	26	NUM
gs-894	280	4	:	:	SYM
gs-894	280	5	2087	2087	NUM
gs-894	280	6	-	-	SYM
gs-894	280	7	95	95	NUM
gs-894	280	8	.	.	PUNCT
gs-894	281	1	36	36	NUM
gs-894	281	2	.	.	PUNCT
gs-894	282	1	ada	ada	PROPN
gs-894	282	2	ada	ada	PROPN
gs-894	282	3	.	.	PROPN
gs-894	283	1	2	2	X
gs-894	283	2	.	.	X
gs-894	283	3	classification	classification	NOUN
gs-894	283	4	and	and	CCONJ
gs-894	283	5	diagnosis	diagnosis	NOUN
gs-894	283	6	of	of	ADP
gs-894	283	7	diabetes	diabetes	NOUN
gs-894	283	8	:	:	PUNCT
gs-894	283	9	standards	standard	NOUN
gs-894	283	10	of	of	ADP
gs-894	283	11	medical	medical	ADJ
gs-894	283	12	care	care	NOUN
gs-894	283	13	in	in	ADP
gs-894	283	14	diabetes2021	diabetes2021	PROPN
gs-894	283	15	.	.	PUNCT
gs-894	284	1	diabetes	diabetes	NOUN
gs-894	284	2	care	care	NOUN
gs-894	284	3	.	.	PUNCT
gs-894	285	1	2021	2021	NUM
gs-894	285	2	;	;	PUNCT
gs-894	285	3	44	44	NUM
gs-894	285	4	:	:	PUNCT
gs-894	285	5	s15	s15	NOUN
gs-894	285	6	-	-	PUNCT
gs-894	285	7	s33	s33	NOUN
gs-894	285	8	.	.	PUNCT
gs-894	286	1	37	37	NUM
gs-894	286	2	.	.	PUNCT
gs-894	287	1	alvaro	alvaro	PROPN
gs-894	287	2	-	-	PUNCT
gs-894	287	3	meca	meca	PROPN
gs-894	287	4	a	a	PRON
gs-894	287	5	,	,	PUNCT
gs-894	287	6	jiménez	jiménez	PROPN
gs-894	287	7	-	-	PUNCT
gs-894	287	8	garcia	garcia	PROPN
gs-894	287	9	r	r	PROPN
gs-894	287	10	,	,	PUNCT
gs-894	287	11	jimenez	jimenez	PROPN
gs-894	287	12	-	-	PUNCT
gs-894	287	13	trujillo	trujillo	PROPN
gs-894	288	1	i	i	PROPN
gs-894	288	2	,	,	PUNCT
gs-894	288	3	et	et	PROPN
gs-894	288	4	al	al	PROPN
gs-894	288	5	.	.	PROPN
gs-894	288	6	fifteen	fifteen	NUM
gs-894	288	7	-	-	PUNCT
gs-894	288	8	year	year	NOUN
gs-894	288	9	trends	trend	NOUN
gs-894	288	10	in	in	ADP
gs-894	288	11	the	the	DET
gs-894	288	12	prevalence	prevalence	NOUN
gs-894	288	13	of	of	ADP
gs-894	288	14	diabetes	diabetes	NOUN
gs-894	288	15	among	among	ADP
gs-894	288	16	hospitalized	hospitalize	VERB
gs-894	288	17	hiv	hiv	PROPN
gs-894	288	18	-	-	PUNCT
gs-894	288	19	infected	infect	VERB
gs-894	288	20	patients	patient	NOUN
gs-894	288	21	in	in	ADP
gs-894	288	22	spain	spain	PROPN
gs-894	288	23	(	(	PUNCT
gs-894	288	24	1997	1997	NUM
gs-894	288	25	-	-	SYM
gs-894	288	26	2012	2012	NUM
gs-894	288	27	)	)	PUNCT
gs-894	288	28	.	.	PUNCT
gs-894	289	1	plos	plos	PROPN
gs-894	289	2	one	one	NUM
gs-894	289	3	.	.	PROPN
gs-894	289	4	2016	2016	NUM
gs-894	289	5	;	;	PUNCT
gs-894	289	6	11	11	NUM
gs-894	289	7	:	:	PUNCT
gs-894	289	8	e0161953	e0161953	PROPN
gs-894	289	9	.	.	PROPN
gs-894	290	1	38	38	NUM
gs-894	290	2	.	.	PUNCT
gs-894	291	1	capeau	capeau	PROPN
gs-894	291	2	j	j	PROPN
gs-894	291	3	,	,	PUNCT
gs-894	291	4	bouteloup	bouteloup	PROPN
gs-894	291	5	v	v	NOUN
gs-894	291	6	,	,	PUNCT
gs-894	291	7	katlama	katlama	NOUN
gs-894	291	8	c	c	NOUN
gs-894	291	9	,	,	PUNCT
gs-894	291	10	et	et	PROPN
gs-894	291	11	al	al	PROPN
gs-894	291	12	.	.	PROPN
gs-894	291	13	ten	ten	NUM
gs-894	291	14	-	-	PUNCT
gs-894	291	15	year	year	NOUN
gs-894	291	16	diabetes	diabetes	NOUN
gs-894	291	17	incidence	incidence	NOUN
gs-894	291	18	in	in	ADP
gs-894	291	19	1046	1046	NUM
gs-894	291	20	hiv	hiv	PROPN
gs-894	291	21	-	-	PUNCT
gs-894	291	22	infected	infect	VERB
gs-894	291	23	patients	patient	NOUN
gs-894	291	24	started	start	VERB
gs-894	291	25	on	on	ADP
gs-894	291	26	a	a	DET
gs-894	291	27	combination	combination	NOUN
gs-894	291	28	antiretroviral	antiretroviral	ADJ
gs-894	291	29	treatment	treatment	NOUN
gs-894	291	30	.	.	PUNCT
gs-894	292	1	aids	aids	PROPN
gs-894	292	2	(	(	PUNCT
gs-894	292	3	london	london	PROPN
gs-894	292	4	,	,	PUNCT
gs-894	292	5	england	england	PROPN
gs-894	292	6	)	)	PUNCT
gs-894	292	7	.	.	PUNCT
gs-894	293	1	2012	2012	NUM
gs-894	293	2	;	;	PUNCT
gs-894	293	3	26	26	NUM
gs-894	293	4	:	:	PUNCT
gs-894	293	5	303	303	NUM
gs-894	293	6	-	-	SYM
gs-894	293	7	14	14	NUM
gs-894	293	8	.	.	PUNCT
gs-894	293	9	39	39	NUM
gs-894	293	10	.	.	PUNCT
gs-894	294	1	tripathi	tripathi	PROPN
gs-894	294	2	a	a	PROPN
gs-894	294	3	,	,	PUNCT
gs-894	294	4	liese	liese	NOUN
gs-894	294	5	ad	ad	NOUN
gs-894	294	6	,	,	PUNCT
gs-894	294	7	jerrell	jerrell	PROPN
gs-894	294	8	jm	jm	PROPN
gs-894	294	9	,	,	PUNCT
gs-894	294	10	et	et	PROPN
gs-894	294	11	al	al	PROPN
gs-894	294	12	.	.	PROPN
gs-894	294	13	incidence	incidence	NOUN
gs-894	294	14	of	of	ADP
gs-894	294	15	diabetes	diabetes	NOUN
gs-894	294	16	mellitus	mellitus	NOUN
gs-894	294	17	in	in	ADP
gs-894	294	18	a	a	DET
gs-894	294	19	population	population	NOUN
gs-894	294	20	-	-	PUNCT
gs-894	294	21	based	base	VERB
gs-894	294	22	cohort	cohort	NOUN
gs-894	294	23	of	of	ADP
gs-894	294	24	hiv	hiv	PROPN
gs-894	294	25	-	-	PUNCT
gs-894	294	26	infected	infect	VERB
gs-894	294	27	and	and	CCONJ
gs-894	294	28	non	non	ADJ
gs-894	294	29	-	-	ADJ
gs-894	294	30	hiv	hiv	ADJ
gs-894	294	31	-	-	PUNCT
gs-894	294	32	infected	infect	VERB
gs-894	294	33	persons	person	NOUN
gs-894	294	34	:	:	PUNCT
gs-894	294	35	the	the	DET
gs-894	294	36	impact	impact	NOUN
gs-894	294	37	of	of	ADP
gs-894	294	38	clinical	clinical	ADJ
gs-894	294	39	and	and	CCONJ
gs-894	294	40	therapeutic	therapeutic	ADJ
gs-894	294	41	factors	factor	NOUN
gs-894	294	42	over	over	ADP
gs-894	294	43	time	time	NOUN
gs-894	294	44	.	.	PUNCT
gs-894	295	1	diabetic	diabetic	ADJ
gs-894	295	2	medicine	medicine	NOUN
gs-894	295	3	:	:	PUNCT
gs-894	295	4	a	a	DET
gs-894	295	5	journal	journal	NOUN
gs-894	295	6	of	of	ADP
gs-894	295	7	the	the	DET
gs-894	295	8	british	british	PROPN
gs-894	295	9	diabetic	diabetic	PROPN
gs-894	295	10	association	association	PROPN
gs-894	295	11	.	.	PUNCT
gs-894	296	1	2014	2014	NUM
gs-894	296	2	;	;	PUNCT
gs-894	296	3	31	31	NUM
gs-894	296	4	:	:	SYM
gs-894	296	5	1185	1185	NUM
gs-894	296	6	-	-	SYM
gs-894	296	7	93	93	NUM
gs-894	296	8	.	.	PUNCT
gs-894	297	1	40	40	NUM
gs-894	297	2	.	.	PUNCT
gs-894	298	1	wada	wada	PROPN
gs-894	298	2	n	n	PROPN
gs-894	298	3	,	,	PUNCT
gs-894	298	4	jacobson	jacobson	PROPN
gs-894	298	5	lp	lp	PROPN
gs-894	298	6	,	,	PUNCT
gs-894	298	7	cohen	cohen	PROPN
gs-894	298	8	m	m	PROPN
gs-894	298	9	,	,	PUNCT
gs-894	298	10	french	french	ADJ
gs-894	298	11	a	a	PRON
gs-894	298	12	,	,	PUNCT
gs-894	298	13	phair	phair	NOUN
gs-894	298	14	j	j	PROPN
gs-894	298	15	and	and	CCONJ
gs-894	298	16	muñoz	muñoz	PROPN
gs-894	298	17	a.	a.	PROPN
gs-894	298	18	cause	cause	PROPN
gs-894	298	19	-	-	PUNCT
gs-894	298	20	specific	specific	ADJ
gs-894	298	21	mortality	mortality	NOUN
gs-894	298	22	among	among	ADP
gs-894	298	23	hiv	hiv	PROPN
gs-894	298	24	-	-	PUNCT
gs-894	298	25	infected	infect	VERB
gs-894	298	26	individuals	individual	NOUN
gs-894	298	27	,	,	PUNCT
gs-894	298	28	by	by	ADP
gs-894	298	29	cd4(+	cd4(+	NOUN
gs-894	298	30	)	)	PUNCT
gs-894	298	31	cell	cell	NOUN
gs-894	298	32	count	count	NOUN
gs-894	298	33	at	at	ADP
gs-894	298	34	haart	haart	PROPN
gs-894	298	35	initiation	initiation	NOUN
gs-894	298	36	,	,	PUNCT
gs-894	298	37	compared	compare	VERB
gs-894	298	38	with	with	ADP
gs-894	298	39	hiv	hiv	PROPN
gs-894	298	40	-	-	PUNCT
gs-894	298	41	uninfected	uninfected	ADJ
gs-894	298	42	individuals	individual	NOUN
gs-894	298	43	.	.	PUNCT
gs-894	299	1	aids	aids	PROPN
gs-894	299	2	(	(	PUNCT
gs-894	299	3	london	london	PROPN
gs-894	299	4	,	,	PUNCT
gs-894	299	5	england	england	PROPN
gs-894	299	6	)	)	PUNCT
gs-894	299	7	.	.	PUNCT
gs-894	300	1	2014	2014	NUM
gs-894	300	2	;	;	PUNCT
gs-894	300	3	28	28	NUM
gs-894	300	4	:	:	PUNCT
gs-894	300	5	257	257	NUM
gs-894	300	6	-	-	SYM
gs-894	300	7	65	65	NUM
gs-894	300	8	.	.	PUNCT
gs-894	301	1	41	41	NUM
gs-894	301	2	.	.	PUNCT
gs-894	302	1	rasmussen	rasmussen	PROPN
gs-894	302	2	ld	ld	PROPN
gs-894	302	3	,	,	PUNCT
gs-894	302	4	mathiesen	mathiesen	PROPN
gs-894	302	5	er	er	INTJ
gs-894	302	6	,	,	PUNCT
gs-894	302	7	kronborg	kronborg	ADJ
gs-894	302	8	g	g	NOUN
gs-894	302	9	,	,	PUNCT
gs-894	302	10	pedersen	pedersen	NOUN
gs-894	302	11	c	c	PROPN
gs-894	302	12	,	,	PUNCT
gs-894	302	13	gerstoft	gerstoft	PROPN
gs-894	302	14	j	j	PROPN
gs-894	302	15	and	and	CCONJ
gs-894	302	16	obel	obel	PROPN
gs-894	302	17	n.	n.	PROPN
gs-894	302	18	risk	risk	NOUN
gs-894	302	19	of	of	ADP
gs-894	302	20	diabetes	diabetes	NOUN
gs-894	302	21	mellitus	mellitus	NOUN
gs-894	302	22	in	in	ADP
gs-894	302	23	persons	person	NOUN
gs-894	302	24	with	with	ADP
gs-894	302	25	and	and	CCONJ
gs-894	302	26	without	without	ADP
gs-894	302	27	hiv	hiv	PROPN
gs-894	302	28	:	:	PUNCT
gs-894	302	29	a	a	DET
gs-894	302	30	danish	danish	ADJ
gs-894	302	31	nationwide	nationwide	ADJ
gs-894	302	32	population	population	NOUN
gs-894	302	33	-	-	PUNCT
gs-894	302	34	based	base	VERB
gs-894	302	35	cohort	cohort	NOUN
gs-894	302	36	study	study	NOUN
gs-894	302	37	.	.	PUNCT
gs-894	303	1	plos	plos	PROPN
gs-894	303	2	one	one	NUM
gs-894	303	3	.	.	PUNCT
gs-894	303	4	2012	2012	NUM
gs-894	303	5	;	;	PUNCT
gs-894	303	6	7	7	NUM
gs-894	303	7	:	:	PUNCT
gs-894	303	8	e44575	e44575	VERB
gs-894	303	9	.	.	PROPN
gs-894	304	1	42	42	NUM
gs-894	304	2	.	.	PUNCT
gs-894	304	3	worm	worm	PROPN
gs-894	304	4	sw	sw	PROPN
gs-894	304	5	,	,	PUNCT
gs-894	304	6	de	de	X
gs-894	304	7	wit	wit	NOUN
gs-894	304	8	s	s	PROPN
gs-894	304	9	,	,	PUNCT
gs-894	304	10	weber	weber	PROPN
gs-894	304	11	r	r	PROPN
gs-894	304	12	,	,	PUNCT
gs-894	304	13	et	et	PROPN
gs-894	304	14	al	al	PROPN
gs-894	304	15	.	.	PROPN
gs-894	305	1	diabetes	diabetes	PROPN
gs-894	305	2	mellitus	mellitus	NOUN
gs-894	305	3	,	,	PUNCT
gs-894	305	4	preexisting	preexist	VERB
gs-894	305	5	coronary	coronary	ADJ
gs-894	305	6	heart	heart	NOUN
gs-894	305	7	disease	disease	NOUN
gs-894	305	8	,	,	PUNCT
gs-894	305	9	and	and	CCONJ
gs-894	305	10	the	the	DET
gs-894	305	11	risk	risk	NOUN
gs-894	305	12	of	of	ADP
gs-894	305	13	subsequent	subsequent	ADJ
gs-894	305	14	coronary	coronary	ADJ
gs-894	305	15	heart	heart	NOUN
gs-894	305	16	disease	disease	NOUN
gs-894	305	17	events	event	NOUN
gs-894	305	18	in	in	ADP
gs-894	305	19	patients	patient	NOUN
gs-894	305	20	infected	infect	VERB
gs-894	305	21	with	with	ADP
gs-894	305	22	human	human	ADJ
gs-894	305	23	immunodeficiency	immunodeficiency	NOUN
gs-894	305	24	virus	virus	NOUN
gs-894	305	25	:	:	PUNCT
gs-894	305	26	the	the	DET
gs-894	305	27	data	data	NOUN
gs-894	305	28	collection	collection	NOUN
gs-894	305	29	on	on	ADP
gs-894	305	30	adverse	adverse	ADJ
gs-894	305	31	events	event	NOUN
gs-894	305	32	of	of	ADP
gs-894	305	33	anti	anti	ADJ
gs-894	305	34	-	-	ADJ
gs-894	305	35	hiv	hiv	ADJ
gs-894	305	36	drugs	drug	NOUN
gs-894	305	37	(	(	PUNCT
gs-894	305	38	d	d	NOUN
gs-894	305	39	:	:	PUNCT
gs-894	305	40	a	a	PRON
gs-894	305	41	:	:	PUNCT
gs-894	305	42	d	d	X
gs-894	305	43	study	study	NOUN
gs-894	305	44	)	)	PUNCT
gs-894	305	45	.	.	PUNCT
gs-894	306	1	circulation	circulation	NOUN
gs-894	306	2	.	.	PUNCT
gs-894	307	1	2009	2009	NUM
gs-894	307	2	;	;	PUNCT
gs-894	307	3	119	119	NUM
gs-894	307	4	:	:	PUNCT
gs-894	307	5	805	805	NUM
gs-894	307	6	-	-	SYM
gs-894	307	7	11	11	NUM
gs-894	307	8	.	.	PUNCT
gs-894	308	1	georgian	georgian	ADJ
gs-894	308	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-894	308	3	მეცნიერები	მეცნიერები	VERB
gs-894	308	4	4(02	4(02	NUM
gs-894	308	5	)	)	PUNCT
gs-894	308	6	,	,	PUNCT
gs-894	308	7	2022	2022	NUM
gs-894	308	8	204	204	NUM
gs-894	308	9	43	43	NUM
gs-894	308	10	.	.	PUNCT
gs-894	309	1	pealing	peal	VERB
gs-894	309	2	l	l	NOUN
gs-894	309	3	,	,	PUNCT
gs-894	309	4	wing	wing	NOUN
gs-894	309	5	k	k	PROPN
gs-894	309	6	,	,	PUNCT
gs-894	309	7	mathur	mathur	PROPN
gs-894	309	8	r	r	PROPN
gs-894	309	9	,	,	PUNCT
gs-894	309	10	prieto	prieto	NOUN
gs-894	309	11	-	-	PUNCT
gs-894	309	12	merino	merino	NOUN
gs-894	309	13	d	d	NOUN
gs-894	309	14	,	,	PUNCT
gs-894	309	15	smeeth	smeeth	PROPN
gs-894	309	16	l	l	PROPN
gs-894	309	17	and	and	CCONJ
gs-894	309	18	moore	moore	PROPN
gs-894	309	19	daj	daj	PROPN
gs-894	309	20	.	.	PUNCT
gs-894	310	1	risk	risk	NOUN
gs-894	310	2	of	of	ADP
gs-894	310	3	tuberculosis	tuberculosis	NOUN
gs-894	310	4	in	in	ADP
gs-894	310	5	patients	patient	NOUN
gs-894	310	6	with	with	ADP
gs-894	310	7	diabetes	diabetes	NOUN
gs-894	310	8	:	:	PUNCT
gs-894	310	9	population	population	NOUN
gs-894	310	10	based	base	VERB
gs-894	310	11	cohort	cohort	NOUN
gs-894	310	12	study	study	NOUN
gs-894	310	13	using	use	VERB
gs-894	310	14	the	the	DET
gs-894	310	15	uk	uk	PROPN
gs-894	310	16	clinical	clinical	ADJ
gs-894	310	17	practice	practice	NOUN
gs-894	310	18	research	research	NOUN
gs-894	310	19	datalink	datalink	NOUN
gs-894	310	20	.	.	PUNCT
gs-894	311	1	bmc	bmc	ADJ
gs-894	311	2	medicine	medicine	NOUN
gs-894	311	3	.	.	PUNCT
gs-894	312	1	2015	2015	NUM
gs-894	312	2	;	;	PUNCT
gs-894	312	3	13	13	NUM
gs-894	312	4	:	:	SYM
gs-894	312	5	135	135	NUM
gs-894	312	6	.	.	X
gs-894	312	7	44	44	NUM
gs-894	312	8	.	.	PUNCT
gs-894	313	1	chkhartishvili	chkhartishvili	NOUN
gs-894	313	2	n	n	NOUN
gs-894	313	3	,	,	PUNCT
gs-894	313	4	sharvadze	sharvadze	PROPN
gs-894	313	5	l	l	PROPN
gs-894	313	6	,	,	PUNCT
gs-894	313	7	chokoshvili	chokoshvili	PROPN
gs-894	313	8	o	o	NOUN
gs-894	313	9	,	,	PUNCT
gs-894	313	10	et	et	PROPN
gs-894	313	11	al	al	PROPN
gs-894	313	12	.	.	PUNCT
gs-894	313	13	mortality	mortality	NOUN
gs-894	313	14	and	and	CCONJ
gs-894	313	15	causes	cause	NOUN
gs-894	313	16	of	of	ADP
gs-894	313	17	death	death	NOUN
gs-894	313	18	among	among	ADP
gs-894	313	19	hivinfected	hivinfecte	VERB
gs-894	313	20	individuals	individual	NOUN
gs-894	313	21	in	in	ADP
gs-894	313	22	the	the	DET
gs-894	313	23	country	country	NOUN
gs-894	313	24	of	of	ADP
gs-894	313	25	georgia	georgia	PROPN
gs-894	313	26	:	:	PUNCT
gs-894	313	27	1989–2012	1989–2012	NUM
gs-894	313	28	.	.	PUNCT
gs-894	314	1	aids	aids	PROPN
gs-894	314	2	research	research	PROPN
gs-894	314	3	and	and	CCONJ
gs-894	314	4	human	human	ADJ
gs-894	314	5	retroviruses	retrovirus	NOUN
gs-894	314	6	.	.	PUNCT
gs-894	315	1	2014	2014	NUM
gs-894	315	2	;	;	PUNCT
gs-894	315	3	30	30	NUM
gs-894	315	4	:	:	PUNCT
gs-894	315	5	560	560	NUM
gs-894	315	6	-	-	SYM
gs-894	315	7	6	6	NUM
gs-894	315	8	.	.	NOUN
gs-894	315	9	45	45	NUM
gs-894	315	10	.	.	PUNCT
gs-894	315	11	moreira	moreira	PROPN
gs-894	315	12	j	j	PROPN
gs-894	315	13	,	,	PUNCT
gs-894	315	14	castro	castro	PROPN
gs-894	315	15	r	r	VERB
gs-894	315	16	,	,	PUNCT
gs-894	315	17	lamas	lama	NOUN
gs-894	315	18	c	c	NOUN
gs-894	315	19	,	,	PUNCT
gs-894	315	20	ribeiro	ribeiro	PROPN
gs-894	315	21	s	s	PROPN
gs-894	315	22	,	,	PUNCT
gs-894	315	23	grinsztejn	grinsztejn	PROPN
gs-894	315	24	b	b	PROPN
gs-894	315	25	and	and	CCONJ
gs-894	315	26	veloso	veloso	PROPN
gs-894	315	27	vg	vg	PROPN
gs-894	315	28	.	.	PUNCT
gs-894	315	29	hyperglycemia	hyperglycemia	NOUN
gs-894	315	30	during	during	ADP
gs-894	315	31	tuberculosis	tuberculosis	NOUN
gs-894	315	32	treatment	treatment	NOUN
gs-894	315	33	increases	increase	VERB
gs-894	315	34	morbidity	morbidity	NOUN
gs-894	315	35	and	and	CCONJ
gs-894	315	36	mortality	mortality	NOUN
gs-894	315	37	in	in	ADP
gs-894	315	38	a	a	DET
gs-894	315	39	contemporary	contemporary	ADJ
gs-894	315	40	cohort	cohort	NOUN
gs-894	315	41	of	of	ADP
gs-894	315	42	hiv	hiv	PROPN
gs-894	315	43	-	-	PUNCT
gs-894	315	44	infected	infect	VERB
gs-894	315	45	patients	patient	NOUN
gs-894	315	46	in	in	ADP
gs-894	315	47	rio	rio	PROPN
gs-894	315	48	de	de	PROPN
gs-894	315	49	janeiro	janeiro	PROPN
gs-894	315	50	,	,	PUNCT
gs-894	315	51	brazil	brazil	PROPN
gs-894	315	52	.	.	PUNCT
gs-894	316	1	international	international	ADJ
gs-894	316	2	journal	journal	PROPN
gs-894	316	3	of	of	ADP
gs-894	316	4	infectious	infectious	ADJ
gs-894	316	5	diseases	disease	NOUN
gs-894	316	6	:	:	PUNCT
gs-894	316	7	ijid	ijid	NOUN
gs-894	316	8	:	:	PUNCT
gs-894	316	9	official	official	ADJ
gs-894	316	10	publication	publication	NOUN
gs-894	316	11	of	of	ADP
gs-894	316	12	the	the	DET
gs-894	316	13	international	international	ADJ
gs-894	316	14	society	society	NOUN
gs-894	316	15	for	for	ADP
gs-894	316	16	infectious	infectious	ADJ
gs-894	316	17	diseases	disease	NOUN
gs-894	316	18	.	.	PUNCT
gs-894	316	19	2018	2018	NUM
gs-894	316	20	;	;	PUNCT
gs-894	316	21	69	69	NUM
gs-894	316	22	:	:	SYM
gs-894	316	23	11	11	NUM
gs-894	316	24	-	-	SYM
gs-894	316	25	9	9	NUM
gs-894	316	26	.	.	NOUN
gs-894	316	27	46	46	NUM
gs-894	316	28	.	.	PUNCT
gs-894	317	1	friis	friis	NOUN
gs-894	317	2	-	-	PUNCT
gs-894	317	3	møller	møller	NOUN
gs-894	317	4	n	n	NOUN
gs-894	317	5	,	,	PUNCT
gs-894	317	6	sabin	sabin	PROPN
gs-894	317	7	ca	ca	PROPN
gs-894	318	1	,	,	PUNCT
gs-894	318	2	weber	weber	PROPN
gs-894	318	3	r	r	PROPN
gs-894	318	4	,	,	PUNCT
gs-894	318	5	et	et	PROPN
gs-894	318	6	al	al	PROPN
gs-894	318	7	.	.	PROPN
gs-894	318	8	combination	combination	NOUN
gs-894	318	9	antiretroviral	antiretroviral	ADJ
gs-894	318	10	therapy	therapy	NOUN
gs-894	318	11	and	and	CCONJ
gs-894	318	12	the	the	DET
gs-894	318	13	risk	risk	NOUN
gs-894	318	14	of	of	ADP
gs-894	318	15	myocardial	myocardial	ADJ
gs-894	318	16	infarction	infarction	NOUN
gs-894	318	17	.	.	PUNCT
gs-894	319	1	the	the	DET
gs-894	319	2	new	new	PROPN
gs-894	319	3	england	england	PROPN
gs-894	319	4	journal	journal	PROPN
gs-894	319	5	of	of	ADP
gs-894	319	6	medicine	medicine	NOUN
gs-894	319	7	.	.	PUNCT
gs-894	320	1	2003	2003	NUM
gs-894	320	2	;	;	PUNCT
gs-894	320	3	349	349	NUM
gs-894	320	4	:	:	SYM
gs-894	320	5	1993	1993	NUM
gs-894	320	6	-	-	SYM
gs-894	320	7	2003	2003	NUM
gs-894	320	8	.	.	PUNCT
gs-894	321	1	47	47	NUM
gs-894	321	2	.	.	PUNCT
gs-894	322	1	friis	friis	NOUN
gs-894	322	2	-	-	PUNCT
gs-894	322	3	møller	møller	NOUN
gs-894	322	4	n	n	NOUN
gs-894	322	5	,	,	PUNCT
gs-894	322	6	thiébaut	thiébaut	NOUN
gs-894	322	7	r	r	NOUN
gs-894	322	8	,	,	PUNCT
gs-894	322	9	reiss	reiss	PROPN
gs-894	322	10	p	p	NOUN
gs-894	322	11	,	,	PUNCT
gs-894	322	12	et	et	PROPN
gs-894	322	13	al	al	PROPN
gs-894	322	14	.	.	PROPN
gs-894	323	1	predicting	predict	VERB
gs-894	323	2	the	the	DET
gs-894	323	3	risk	risk	NOUN
gs-894	323	4	of	of	ADP
gs-894	323	5	cardiovascular	cardiovascular	ADJ
gs-894	323	6	disease	disease	NOUN
gs-894	323	7	in	in	ADP
gs-894	323	8	hivinfected	hivinfected	ADJ
gs-894	323	9	patients	patient	NOUN
gs-894	323	10	:	:	PUNCT
gs-894	323	11	the	the	DET
gs-894	323	12	data	data	NOUN
gs-894	323	13	collection	collection	NOUN
gs-894	323	14	on	on	ADP
gs-894	323	15	adverse	adverse	ADJ
gs-894	323	16	effects	effect	NOUN
gs-894	323	17	of	of	ADP
gs-894	323	18	anti	anti	ADJ
gs-894	323	19	-	-	ADJ
gs-894	323	20	hiv	hiv	ADJ
gs-894	323	21	drugs	drug	NOUN
gs-894	323	22	study	study	NOUN
gs-894	323	23	.	.	PUNCT
gs-894	324	1	european	european	PROPN
gs-894	324	2	journal	journal	PROPN
gs-894	324	3	of	of	ADP
gs-894	324	4	cardiovascular	cardiovascular	ADJ
gs-894	324	5	prevention	prevention	NOUN
gs-894	324	6	and	and	CCONJ
gs-894	324	7	rehabilitation	rehabilitation	NOUN
gs-894	324	8	:	:	PUNCT
gs-894	324	9	official	official	ADJ
gs-894	324	10	journal	journal	NOUN
gs-894	324	11	of	of	ADP
gs-894	324	12	the	the	DET
gs-894	324	13	european	european	PROPN
gs-894	324	14	society	society	PROPN
gs-894	324	15	of	of	ADP
gs-894	324	16	cardiology	cardiology	NOUN
gs-894	324	17	,	,	PUNCT
gs-894	324	18	working	work	VERB
gs-894	324	19	groups	group	NOUN
gs-894	324	20	on	on	ADP
gs-894	324	21	epidemiology	epidemiology	NOUN
gs-894	324	22	&	&	CCONJ
gs-894	324	23	prevention	prevention	NOUN
gs-894	324	24	and	and	CCONJ
gs-894	324	25	cardiac	cardiac	ADJ
gs-894	324	26	rehabilitation	rehabilitation	NOUN
gs-894	324	27	and	and	CCONJ
gs-894	324	28	exercise	exercise	NOUN
gs-894	324	29	physiology	physiology	NOUN
gs-894	324	30	.	.	PUNCT
gs-894	325	1	2010	2010	NUM
gs-894	325	2	;	;	PUNCT
gs-894	325	3	17	17	NUM
gs-894	325	4	:	:	PUNCT
gs-894	325	5	491	491	NUM
gs-894	325	6	-	-	SYM
gs-894	325	7	501	501	NUM
gs-894	325	8	.	.	PUNCT
gs-894	326	1	48	48	NUM
gs-894	326	2	.	.	PUNCT
gs-894	327	1	kruglikov	kruglikov	PROPN
gs-894	327	2	il	il	PROPN
gs-894	327	3	,	,	PUNCT
gs-894	327	4	shah	shah	PROPN
gs-894	327	5	m	m	PROPN
gs-894	327	6	and	and	CCONJ
gs-894	327	7	scherer	scherer	PROPN
gs-894	327	8	pe	pe	PROPN
gs-894	327	9	.	.	PUNCT
gs-894	327	10	obesity	obesity	NOUN
gs-894	327	11	and	and	CCONJ
gs-894	327	12	diabetes	diabetes	NOUN
gs-894	327	13	as	as	ADP
gs-894	327	14	comorbidities	comorbiditie	NOUN
gs-894	327	15	for	for	ADP
gs-894	327	16	covid-19	covid-19	PROPN
gs-894	327	17	:	:	PUNCT
gs-894	327	18	underlying	underlying	ADJ
gs-894	327	19	mechanisms	mechanism	NOUN
gs-894	327	20	and	and	CCONJ
gs-894	327	21	the	the	DET
gs-894	327	22	role	role	NOUN
gs-894	327	23	of	of	ADP
gs-894	327	24	viral	viral	ADJ
gs-894	327	25	-	-	PUNCT
gs-894	327	26	bacterial	bacterial	ADJ
gs-894	327	27	interactions	interaction	NOUN
gs-894	327	28	.	.	PUNCT
gs-894	328	1	elife	elife	NOUN
gs-894	328	2	.	.	PUNCT
gs-894	329	1	2020	2020	NUM
gs-894	329	2	;	;	PUNCT
gs-894	330	1	9	9	NUM
gs-894	330	2	.	.	NOUN
gs-894	330	3	49	49	NUM
gs-894	330	4	.	.	PUNCT
gs-894	331	1	hill	hill	PROPN
gs-894	331	2	md	md	PROPN
gs-894	331	3	.	.	PROPN
gs-894	332	1	stroke	stroke	PROPN
gs-894	332	2	and	and	CCONJ
gs-894	332	3	diabetes	diabetes	NOUN
gs-894	332	4	mellitus	mellitus	NOUN
gs-894	332	5	.	.	PUNCT
gs-894	333	1	handbook	handbook	NOUN
gs-894	333	2	of	of	ADP
gs-894	333	3	clinical	clinical	ADJ
gs-894	333	4	neurology	neurology	NOUN
gs-894	333	5	.	.	PUNCT
gs-894	334	1	2014	2014	NUM
gs-894	334	2	;	;	PUNCT
gs-894	334	3	126	126	NUM
gs-894	334	4	:	:	PUNCT
gs-894	334	5	167	167	NUM
gs-894	334	6	-	-	SYM
gs-894	334	7	74	74	NUM
gs-894	334	8	.	.	PUNCT
gs-894	335	1	50	50	NUM
gs-894	335	2	.	.	PUNCT
gs-894	336	1	ergul	ergul	NOUN
gs-894	336	2	a	a	PRON
gs-894	336	3	,	,	PUNCT
gs-894	336	4	li	li	PROPN
gs-894	336	5	w	w	PROPN
gs-894	336	6	,	,	PUNCT
gs-894	336	7	elgebaly	elgebaly	PROPN
gs-894	336	8	mm	mm	PROPN
gs-894	336	9	,	,	PUNCT
gs-894	336	10	bruno	bruno	PROPN
gs-894	336	11	a	a	PRON
gs-894	336	12	and	and	CCONJ
gs-894	336	13	fagan	fagan	PROPN
gs-894	336	14	sc	sc	PROPN
gs-894	336	15	.	.	PUNCT
gs-894	336	16	hyperglycemia	hyperglycemia	NOUN
gs-894	336	17	,	,	PUNCT
gs-894	336	18	diabetes	diabetes	NOUN
gs-894	336	19	and	and	CCONJ
gs-894	336	20	stroke	stroke	NOUN
gs-894	336	21	:	:	PUNCT
gs-894	336	22	focus	focus	VERB
gs-894	336	23	on	on	ADP
gs-894	336	24	the	the	DET
gs-894	336	25	cerebrovasculature	cerebrovasculature	NOUN
gs-894	336	26	.	.	PUNCT
gs-894	337	1	vascular	vascular	ADJ
gs-894	337	2	pharmacology	pharmacology	NOUN
gs-894	337	3	.	.	PUNCT
gs-894	338	1	2009	2009	NUM
gs-894	338	2	;	;	PUNCT
gs-894	338	3	51	51	NUM
gs-894	338	4	:	:	SYM
gs-894	338	5	44	44	NUM
gs-894	338	6	-	-	SYM
gs-894	338	7	9	9	NUM
gs-894	338	8	.	.	NUM
gs-894	338	9	51	51	NUM
gs-894	338	10	.	.	PUNCT
gs-894	339	1	lim	lim	PROPN
gs-894	339	2	a.	a.	PROPN
gs-894	339	3	diabetic	diabetic	PROPN
gs-894	339	4	nephropathy	nephropathy	ADJ
gs-894	339	5	complications	complication	NOUN
gs-894	339	6	and	and	CCONJ
gs-894	339	7	treatment	treatment	NOUN
gs-894	339	8	.	.	PUNCT
gs-894	340	1	international	international	ADJ
gs-894	340	2	journal	journal	PROPN
gs-894	340	3	of	of	ADP
gs-894	340	4	nephrology	nephrology	NOUN
gs-894	340	5	and	and	CCONJ
gs-894	340	6	renovascular	renovascular	ADJ
gs-894	340	7	disease	disease	NOUN
gs-894	340	8	.	.	PUNCT
gs-894	341	1	2014	2014	NUM
gs-894	341	2	;	;	PUNCT
gs-894	341	3	7	7	NUM
gs-894	341	4	:	:	SYM
gs-894	341	5	361	361	NUM
gs-894	341	6	-	-	SYM
gs-894	341	7	81	81	NUM
gs-894	341	8	.	.	PUNCT
gs-894	342	1	52	52	NUM
gs-894	342	2	.	.	PUNCT
gs-894	343	1	mocroft	mocroft	ADV
gs-894	343	2	a	a	PRON
gs-894	343	3	,	,	PUNCT
gs-894	343	4	lundgren	lundgren	PROPN
gs-894	343	5	jd	jd	PROPN
gs-894	343	6	,	,	PUNCT
gs-894	343	7	ross	ross	PROPN
gs-894	343	8	m	m	PROPN
gs-894	343	9	,	,	PUNCT
gs-894	343	10	et	et	PROPN
gs-894	343	11	al	al	PROPN
gs-894	343	12	.	.	PROPN
gs-894	343	13	development	development	PROPN
gs-894	343	14	and	and	CCONJ
gs-894	343	15	validation	validation	NOUN
gs-894	343	16	of	of	ADP
gs-894	343	17	a	a	DET
gs-894	343	18	risk	risk	NOUN
gs-894	343	19	score	score	NOUN
gs-894	343	20	for	for	ADP
gs-894	343	21	chronic	chronic	ADJ
gs-894	343	22	kidney	kidney	NOUN
gs-894	343	23	disease	disease	NOUN
gs-894	343	24	in	in	ADP
gs-894	343	25	hiv	hiv	PROPN
gs-894	343	26	infection	infection	NOUN
gs-894	343	27	using	use	VERB
gs-894	343	28	prospective	prospective	ADJ
gs-894	343	29	cohort	cohort	NOUN
gs-894	343	30	data	datum	NOUN
gs-894	343	31	from	from	ADP
gs-894	343	32	the	the	DET
gs-894	343	33	d	d	NOUN
gs-894	343	34	:	:	PUNCT
gs-894	343	35	a	a	DET
gs-894	343	36	:	:	PUNCT
gs-894	343	37	d	d	X
gs-894	343	38	study	study	NOUN
gs-894	343	39	.	.	PUNCT
gs-894	344	1	plos	plos	PROPN
gs-894	344	2	medicine	medicine	PROPN
gs-894	344	3	.	.	PUNCT
gs-894	345	1	2015	2015	NUM
gs-894	345	2	;	;	PUNCT
gs-894	345	3	12	12	NUM
gs-894	345	4	:	:	PUNCT
gs-894	345	5	e1001809	e1001809	NOUN
gs-894	345	6	.	.	PUNCT
gs-894	346	1	georgian	georgian	PROPN
gs-894	346	2	scientists/ქართველი	scientists/ქართველი	PROPN
gs-894	346	3	მეცნიერები	მეცნიერები	VERB
gs-894	346	4	4(02	4(02	NUM
gs-894	346	5	)	)	PUNCT
gs-894	346	6	,	,	PUNCT
gs-894	346	7	2022	2022	NUM
gs-894	346	8	205	205	NUM
gs-894	346	9	ტიპი	ტიპი	NOUN
gs-894	346	10	2	2	NUM
gs-894	346	11	შაქრიანი	შაქრიანი	PROPN
gs-894	346	12	დიაბეტის	დიაბეტის	NOUN
gs-894	346	13	გავრცელება	გავრცელება	X
gs-894	346	14	აივ	აივ	PROPN
gs-894	346	15	ინფიცირებულ	ინფიცირებულ	NOUN
gs-894	346	16	პირებში	პირებში	NOUN
gs-894	346	17	,	,	PUNCT
gs-894	346	18	საქართველოში	საქართველოში	PROPN
gs-894	346	19	თ.ბორკოვსკა1	თ.ბორკოვსკა1	PROPN
gs-894	346	20	,	,	PUNCT
gs-894	346	21	ე.	ე.	NOUN
gs-894	346	22	ქარქაშაძე1	ქარქაშაძე1	PROPN
gs-894	346	23	,	,	PUNCT
gs-894	346	24	ო.ჩოკოშვილი1	ო.ჩოკოშვილი1	NOUN
gs-894	346	25	,	,	PUNCT
gs-894	346	26	ნ.ჩხარტიშვილი1	ნ.ჩხარტიშვილი1	NOUN
gs-894	346	27	,	,	PUNCT
gs-894	346	28	თ.ცერცვაძე1	თ.ცერცვაძე1	NOUN
gs-894	346	29	1ინფექციური	1ინფექციური	PROPN
gs-894	346	30	პათოლოგიის	პათოლოგიის	NOUN
gs-894	346	31	,	,	PUNCT
gs-894	347	1	შიდსისა	შიდსისა	VERB
gs-894	347	2	და	და	NOUN
gs-894	347	3	კლინიკური	კლინიკური	PROPN
gs-894	347	4	იმუნოლოგიის	იმუნოლოგიის	PROPN
gs-894	347	5	სამეცნიერო	სამეცნიერო	PROPN
gs-894	347	6	პრაქტიკული	პრაქტიკული	PROPN
gs-894	347	7	ცენტრი	ცენტრი	PROPN
gs-894	347	8	აბსტრაქტი	აბსტრაქტი	NOUN
gs-894	347	9	შესავალი	შესავალი	PROPN
gs-894	347	10	:	:	PUNCT
gs-894	347	11	ადამიანის	ადამიანის	NOUN
gs-894	347	12	იმუნოდეფიციტის	იმუნოდეფიციტის	NOUN
gs-894	347	13	ვირუსით	ვირუსით	NOUN
gs-894	347	14	(	(	PUNCT
gs-894	347	15	აივ	აივ	ADJ
gs-894	347	16	)	)	PUNCT
gs-894	347	17	მცხოვრებთა	მცხოვრებთა	NOUN
gs-894	347	18	რიცხვი	რიცხვი	NOUN
gs-894	347	19	იზრდება	იზრდება	PROPN
gs-894	347	20	გაუმჯობესებული	გაუმჯობესებული	PROPN
gs-894	347	21	სკრინინგის	სკრინინგის	PROPN
gs-894	347	22	,	,	PUNCT
gs-894	347	23	სწრაფი	სწრაფი	NOUN
gs-894	347	24	დიაგნოზის	დიაგნოზის	NOUN
gs-894	347	25	,	,	PUNCT
gs-894	347	26	ახალი	ახალი	ADJ
gs-894	347	27	მეთოდების	მეთოდების	NOUN
gs-894	347	28	,	,	PUNCT
gs-894	347	29	მკურნალობის	მკურნალობის	NOUN
gs-894	347	30	ხელმისაწვდომობისა	ხელმისაწვდომობისა	NOUN
gs-894	347	31	და	და	PROPN
gs-894	347	32	მკურნალობის	მკურნალობის	PROPN
gs-894	347	33	მიღების	მიღების	NOUN
gs-894	347	34	გამო.	გამო.	NOUN
gs-894	347	35	არაგადამდები	არაგადამდები	NOUN
gs-894	347	36	დაავადებების	დაავადებების	NOUN
gs-894	347	37	,	,	PUNCT
gs-894	347	38	განსაკუთრებით	განსაკუთრებით	PROPN
gs-894	347	39	მეტაბოლური	მეტაბოლური	ADV
gs-894	347	40	დარღვევების	დარღვევების	PROPN
gs-894	347	41	გავრცელებამ	გავრცელებამ	NOUN
gs-894	347	42	მკვეთრად	მკვეთრად	VERB
gs-894	347	43	მოიმატა	მოიმატა	NUM
gs-894	347	44	აივ	აივ	ADJ
gs-894	347	45	ინფიცირებულ	ინფიცირებულ	NOUN
gs-894	347	46	პაციენტებში.	პაციენტებში.	PROPN
gs-894	347	47	კვლევის	კვლევის	PROPN
gs-894	347	48	მიზანია	მიზანია	PROPN
gs-894	347	49	ტიპი	ტიპი	PROPN
gs-894	347	50	2	2	NUM
gs-894	347	51	შაქრიანი	შაქრიანი	PROPN
gs-894	347	52	დიაბეტის	დიაბეტის	VERB
gs-894	347	53	გავრცელების	გავრცელების	ADJ
gs-894	347	54	გამოთვლა	გამოთვლა	PROPN
gs-894	347	55	,	,	PUNCT
gs-894	347	56	შაქრიანი	შაქრიანი	NOUN
gs-894	347	57	დიაბეტისა	დიაბეტისა	VERB
gs-894	347	58	და	და	NOUN
gs-894	347	59	თანმხლები	თანმხლები	NOUN
gs-894	347	60	დაავადებებს	დაავადებებს	NOUN
gs-894	347	61	შორის	შორის	PROPN
gs-894	347	62	ასოციაციის	ასოციაციის	PROPN
gs-894	347	63	პოვნა	პოვნა	NOUN
gs-894	347	64	,	,	PUNCT
gs-894	347	65	არსებული	არსებული	PROPN
gs-894	347	66	საკითხის	საკითხის	PROPN
gs-894	347	67	ირგვლივ	ირგვლივ	PROPN
gs-894	347	68	ცოდნის	ცოდნის	PROPN
gs-894	347	69	გაღრმავება.	გაღრმავება.	PROPN
gs-894	347	70	კვლევის	კვლევის	PROPN
gs-894	347	71	მეთოდები	მეთოდები	PROPN
gs-894	347	72	:	:	PUNCT
gs-894	347	73	ინფექციური	ინფექციური	PROPN
gs-894	347	74	პათოლოგიის	პათოლოგიის	PROPN
gs-894	347	75	,	,	PUNCT
gs-894	347	76	შიდსისა	შიდსისა	VERB
gs-894	347	77	და	და	NOUN
gs-894	347	78	კლინიკური	კლინიკური	PROPN
gs-894	347	79	იმუნოლოგიის	იმუნოლოგიის	PROPN
gs-894	347	80	სამეცნიერო	სამეცნიერო	PROPN
gs-894	347	81	პრაქტიკულ	პრაქტიკულ	NOUN
gs-894	347	82	ცენტრში	ცენტრში	PROPN
gs-894	347	83	ჩავატარეთ	ჩავატარეთ	PROPN
gs-894	347	84	პროსპექტული	პროსპექტული	PROPN
gs-894	347	85	კოჰორტული	კოჰორტული	PROPN
gs-894	347	86	კვლევა.	კვლევა.	PROPN
gs-894	347	87	კვლევაში	კვლევაში	PROPN
gs-894	347	88	მონაწილეობდა	მონაწილეობდა	PROPN
gs-894	347	89	მოზრდილი	მოზრდილი	PROPN
gs-894	347	90	(	(	PUNCT
gs-894	347	91	ასაკი≥18წელი	ასაკი≥18წელი	NOUN
gs-894	347	92	)	)	PUNCT
gs-894	347	93	პირები	პირები	NOUN
gs-894	347	94	,	,	PUNCT
gs-894	347	95	რომლებსაც	რომლებსაც	VERB
gs-894	347	96	აივ	აივ	PROPN
gs-894	347	97	დიაგნოზი	დიაგნოზი	PROPN
gs-894	347	98	დაესვათ	დაესვათ	PROPN
gs-894	347	99	20122018	20122018	NUM
gs-894	347	100	წლებში.	წლებში.	VERB
gs-894	347	101	პაცინტებზე	პაცინტებზე	PROPN
gs-894	347	102	დაკვირვება	დაკვირვება	ADV
gs-894	347	103	ხორციელდებოდა	ხორციელდებოდა	X
gs-894	347	104	2021	2021	NUM
gs-894	347	105	წლის	წლის	NOUN
gs-894	347	106	1	1	NUM
gs-894	347	107	ოქტომბრამდე.	ოქტომბრამდე.	NOUN
gs-894	347	108	ჰიპერგლიკემიისა	ჰიპერგლიკემიისა	VERB
gs-894	347	109	და	და	PROPN
gs-894	347	110	შაქრიანი	შაქრიანი	PROPN
gs-894	347	111	დიაბეტის	დიაბეტის	NOUN
gs-894	347	112	განმარტებებისთვის	განმარტებებისთვის	NOUN
gs-894	347	113	გამოვიყენეთ	გამოვიყენეთ	PROPN
gs-894	347	114	ამერიკის	ამერიკის	PROPN
gs-894	347	115	დიაბეტის	დიაბეტის	PROPN
gs-894	347	116	ასოციაციის	ასოციაციის	PROPN
gs-894	347	117	(	(	PUNCT
gs-894	347	118	ada	ada	PROPN
gs-894	347	119	)	)	PUNCT
gs-894	347	120	გაიდლაინბი.	გაიდლაინბი.	PROPN
gs-894	347	121	შედეგები	შედეგები	NOUN
gs-894	347	122	:	:	PUNCT
gs-894	347	123	მთლიან	მთლიან	PROPN
gs-894	347	124	კოჰორტაში	კოჰორტაში	VERB
gs-894	347	125	4.47	4.47	NUM
gs-894	347	126	%	%	NOUN
gs-894	347	127	ჰქონდა	ჰქონდა	NOUN
gs-894	347	128	პრედიაბეტი	პრედიაბეტი	PROPN
gs-894	347	129	,	,	PUNCT
gs-894	347	130	ხოლო	ხოლო	NOUN
gs-894	347	131	2.65	2.65	NUM
gs-894	347	132	%	%	NOUN
gs-894	347	133	ტიპი	ტიპი	NOUN
gs-894	347	134	2	2	NUM
gs-894	347	135	შაქრიანი	შაქრიანი	NOUN
gs-894	347	136	დიაბეტი.	დიაბეტი.	NOUN
gs-894	347	137	ჩვენი	ჩვენი	NOUN
gs-894	347	138	კვლევის	კვლევის	NOUN
gs-894	347	139	მიხედვით	მიხედვით	PROPN
gs-894	347	140	ჰიპერგლიკემიის	ჰიპერგლიკემიის	PROPN
gs-894	347	141	პრევალენტობა	პრევალენტობა	PROPN
gs-894	347	142	იზრდება	იზრდება	PROPN
gs-894	347	143	ასაკის	ასაკის	PROPN
gs-894	347	144	მატებასთან	მატებასთან	PROPN
gs-894	347	145	ერთად.	ერთად.	NOUN
gs-894	347	146	ჯამში	ჯამში	VERB
gs-894	347	147	171	171	NUM
gs-894	347	148	(	(	PUNCT
gs-894	347	149	5.87	5.87	NUM
gs-894	347	150	%	%	NOUN
gs-894	347	151	)	)	PUNCT
gs-894	347	152	მონაწილეს	მონაწილეს	NOUN
gs-894	347	153	ჰქონდა	ჰქონდა	VERB
gs-894	347	154	ტუბერკულოზი.	ტუბერკულოზი.	PROPN
gs-894	347	155	ტუბერკულოზის	ტუბერკულოზის	VERB
gs-894	347	156	მქონე	მქონე	PROPN
gs-894	347	157	48.5	48.5	NUM
gs-894	347	158	%	%	NOUN
gs-894	347	159	(	(	PUNCT
gs-894	347	160	83	83	NUM
gs-894	347	161	)	)	PUNCT
gs-894	347	162	ჰქონდა	ჰქონდა	NOUN
gs-894	347	163	ჰიპერგლიკემიაც.	ჰიპერგლიკემიაც.	PROPN
gs-894	347	164	ტუბერკულოზის	ტუბერკულოზის	PROPN
gs-894	347	165	rr=0.94	rr=0.94	PROPN
gs-894	347	166	(	(	PUNCT
gs-894	347	167	95	95	NUM
gs-894	347	168	%	%	NOUN
gs-894	347	169	ci	ci	NOUN
gs-894	347	170	:	:	PUNCT
gs-894	347	171	0.85	0.85	NUM
gs-894	347	172	-	-	SYM
gs-894	347	173	1.56	1.56	NUM
gs-894	347	174	)	)	PUNCT
gs-894	347	175	.	.	PUNCT
gs-894	348	1	32	32	NUM
gs-894	348	2	მონაწილეს	მონაწილეს	PROPN
gs-894	348	3	ckd	ckd	PROPN
gs-894	348	4	ჰქონდა	ჰქონდა	PROPN
gs-894	348	5	,	,	PUNCT
gs-894	348	6	მათგან	მათგან	NOUN
gs-894	348	7	50	50	NUM
gs-894	348	8	%	%	NOUN
gs-894	348	9	(	(	PUNCT
gs-894	348	10	p=0.08	p=0.08	NOUN
gs-894	348	11	)	)	PUNCT
gs-894	348	12	ჰიპერგლიკემიაც.	ჰიპერგლიკემიაც.	PROPN
gs-894	348	13	cvd	cvd	PROPN
gs-894	348	14	92	92	NUM
gs-894	348	15	პაციენტს	პაციენტს	ADJ
gs-894	348	16	დაუფიქსირდა	დაუფიქსირდა	NOUN
gs-894	348	17	,	,	PUNCT
gs-894	348	18	მათგან	მათგან	NOUN
gs-894	348	19	44.6	44.6	NUM
gs-894	348	20	%	%	NOUN
gs-894	348	21	(	(	PUNCT
gs-894	348	22	p=0.07	p=0.07	NOUN
gs-894	348	23	)	)	PUNCT
gs-894	348	24	კი	კი	PROPN
gs-894	348	25	ჰიპერგლიკემია	ჰიპერგლიკემია	PROPN
gs-894	348	26	ჰქონდა.16	ჰქონდა.16	PROPN
gs-894	348	27	მონაწილეს	მონაწილეს	PROPN
gs-894	348	28	ინსულტი	ინსულტი	PROPN
gs-894	348	29	განუვითარდა	განუვითარდა	ADJ
gs-894	348	30	,	,	PUNCT
gs-894	348	31	მათგან	მათგან	NOUN
gs-894	348	32	11	11	NUM
gs-894	348	33	(	(	PUNCT
gs-894	348	34	68.8	68.8	NUM
gs-894	348	35	%	%	NOUN
gs-894	348	36	)	)	PUNCT
gs-894	348	37	პარალელურად	პარალელურად	NOUN
gs-894	348	38	ჰიპერგლიკემიაც	ჰიპერგლიკემიაც	NOUN
gs-894	348	39	ჰქონდა.	ჰქონდა.	NOUN
gs-894	348	40	ინსულტის	ინსულტის	NOUN
gs-894	348	41	rr	rr	NOUN
gs-894	348	42	=	=	NOUN
gs-894	348	43	1.8	1.8	NUM
gs-894	348	44	(	(	PUNCT
gs-894	348	45	95	95	NUM
gs-894	348	46	%	%	NOUN
gs-894	348	47	ci	ci	NOUN
gs-894	348	48	:	:	PUNCT
gs-894	348	49	1.45	1.45	NUM
gs-894	348	50	-	-	SYM
gs-894	348	51	4.76	4.76	NUM
gs-894	348	52	)	)	PUNCT
gs-894	348	53	.	.	PUNCT
gs-894	349	1	550	550	NUM
gs-894	349	2	(	(	PUNCT
gs-894	349	3	18.9	18.9	NUM
gs-894	349	4	%	%	NOUN
gs-894	349	5	)	)	PUNCT
gs-894	349	6	მონაწილეს	მონაწილეს	NOUN
gs-894	349	7	მომატებული	მომატებული	PROPN
gs-894	349	8	ჰქონდა	ჰქონდა	VERB
gs-894	349	9	საერთო	საერთო	ADJ
gs-894	349	10	ქოლესტერინისა	ქოლესტერინისა	VERB
gs-894	349	11	და	და	NOUN
gs-894	349	12	ldl	ldl	NOUN
gs-894	349	13	კონცენტრაცია	კონცენტრაცია	NOUN
gs-894	349	14	,	,	PUNCT
gs-894	349	15	მათგან195	მათგან195	PROPN
gs-894	349	16	(	(	PUNCT
gs-894	349	17	35	35	NUM
gs-894	349	18	%	%	NOUN
gs-894	349	19	)	)	PUNCT
gs-894	349	20	ჰიპერგლიკემიაც	ჰიპერგლიკემიაც	PROPN
gs-894	349	21	ჰქონდა.	ჰქონდა.	ADJ
gs-894	349	22	დასკვნა	დასკვნა	NOUN
gs-894	349	23	:	:	PUNCT
gs-894	349	24	ტიპი	ტიპი	PROPN
gs-894	349	25	2	2	NUM
gs-894	349	26	დიაბეტის	დიაბეტის	NOUN
gs-894	349	27	პრევენცია	პრევენცია	NOUN
gs-894	349	28	,	,	PUNCT
gs-894	349	29	ადრეული	ადრეული	PROPN
gs-894	349	30	გამოვლენა	გამოვლენა	PROPN
gs-894	349	31	და	და	PROPN
gs-894	349	32	მეტაბოლური	მეტაბოლური	PROPN
gs-894	349	33	დარღვევების	დარღვევების	PROPN
gs-894	349	34	დროული	დროული	PROPN
gs-894	349	35	მართვა	მართვა	PROPN
gs-894	349	36	შეამცირებს	შეამცირებს	PROPN
gs-894	349	37	ავადობისა	ავადობისა	PROPN
gs-894	349	38	და	და	PROPN
gs-894	349	39	სიკვდილიანობის	სიკვდილიანობის	PROPN
gs-894	349	40	რისკს	რისკს	PROPN
gs-894	350	1	აივ	აივ	PROPN
gs-894	350	2	ინფექციის	ინფექციის	PROPN
gs-894	350	3	დროს.	დროს.	VERB
gs-894	350	4	ჰიპერგლიკემიის	ჰიპერგლიკემიის	PROPN
gs-894	350	5	სკრინინგი	სკრინინგი	PROPN
gs-894	350	6	და	და	PROPN
gs-894	350	7	მენეჯმენტი	მენეჯმენტი	PROPN
gs-894	350	8	ინტერგრირებული	ინტერგრირებული	PROPN
gs-894	350	9	უნდა	უნდა	NOUN
gs-894	350	10	იყოს	იყოს	VERB
gs-894	350	11	აივ-ის	აივ-ის	PROPN
gs-894	350	12	რუტინული	რუტინული	PROPN
gs-894	350	13	კლინიკური	კლინიკური	PROPN
gs-894	350	14	კვლევის	კვლევის	PROPN
gs-894	350	15	პაკეტში.	პაკეტში.	PROPN
gs-894	350	16	საკვანძო	საკვანძო	PROPN
gs-894	350	17	სიტყვები	სიტყვები	NOUN
gs-894	350	18	:	:	PUNCT
gs-894	350	19	ტიპი	ტიპი	PROPN
gs-894	350	20	2	2	NUM
gs-894	350	21	შაქრიანი	შაქრიანი	PROPN
gs-894	350	22	დიაბეტი	დიაბეტი	PROPN
gs-894	350	23	,	,	PUNCT
gs-894	350	24	ჰიპერგლიკემია	ჰიპერგლიკემია	PROPN
gs-894	350	25	,	,	PUNCT
gs-894	350	26	აივ	აივ	ADJ
gs-894	350	27	,	,	PUNCT
gs-894	350	28	პრევალენტობა	პრევალენტობა	NOUN
gs-894	350	29	,	,	PUNCT
gs-894	350	30	საქართველო	საქართველო	NOUN